

PTO/SB/21 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	09/611,257	
	Filing Date	July 6, 2000	
	First Named Inventor	Terrance P. SNUTCH	
	Art Unit	1646	
	Examiner Name	N. S. Basi	
Total Number of Pages in This Submission	8	Attorney Docket Number	381092000721

## ENCLOSURES (Check all that apply)

<input checked="" type="checkbox"/> Fee Transmittal Form (1 page + duplicate for fee processing)  <input type="checkbox"/> Fee Attached  <input type="checkbox"/> Amendment/Reply  <input type="checkbox"/> After Final  <input type="checkbox"/> Affidavits/declaration(s)  <input type="checkbox"/> Extension of Time Request  <input type="checkbox"/> Express Abandonment Request  <input checked="" type="checkbox"/> Information Disclosure Statement Supplemental (3 pages)  <input type="checkbox"/> Certified Copy of Priority Document(s)  <input type="checkbox"/> Response to Missing Parts/ Incomplete Application  <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s)  <input type="checkbox"/> Licensing-related Papers  <input type="checkbox"/> Petition  <input type="checkbox"/> Petition to Convert to a Provisional Application  <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address  <input type="checkbox"/> Terminal Disclaimer  <input type="checkbox"/> Request for Refund  <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance communication to Technology Center (TC)  <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences  <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)  <input type="checkbox"/> Proprietary Information  <input type="checkbox"/> Status Letter  <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):  Form PTO-1449 (1 page + duplicate) Copies of 7 References Return Receipt Postcard						
<table><tr><td>Remarks</td><td><b>Customer No. 25225</b></td><td><b>SEP 27 2004</b></td></tr><tr><td colspan="2"></td><td><b>TECH CENTER 1000/2500</b></td></tr></table>			Remarks	<b>Customer No. 25225</b>	<b>SEP 27 2004</b>			<b>TECH CENTER 1000/2500</b>
Remarks	<b>Customer No. 25225</b>	<b>SEP 27 2004</b>						
		<b>TECH CENTER 1000/2500</b>						

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	MORRISON & FOERSTER LLP Kate H. Murashige - 29,959
Signature	<i>Kate H. Murashige</i>
Date	September 20, 2004

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: September 20, 2004

Signature: *Marian L. Christopher* (Marian L. Christopher)

01 P E JC116  
SEP 23 2004  
PATENT & TRADEMARK OFFICE

PTO/SB/17 (10-03)

Approved for use through 7/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# FEE TRANSMITTAL for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 180.00

## Complete if Known

Application Number 09/611,257  
Filing Date July 6, 2000  
First Named Inventor Terrance P. SNUTCH  
Examiner Name N. S. Basi  
Art Unit 1646  
Attorney Docket No. 381092000721

## METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit Card ☐ Money Order ☐ Other ☐ None

☒ Deposit Account:

Deposit Account Number

03-1952

Deposit Account Name

Morrison & Foerster LLP

The Director is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments

☒ Charge any additional fee(s) or any underpayment of fee(s)

☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

## FEE CALCULATION

### 1. BASIC FILING FEE

Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
1001	770	2001	385	Utility filing fee	
1002	340	2002	170	Design filing fee	
1003	530	2003	265	Plant filing fee	
1004	770	2004	385	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	

SUBTOTAL (1) (\$) 0.00

### 2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims	Extra Claims	Fee from below	Fee Paid
Independent Claims	-20** =	x	=
Multiple Dependent	-3** =	x	=

Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description
1202	18	2202	9	Claims in excess of 20
1201	86	2201	43	Independent claims in excess of 3
1203	290	2203	145	Multiple dependent claim, if not paid
1204	86	2204	43	** Reissue independent claims over original patent
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$) 0.00

\*\*or number previously paid, if greater; For Reissues, see above

## FEE CALCULATION (continued)

### 3. ADDITIONAL FEES

Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for ex parte reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	420	2252	210	Extension for reply within second month	
1253	950	2253	475	Extension for reply within third month	
1254	1,480	2254	740	Extension for reply within fourth month	
1255	2,010	2255	1,005	Extension for reply within fifth month	
1401	330	2401	165	Notice of Appeal	
1402	330	2402	165	Filing a brief in support of an appeal	
1403	290	2403	145	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1,330	2453	665	Petition to revive - unintentional	
1501	1,330	2501	665	Utility issue fee (or reissue)	
1502	480	2502	240	Design issue fee	
1503	640	2503	320	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)	
1806	180	1806	180	Submission of Information Disclosure Stmt	180.00
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	770	2809	385	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	770	2810	385	For each additional invention to be examined (37CFR 1.129(b))	
1801	770	2801	385	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify)

\*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$) 180.00

## SUBMITTED BY

(Complete (if applicable))

Name (Print/Type) Kate H. Murashige

Registration No. (Attorney/Agent) 29,959


Telephone (858) 720-5112

Signature

Kate H. Murashige

Date

September 20, 2004



71 1646 \$

PATENT  
Docket No. 381092000721

**CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on September 20, 2004.

*Marian Christopher*  
Marian Christopher

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In the application of:

Terrance P. SNUTCH et al.

Serial No.: 09/611,257

Filing Date: July 6, 2000

For: MAMMALIAN T-TYPE CALCIUM  
CHANNELS

Examiner: N. S. Basi

Group Art Unit: 1646

**SEP 27 2004**

**TECH CENTER 1600/2900**

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. A copy of the documents is also submitted herewith. The Examiner is requested to make these documents of record.

09/24/2004 SSESHE1 00000064 031952 09611257  
01 FC:1806 180.00 DA

sd-219629

SEP 23 2004

<b>Form PTO-1449</b>  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  <i>(Use several sheets if necessary)</i>	Docket Number 381092000721	Application Number 09/611,257
	Applicant  Terrance P. SNUTCH et al.	
	Filing Date July 6, 2000	Group Art Unit 1646
	Mailing Date September 20, 2004	

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.		60/117,339				January 27, 1999
	2.		08/985,809				December 5, 1997
	3.	10/2001	6,309,858	Dietrich et al.	435	69.1	
	4.	03/2002	6,358,706	Dubin et al.	435	69.1	
	5.	03/2003	6,528,630	Williams et al.	536	23.1	
	6.	07/2003	2003/125269	Li	514	44	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	7.	11/2000	00/70044	WIPO			

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title

SEP 27 2004

TECH CENTER 1600/2900

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



Form PTO-1449

Docket Number 381092000721

Application Number 09/611,257

# INFORMATION DISCLOSURE CITATION IN AN APPLICATION

*(Use several sheets if necessary)*

Applicant

Terrance P. SNUTCH et al.

Filing Date July 6, 2000

Group Art Unit 1646

Mailing Date September 20, 2004

**COPY**

## U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.		60/117,339				January 27, 1999
	2.		08/985,809				December 5, 1997
	3.	10/2001	6,309,858	Dietrich et al.	435	69.1	
	4.	03/2002	6,358,706	Dubin et al.	435	69.1	
	5.	03/2003	6,528,630	Williams et al.	536	23.1	
	6.	07/2003	2003/125269	Li	514	44	

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	7.	11/2000	00/70044	WIPO			

## OTHER DOCUMENTS

*(including author, title, Date, Pertinent Pages, Etc.)*

Examiner Initials	Ref. No.	Title

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
- ☐ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
- ☒ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
  - ☐ A fee is required. A check in the amount of \_\_\_ is enclosed.
  - ☒ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of \_\_\_ is enclosed.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. §1.17(p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing **381092000721**. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: September 20, 2004

Respectfully submitted,

By: Kate H. Murashige  
Kate H. Murashige  
Registration No. 29,959

Morrison & Foerster LLP  
3811 Valley Centre Drive  
Suite 500  
San Diego, California 92130-2332  
Telephone: (858) 720-5112  
Facsimile: (858) 720-5125



REC'D 12 JAN 1999

WIPO PCT

E.J.

# THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office

January 7, 1999

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: 08/985,809

FILING DATE: December 5, 1997

PCT APPLICATION NUMBER: PCT/US98/23161

## PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)



By Authority of the  
COMMISSIONER OF PATENTS AND TRADEMARKS

*T. Wallace*  
T. WALLACE

Certifying Officer

# CS 438

## S P E C I F I C A T I O N

TO ALL WHOM IT MAY CONCERN:

Be it known that Edward Perez-Reyes and Leanne L. Cribbs, citizens of the United states of America, and resident at 320 South Birchwood Drive, Naperville, IL 60540-5033 and 1737 N. Natoma, Chicago, IL 60707, respectively, have invented a certain new and useful T-TYPE VOLTAGE-GATED CALCIUM CHANNELS AND METHOD OF USING SAME of which the following is a specification.

## T-TYPE VOLTAGE-GATED CALCIUM CHANNELS AND METHOD OF USING SAME

### STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT

This invention was made with Government support under Grant Number HL58728 awarded by the National Heart, Lung, and Blood Institute of the National Institutes of Health. The United States Government may have certain rights in this invention.

### TECHNICAL FIELD OF THE INVENTION

The present invention relates to molecular biology, and more particularly to cloned T-type calcium channels.

### BACKGROUND OF THE INVENTION

Biological membranes are themselves generally impermeable to ionic species. Thus, ions enter cells through regulated pores formed from membrane-associated proteins. Most of these regulated pores are voltage-dependent and are thus able to transduce changes in the transmembrane potential into ion flux. Voltage-gated ion channels form a "superfamily" of related proteins (cf. Jan et al., *Nature*, 345, 672 (1990)). Peculiar to this genus is a high degree of conservation in molecular structure. Generally, voltage-gated channels are membrane bound glycosylated proteins formed of many subunits. Large  $\alpha$  subunits form a pore in the membrane that is selective for a given ionic species. Each  $\alpha$  subunit contains four domains (I, II, III, and IV). Each channel domain has six putative transmembrane helical segments ( $S_1$ - $S_6$ ). In general, the segments within each domain are similar but not identical. Aside from overall structural conservation, certain charged residues within the domains are highly conserved among voltage-gated ion channels (Jan et al., *supra*; Stühmer et al., *Nature*, 339, 597-603 (1989)).

Differences in charged residues between groups of voltage-gated ion channels confer properties unique to each subgroup, such as ion selectivity. For example, most voltage gated ion channels are selective for either sodium, potassium or calcium. Known calcium channels require a ring of negative charge provided by glutamate residues found at similar locations in each of the domains (Yang et al., *Nature*, 366, 158-61 (1993)).

Voltage-gated channels are often classified on the basis of their electrophysiology. The resting membrane potential of most animal cells is between about -70 mV and -80 mV. When the membrane becomes depolarized (moved towards 0 mV), various membrane channels become activated (they are said to "open"). Thus, one category for classifying membrane channels is on the basis of the membrane potential necessary to

activate (or "gate") them (voltage dependency). For example, "T-type" calcium channels are activated at a lower voltage than L- or N-type channels (Nowycky et al., *Nature*, 316, 440-43 (1985)). Other physiological properties are the activation kinetics, inactivation kinetics, tail current (deactivation kinetics), and single channel conductance. Thus, in comparison to other calcium currents, T-type calcium current is characteristically short (Chen et al., *J. Gen. Physiol.*, 96, 603-30 (1990)), and it exhibits characteristically slow activation kinetics near threshold, fast inactivation kinetics, and slow tail current (Randall et al., *Neuropharmacol.*, 63, 879-93 (1997); Carbone et al., *Nature*, 310, 501-02 (1984); Nilius et al., *Nature*, 316, 443-46 (1985)).

Calcium currents have been implicated in many neurological and muscular functions. For example, T-type calcium current is associated with cardiac pacemaker activity, pain transmission in the central nervous system, and in other physiological functions. Defects in T-type calcium current have been implicated in cardiac arrhythmia, hypertension, and epilepsy. Given their potential clinical value, the pharmacological properties of calcium channels have been the subject of extensive study. Most such studies have involved L-type channels because, unlike T-type channels, L-type calcium channels are readily purified from cell extracts. For example, L-type calcium channels have been purified using dihydropyridine drugs (e.g., nifedipine) which can bind with sufficiently high affinity to serve as a ligand for purifying L-type calcium channels. Such purified and cloned L-type calcium channels have been used to develop assays for drugs affecting L-type calcium channels (see, e.g., U.S. Patents 5,429,921 and 5,386,025).

While many electrophysiological characteristics of T-type calcium currents are known, the lack of isolated T-type channels has stalled research into the pharmacology and biophysics underlying the T-type calcium current, at least in comparison with other calcium channels. Indeed, while it is generally assumed that voltage-sensitive ion channels are responsible for the current, no such channel protein, nor any nucleic acid encoding such a protein, has been isolated. In view of the foregoing problems, there exists a need for an isolated T-type calcium channel and a nucleic acid encoding a T-type calcium channel.

#### BRIEF SUMMARY OF THE INVENTION

The present invention provides an isolated or substantially purified nucleic acid encoding a protein comprising at least one domain of a T-type calcium channel and cells expressing such nucleic acids. The present invention also provides an isolated or substantially purified T-type calcium channel and an isolated or substantially purified antibody molecule recognizing an epitope on a T-type calcium channel protein.

The present invention is useful for exploring the electrophysiology and pharmacology of the T-type calcium current. Such knowledge can lead to the development of drugs for potentiating or attenuating T-type calcium channels. Thus, the present invention provides an assay for identifying potential drugs affecting T-type calcium channels by exposing cells expressing a T-type calcium channel to a putative drug and then measuring the calcium flux in response to a change in membrane potential. The identification of drugs affecting T-type calcium channels will facilitate even greater understanding of the biophysics of these proteins. Furthermore, some such drugs could have potential clinical applications.

The invention can best be understood with reference to the accompanying drawings and in the following detailed description of the preferred embodiments.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A-1G show the complete nucleotide and amino acid sequences (SEQ ID NO:1 and SEQ ID NO:2) of a T-type calcium channel ( $\alpha 1G$  or  $C_{av}T.1$ ), and the conserved functional domains.

Figures 2A-2F show the complete nucleotide and amino acid sequences (SEQ ID NO:3 and SEQ ID NO:4) of a T-type calcium channel ( $\alpha 1H$  or  $C_{av}T.2$ ), indicating conserved functional domains.

Figure 3 compares the amino acid sequences of domains of the T-type calcium channels with those of other calcium channels.

Figures 4A-4D are graphic representations of the current-voltage relationships of two cloned T-type calcium channels (Figures 4A and 4B), a native T-type calcium current in NIE-115 cells (Figure 4C), and a cloned R-type calcium channel (Figure 4D).

Figure 5A is a graphic representation of the average current-voltage curve for cloned T-type calcium channels ( $\alpha 1G$ , closed circle,  $\alpha 1H$ , open circle), a native T-type calcium current in NIE-115 cells (triangles), and a cloned R-type calcium channel (filled squares). Figures 5B and 5C are graphic representations of the conductance of calcium channels. Figure 5B compares the conductance in 2 mM  $BaCl_2$  of cloned T-type calcium channels ( $\alpha 1G$ , closed circle,  $\alpha 1H$ , open circle), a native T-type calcium current in NIE-115 cells (triangles), and a cloned R-type calcium channel (filled squares). Figure 5C compares the normalized conductance of a cloned T-type calcium channel at three different concentrations of  $BaCl_2$ .

Figures 6A and 6B are graphic depictions of the kinetics of a cloned T-type calcium channel. Figure 6A compares the current recorded in cells expressing cloned T-type ( $\alpha 1G$ ) or L-type ( $\alpha 1E$ ) calcium channels at -20 mV. Figure 6B compares the



voltage dependent time constants of cloned T-type calcium channel activation and inactivation.

Figures 7A-7F are graphic depictions of the tail current of a cloned T-type calcium channel. Figures 7A and 7D depict tail current amplitudes for  $\alpha 1G$  and  $\alpha 1H$ , respectively. Figures 7B and 7E depict tail current at several test potentials for  $\alpha 1G$  and  $\alpha 1H$ , respectively. Figures 7C and 7F depict average kinetics of the tail current as a function of repolarization potential for  $\alpha 1G$  and  $\alpha 1H$ , respectively.

Figures 8A-C graphically illustrate the voltage dependence of the inactivation of a cloned T-type calcium channel. Figure 8A illustrates the inactivation of cloned T-type calcium channels due to 200 ms pre-pulses at various potentials followed by a test pulse to -20 mV. Figure 8B compares the inactivation of cloned T-type (circles) and R-type (squares) calcium channels due to 200 ms pre-pulses at various potentials followed by a test pulse to -20 mV in comparison to a -100 mV control. Figure 8C depicts the voltage dependence of inactivation induced by 10 s pre-pulses for cloned T-type (circles) and R-type (squares) calcium channels.

Figures 9A-9C graphically illustrate the single channel conductance of a cloned T-type calcium channel. Figure 9A depicts the raw data collected from a patch of membrane on an oocyte expressing a cloned T-type calcium channel at various voltage protocols. Figure 9B represents the ensemble current recorded from 100 sweeps. Figure 9C graphically illustrates the single channel amplitude plotted against test potential.

Figures 10A and 10B graphically present data concerning the use of a cloned T-type calcium channel to detect drugs affecting the channel. Figure 10A depicts the effect of 100  $\mu M$  on current-voltage relationships with a single dosage of mibefradil. Figure 10B illustrates the effect on T-type channel conductance of various doses of mibefradil.

#### DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention provides an isolated or substantially purified nucleic acid encoding a protein comprising at least one domain of a T-type calcium channel  $\alpha$  subunit. The nucleic acid can be of any type, and it can include other elements aside from a sequence encoding a T-type calcium channel domain or domains. For example, where the nucleic acid comprises RNA, it can also include regulatory sequences suitable to permit translation of the RNA. Thus, an RNA nucleic acid of the present invention preferably has at least one ribosome entry site, and preferably has a poly-adenosine tail for stabilizing the RNA in the cellular environment.

Similarly, DNA nucleic acids of the present invention can have regulatory elements for promoting the transcription of sequence encoding the T-type calcium

channel into an RNA such as that described above. For example, a DNA nucleic acid of the present invention can have a promoter and/or an enhancer sequence.

The choice of promoter and/or an enhancer will largely depend on the milieu in which the nucleic acid is to be expressed. Thus, for expression in bacterial cells, the regulatory elements are bacterial promoters. Similarly, for expression in mammalian cells, the regulatory elements are able to effect expression in mammalian cells.

While many such regulatory elements are known in the art, examples include prokaryotic promoters and viral promoters (e.g., retroviral ITRs, LTRs, immediate early viral promoters (IEp), such as herpesvirus IEp (e.g., ICP4-IEp and ICP0-IEp), cytomegalovirus (CMV) IEp, and other viral promoters, such as Rous Sarcoma Virus (RSV) promoters, and Murine Leukemia Virus (MLV) promoters). Other suitable promoters are eukaryotic promoters, such as enhancers (e.g., the rabbit  $\beta$ -globin regulatory elements), constitutively active promoters (e.g., the  $\beta$ -actin promoter, etc.), signal specific promoters (e.g., inducible promoters such as a promoter responsive to RU486, etc.), and tissue-specific promoters (e.g., those active in epidermal tissue, dermal tissue, tissue of the digestive organs (e.g., cells of the esophagus, stomach, intestines, colon, etc., or their related glands), smooth muscles, such as vascular smooth muscles, cardiac muscles, skeletal muscles, lung tissue, hepatocytes, lymphocytes, endothelial cells, sclerocytes, kidney cells, glandular cells (e.g., those in the thymus, ovaries, testicles, pancreas, adrenals, pituitary, etc.), tumor cells, cells in connective tissue, cells in the central nervous system (e.g., neurons, neuralgia, etc.), cells in the peripheral nervous system, and other cells of interest). While the nucleic acid can be any type of nucleic acid, the nucleic acid preferably comprises a cDNA. A cDNA nucleic acid is preferred over other nucleic acids to permit the nucleic acid to be readily cloned, sequenced, and expressed in a wide variety of cells.

The isolated or substantially purified nucleic acid of the present invention encodes all or part of a T-type calcium channel  $\alpha$  subunit. As used herein, a "calcium channel" includes a protein structure for facilitating the flux of calcium ions across a biological membrane into which the calcium channel is inserted. As used herein, a "T-type channel" is a type of voltage-gated ion channel that facilitates the flux of ions when the membrane potential of a biological membrane into which it is inserted experiences a slight depolarization. Thus, a T-type calcium channel can gate at about -45 mV to about -30 mV (i.e., about -40 mV to about -35 mV) in 2 mM  $\text{Ba}^{2+}$ . Additionally, T-type channels of the present invention exhibit a slow deactivation (tail current) following depolarization. Thus, a T-type calcium channel can exhibit a tail current that decays exponentially with a tau value from about 2 ms to about 10 ms (e.g., from about 4 ms to about 7 ms, such as about 6 ms) following repolarization to a membrane potential from about -80 mV to

about -60 mV in a solution with a barium concentration of from about 10 mM to about 40 mM. Another defining characteristic of T-type calcium channels is that they exhibit small single channel conductance. Thus, for example, a T-type channel exhibits a single channel conductance of from about 7 pS to about 10 pS (e.g., from about 7.5 pS to about 9.5 pS), and typically from about 8 pS to about 9 pS in a solution with a barium ion concentration of about 0.1 M.

The isolated or substantially purified nucleic acid of the present invention encodes all or part of any T-type calcium channel having at least one of the aforementioned electrophysiological properties when properly assembled within a cellular membrane.

The general structure of calcium channels is summarized above and is otherwise known in the art. Thus, for example, the nucleic acid can encode one of the four functional domains mentioned above. As used herein, a domain of a T-type calcium channel is any protein structure able to associate with three other domains to form a tetrameric body functioning as a T-type calcium channel. While the native T-type calcium channel structure includes all four domains in a single polypeptide (indicated in Figures 1A-G and 2A-2F), a domain can exist as a polypeptide species separate from those containing the other domains. Such separate domains are able to associate within the plasma membrane to form a functional channel. Alternatively, where a plurality of domains are linked within a common polypeptide, the linkage can deviate substantially from the native linkage. Thus, for example, the domains can be linked by polypeptide sequences other than those sequences (see, e.g., Figures 1A-1G and 2A-2F) linking the domains in the native protein (e.g., non-native polyglutamate linkages). Indeed, the domains themselves can include non-native linkages between membrane-spanning elements within the domains. Aside from these modifications, the nucleic acid can encode a chimeric calcium channel domain (or an entire channel) comprising a portion of a T-type calcium channel and a portion derived from another calcium channel (or other channel) protein. For example, the chimera can include portions of domains from T-type channels responsible for low voltage gating and portions of domains from other calcium channels responsible for slow inactivation. Such a protein exhibiting T-type gating but longer inactivation kinetics would facilitate pharmacological research.

As mentioned, nucleic acids of the present invention can encode an entire T-type channel (i.e., a T-type channel protein comprising four functional domains). Examples of the amino acid sequences of two full-length T-type channels are set forth at SEQ ID NO:1, SEQ ID NO:3, and examples of sequences encoding full length T-type calcium channels are SEQ ID NO:2 and SEQ ID NO:4. However, the invention is not limited to these exemplary sequences. Indeed, as mentioned, an amino acid sequence of a T-type calcium channel can vary from those listed, and it is within the state of the art to change a

nucleotide sequence encoding a T-type channel to introduce mutations into the protein. For example, mutations comprising insertions or deletions can be introduced on either the amino- or carboxy-terminus of the protein, or such mutations can be intrasequence insertions or deletions. Where the electrophysiological properties of the calcium channel are to be conserved, such mutations preferably are in regions other than the membrane spanning domains (see, e.g., Figures 1A-1G And 2A-2F). For example, SEQ ID NO:5 and SEQ ID NO: 6 are the sequences of two T-type channels having deletions in the region linking domains III and IV. However, in some applications (e.g., to decrease inactivation kinetics), the changes can be within the membrane-spanning regions. Moreover, as mentioned above, the sequence can form a protein having only one functional domain of a T-type calcium channel. Additionally, the sequence can also form a chimeric protein or domain, such as those described above.

Aside from insertions and deletion mutations of native T-type calcium channel sequences, a T-type calcium channel can include substitutions of amino acid residues, e.g., for those indicated in SEQ ID NO:1 and SEQ ID NO:3. Preferably, and especially where such a substitution is within a membrane spanning region, the substitution is conservative. Thus, within membrane spanning domains, positively-charged residues (H, K, and R) preferably are only substituted with positively-charged residues; negatively-charged residues (D and E) preferably are only substituted with negatively-charged residues; neutral polar residues (C, G, N, Q, S, T, and Y) preferably are only substituted with neutral polar residues; and neutral non-polar residues (A, F, I, L, M, P, V, and W) preferably are only substituted with neutral non-polar residues. Figure 3 indicates the conservation between the S-IV domains of T-type calcium channel  $\alpha$  subunits and those of other calcium channels. Preferably, any amino-acid substitution within the membrane-spanning regions does not alter this conservation. Most preferably, any substitution, deletion, or insertion does not alter the IVs4 domain. In each of the exemplary T-type calcium channel  $\alpha$  subunit sequences (SEQ ID NO:1 and SEQ ID NO:3, SEQ ID NO:5, and SEQ ID NO:6), the putative S4 region comprises Arg Ile Met Arg Val Leu Arg Ile Ala Arg Val Leu Lys Leu Leu Lys Met Ala Val Gly Met Arg Ala (SEQ ID NO:7). Given the strong sequence conservation among families of voltage-gated ion channels, it is likely that SEQ ID NO:7, or a derivative sequence, will be present in T-type channels. Thus, the present invention provides any T-type calcium channel (or a nucleic acid encoding such a T-type calcium channel) comprising SEQ ID NO:7 or a sequence derived from SEQ ID NO:7 having conservative amino acid substitutions, as described above.

The nucleic acid of the present invention encoding all or a part of a T-type calcium channel can be isolated via any suitable method. For example, prior to the present

invention, one of skill in the art could design a probe based on the sequence of known, non-T-type, calcium channels and use such probe to screen a genetic library. If such a screen were to identify a putative calcium channel, the researcher could then attempt to clone the entire nucleic acid to characterize it. Similarly, prior to the present invention, to isolate a nucleic acid encoding a T-type calcium channel, one of skill in the art could consult publicly available databases containing DNA sequences (e.g., Genbank) to locate nucleic or amino acid sequences representing a portion of a T-type calcium channel protein or nucleic acid. However, such databases contain no sequence for a full-length T-type calcium channel. Such methods assume that T-type calcium channels share sufficient sequence identity with known calcium channel nucleic acids to cross-hybridize, an assumption not supported by any published report. Moreover, prior to the present invention, no partial sequence in such databases was identified as corresponding to a T-type calcium channel. Thus, prior to the present invention, the presence of partial sequences in the public DNA databases could facilitate the isolation of T-type calcium channels only with the exercise of a considerable degree of speculation on the part of the researcher.

By providing several sequences pertaining to T-type calcium channels and a comparison presenting conserved regions and domains, the present invention greatly facilitates the isolation of other nucleic acids encoding T-type calcium channels (or derivatives thereof) with much less experimentation. Thus, while any of the methods discussed above can be employed to isolate other members of this genus, preferably, a nucleic acid encoding a T-type calcium channel is isolated by probing a genetic library using a probe that hybridizes to a DNA encoding a peptide sequence contained in (or similar to) a known T-type calcium channel (e.g., SEQ ID NO:1 or SEQ ID NO:3). To facilitate the isolation of a T-type calcium channel, the present invention provides an isolated polynucleotide hybridizing to a portion of the nucleic acid of the present invention encoding a T-type calcium channel (or a portion thereof). Thus, for example, the present invention includes an isolated polynucleotide hybridizing to SEQ ID NO:2 or SEQ ID NO:4. The isolated polynucleotide can hybridize to all or any portion of the sequence encoding the T-type calcium channel.

To isolate such a polynucleotide, any portion of a sequence encoding a T-type calcium channel can be employed as a probe to screen a genetic library, and such screening can be accomplished by standard techniques known in the art. While the probe can hybridize to any portion of such a DNA, preferably the probe is designed to hybridize to a DNA encoding a polypeptide sequence that is highly conserved among T-type calcium channels but is less conserved between the genus of T-type calcium channels and other proteins. Such peptide sequences are readily apparent from the sequence

comparison set forth in Figure 3. Generally, the specificity of hybridization in a genetic screen varies depending on the length of the probe and the stringency (e.g., temperature, salt and detergent concentration, etc.) of hybridization. Stringency of hybridization is broadly classified as "high," "moderate," or "low," and the parameters of these terms are well recognized in the art (see, e.g., Sambrook et al., "Molecular Cloning, a Laboratory Manual," Cold Spring Harbor Press, 1989). The isolated polynucleotide hybridizing to a portion of the nucleic acid encoding a T-type calcium channel can hybridize under any desired stringency conditions. However, for identifying other T-type channels, preferably, the hybridization occurs under moderate stringency, and most preferably under high stringency.

Of course, the isolated or substantially purified polynucleotide can itself be employed as a probe to screen a library as described to isolate a second nucleic acid. In such a screen, one of the polynucleotides will be complementary to a portion of the sequence encoding the T-type calcium channel, and the other isolated nucleic acid will be "sense." Preferably, one of the two isolated polynucleotides (the "sense" strand) itself encodes a T-type calcium channel, or at least one domain thereof. Such a sequence can be cloned to be operably linked to suitable regulatory elements, as described, to produce a T-type calcium channel. Thus, aside from using the nucleic acid of the present invention to produce a T-type calcium channel, the nucleic acids of the present invention are also useful for isolating other sequences encoding T-type calcium channels, or derivatives thereof.

However isolated, the isolated or substantially purified nucleic acid of the present invention is useful, in part, for producing all or a portion of a T-type calcium channel. Thus, the nucleic acid can be introduced into a suitable milieu for driving its expression. Because T-type channels are transmembrane proteins, preferably such a milieu is a living cell. However, it should be understood that the nucleic acid can also be expressed *in vitro* under conditions, such as those known in the art, suitable for *in vitro* transcription and translation. However produced, the present invention includes any protein, such as a recombinant protein or an isolated or substantially purified protein, including all or a portion of a T-type calcium channel or a protein derived from a T-type calcium channel. Such proteins are described above.

For expression in a living cell, the nucleic acid must be introduced into the cell. As nucleic acids are generally introduced into cells as part of genetic vectors, the present invention provides a vector having a T-type calcium channel nucleic acid of the type described above. Any type of vector suitable for introducing the nucleic acid into a host cell is within the context of the present invention. Examples of such vectors include naked DNA and RNA vectors (such as oligonucleotides, plasmids, capped cRNA, etc.),

viral vectors such as adeno-associated viral vectors (Berns et al., *Annals of the New York Academy of Sciences*, 772, 95-104 (1995)), adenoviral vectors (Bain et al., *Gene Therapy*, 1, S68 (1994)), herpesvirus vectors (Fink et al., *Ann. Rev. Neurosci.*, 19, 265-87 (1996)), packaged amplicons (Federoff et al., *Proc. Nat. Acad. Sci. USA*, 89, 1636-40 (1992)),  
5 papilloma virus vectors, picornavirus vectors, polyoma virus vectors, retroviral vectors, SV40 viral vectors, vaccinia virus vectors, and other vectors. Once a given type of vector is selected, its genome must be manipulated for use as a background vector, after which it must be engineered to incorporate exogenous polynucleotides. Such manipulations are known in the art.

10 The vectors of the present invention are useful for introducing a nucleic acid encoding all or a portion of a T-type calcium channel into a host cell. Thus, the present invention provides a cell into which the vector of the present invention has been introduced. The host cell can be any cell suitable for expressing the nucleic acid (e.g., bacteria, insect cells, mammalian cells, etc.). The host cell can thus be *in vitro* or *in vivo*.  
15 Preferably the cells do not exhibit native T-type calcium current. A preferred cell type is HEK-293 cells because they contain genetic elements that facilitate the expression of transgenes from a variety of expression vectors. For facilitating electrophysiological recordings, oocytes (e.g., *Xenopus* oocytes) are preferred, as they are large and readily handled.

20 The vector can be introduced into the cell in any manner suitable for the cell type and vector employed. In one embodiment, the vector can be used to prepare an RNA transcript *in vitro* (e.g., a capped cRNA) which is then introduced into the host cell by standard methods (such as injection). Such techniques are preferred when the host cells do not actively transcribe DNA (such as oocytes). In other embodiments, a DNA vector  
25 is introduced into the cell such that it is transcribed within the cell. For example, the vector can be introduced into the cell such that it forms an extrachromosomal segment of genetic material in the cell, as is the case with many types of viral vectors. Alternatively, the vector can introduce the nucleic acid into the chromosomal DNA of the host cell. In this respect, a cell line comprising chromosomes into which the T-type calcium channel  
30 nucleic acid has been introduced is able to propagate the nucleic acid through several passages (e.g., for at least 10 passages), and, preferably, the nucleic acid is stably integrated into the chromosomes of such cells. Thus, the cell line can propagate the nucleic acid for at least 20 passages, and more preferably significantly more than 20 passages (e.g., at least about 25 passages, or even more).

35 Preferably, a cell into which the nucleic acid is introduced is also able to express the nucleic acid. The expression of the nucleic acid can be detected by probing the cell for the presence of T-type calcium channel mRNA, such as via Northern hybridization



analysis, in situ hybridization, etc. More preferably, however, the cell is able to express the nucleic acid to produce the protein including all or a portion of a T-type calcium channel. In such cells, expression of the nucleic acid is confirmed by detecting the protein, for example, by probing cellular extracts with an antibody recognizing the protein (e.g., on a Western blot, etc.). Of course, the protein contributes to the formation of a functional calcium channel in the membrane of the cell producing the protein. Where the protein encodes an entire  $\alpha$  subunit, the full protein will possess some or all of the electrophysiological properties of T-type calcium channels described above. Where the protein encodes less than an entire channel  $\alpha$  subunit (e.g., a domain), the protein will aggregate with other constituent domains in the membrane to form a functional channel. Thus, the presence of the protein can be detected by assaying the cell for T-type calcium channel activity. Indeed, assaying for channel activity serves to determine whether a nucleic acid encoding a putative calcium channel, in fact, encodes a species of T-type channel (as opposed to a member of another genus of calcium channels). For example, when large cells (e.g., oocytes) are used as the host cells, the electrophysiological properties of the channel can be investigated. Thus, the membrane activity of whole cells expressing the nucleic acid can be measured directly, such as via patch clamp techniques using a voltage clamp electrode and a current electrode (Bernal et al., *J. Pharmacol. Exp. Ther.*, 282, 172-80 (1997)). Alternatively, the activity of single channels can be measured, such as with a standard depolarizing bath and pipette solutions (Lacerda et al., *Biophys. J.*, 66, 183-43 (1994)). However measured, the properties of cells into which the putative nucleic acid is introduced are compared to the known channel conductance, voltage dependency, activation kinetics, inactivation kinetics, and tail current known for T-type channels and discussed above.

Regardless of the cell system, the ability to express a T-type calcium channel nucleic acid within host cells to produce an active channel permits the channel to be further studied. In this regard, the present invention provides a method of identifying a drug which affects T-type calcium channels. The method involves first expressing a T-type calcium channel in a cell to produce an active channel, as herein described. The cell expressing the channel is then exposed to a solution containing a putative drug for interfering with the channel. Thereafter, the presence or absence of calcium flux in response to a change in membrane potential is assayed. A quick method of assaying for calcium flux is first to introduce a calcium-sensitive labile dye into the cells. For example, the dye can be one such as those that fluoresce or change color in the presence of calcium (e.g., Indo-1). Thereafter, the cells are exposed to a depolarizing solution containing high (e.g., about 50 mM) potassium concentration and a drug, and the reaction of the labile dye is compared to control cells. Using a labile dye affords the ability to



assay many putative drugs quickly in a high throughput assay for putative drugs affecting T-type channels. For example, the initial screening can be carried out in 96 well plates. Moreover, dose-response data can be readily generated by exposing the cells to several concentrations of the same putative drug.

5        Once a putative drug is detected, its effect on the electrophysiology of the cell (e.g., single channel conductance, voltage dependency, activation kinetics, inactivation kinetics, and tail current of the cells) can be investigated in detail. Generally, the effect of the putative drug on T-type calcium currents is assessed by measuring the various electrophysiological parameters in the presence of various concentrations of the drugs and  
10        comparing the data to untreated (or sham-treated) control cells. Cells preferably are maintained in a continuous perfusion chamber during such experiments to facilitate changing solutions. The inventive method of identifying a drug which affects T-type calcium channels can employ any nucleic acid encoding a T-type calcium channel (or derivative thereof), such as those nucleic acids described herein. In fact, as several  
15        isoforms of T-type channel exist (e.g.,  $\alpha 1G$  and  $\alpha 1H$ ), the assay method can be repeated using nucleic acids encoding different isoforms to identify drugs that preferentially target a given isoform, or drugs which affect more than one isoform of T-type calcium channels.

20        Aside from affording an *in vitro* assay for detecting potential therapeutic or investigative drugs targeting T-type calcium channels, the method of expressing the T-type calcium channel nucleic acid can also be used *in vivo*. For example, as mentioned, several neurological and muscular diseases or disorders have implicated mutations affecting native nucleic acids encoding T-type calcium channels. The present invention, thus, provides a method of treating a disease or disorder associated with a deficiency in a native T-type calcium channel nucleic acid. The method involves introducing a vector  
25        having the T-type calcium channel nucleic acid into cells of a host in which native expression of the nucleic acid is deficient. Thus, for example, for treating cardiomyopathy associated with deficiencies in T-type calcium channels, the vector is introduced into myocardial cells. Similarly, for treating forms of epilepsy associated with deficiencies in T-type calcium channels, the vector is introduced into neurons (e.g.,  
30        thalamic neurons). Within the target cells, the nucleic acid within the vector is expressed to produce active T-type calcium channel. By similar methods, an nucleic acid having a sequence antisense to a sequence encoding a T-type calcium channel (or a portion thereof) can be expressed within a cell. The presence of an antisense sequence can down-regulate the expression of native T-type calcium channel genes by hybridizing to T-type channel  
35        mRNA within the cell. Thus, the present invention is useful to treating disorders associated with over-expression of T-type calcium channels.

T-type channel proteins (such as whole T-type calcium channels, domains of such channels, chimeras including portions of T-type calcium channels, etc.) can be employed to generate antibodies (e.g., immunoglobulins) to T-type calcium channels. Thus, the present invention provides an isolated and substantially purified antibody molecule recognizing an epitope on a T-type calcium channel. Such antibodies can be monoclonal antibodies or polyclonal antisera. Such antibodies can be produced by any suitable method, many of which are well known in the art. Antibodies recognizing T-type calcium channels can be used to purify the channels from cell extracts or other solutions by standard methodologies (e.g., immunoprecipitation). Moreover, depending on the location of the epitopes for the antibodies on the T-type calcium channel, the antibodies can be used to affect the channel proteins present on the surface of cells. Thus, antibodies directed to T-type calcium channels are potential reagents for studying the channels as well as for therapy.

### EXAMPLES

Several examples are presented below to illustrate the invention. Taken together, the examples demonstrate the cloning of two novel proteins and their characterization as T-type calcium channel  $\alpha$  subunits. These examples are included here for purely illustrative purposes; as such, they are not to be construed so as to limit the scope of any aspect of the invention.

Many procedures employed in the following examples are techniques routinely performed by one of ordinary skill in the art (see generally Sambrook et al., *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1989)) and are not discussed in detail. However, some reagents and methods deserve specific description. Thus, for example, *in vitro* translation and expression were conducted as described previously (Schneider et al., *Receptors and Channels*, 2, 255-70 (1995)). *Xenopus laevis* oocytes were prepared as described previously (Bernal et al., *J. Pharmacol. Exp. Ther.*, 282, 172-80 (1997)). To express proteins, 10 or 30 ng of capped cRNA was injected into the oocytes or NIE-115 cells in a volume of 50 nl. For single channel recording, oocytes were injected with 100 ng capped cRNA and incubated for one week prior to assay.

Cells were voltage clamped using a two-microelectrode voltage clamp amplifier as described (Bernal et al., *J. Pharmacol. Exp. Ther.*, 282, 172-80 (1997)). The standard bath solution contained the following: 40 mM Ba(OH)<sub>2</sub>, 50 mM NaOH, 1 mM KOH, 0.1 mM EDTA, and 5 mM HEPES, adjusted to pH 7.4 with methanesulfonate. The osmolality of the 2 and 10 mM Ba<sup>2+</sup> solutions was balanced by increasing the NaOH concentration as described (Lory et al., *J. Physiol. (London)*, 429, 95-112 (1990)).

Voltage and current electrodes (1.5-1.8 M tip resistance) were filled with 3 M KCl. Except as noted, data were acquired at 4 kHz using the pCLAMP system, and filtered at 1 kHz. Data were analyzed using pCLAMP software. Boltzman fits and linear regression were calculated using Prism.

#### EXAMPLE 1

This example demonstrates the cloning and characterization of two putative T-type calcium channels.

A search of the Genbank library was conducted to identify clones identified as having some degree of homology to calcium channels. The search identified an expressed sequence tagged (EST) partial sequence in a human brain clone (H06096), which was used as a probe to screen a  $\lambda$ gt10 cDNA library prepared from rat brain. Successive screening of the cDNA library identified five overlapping clones which were aligned to construct an entire cDNA sequence, termed  $\alpha$ 1G (representing nucleotides 379-7540 of SEQ ID NO:2).

The  $\alpha$ 1G cDNA was cloned into the pSP72<sup>TM</sup> vector and sequenced by standard computer-assisted sequencing. Using the  $\alpha$ 1G cDNA, the amino acid sequence of the  $\alpha$ 1G protein was deduced (SEQ ID NO:1) and compared to the sequences of other known calcium channel  $\alpha$  subunits. Figure 1 sets forth these sequences and subunits, and it indicates the putative transmembrane domains of the protein. By similar methods, homologous human (H19230 and R19524) and mouse (AA286626) EST clones were also identified and partially sequenced.

A second T-type calcium channel, termed  $\alpha$ 1H, was isolated by screening a human heart cDNA library with a fragment of the  $\alpha$ 1G sequence. The cDNA sequence of  $\alpha$ 1H is set forth at SEQ ID NO:4, and the deduced amino acid sequence is set forth at SEQ ID NO:3. Also, figure 2 sets forth these sequences and indicates the subunits and putative transmembrane domains of the protein.

The  $\alpha$ 1G and  $\alpha$ 1H clones were compared to each other and a known calcium channel ( $\alpha$ 1E) to investigate the conservation of protein structure and function. The comparison indicates that the  $\alpha$ 1G and  $\alpha$ 1H amino acid sequences within the putative membrane-spanning domains are 91% identical to each other, while the  $\alpha$ 1G and  $\alpha$ 1H sequences are only 39% identical to the  $\alpha$ 1E clone. Within the critical IVS4 region, the  $\alpha$ 1G and  $\alpha$ 1H proteins are 100% identical, while each is only 44% identical to the  $\alpha$ 1E clone.

Figure 3 indicates this conservation between the proteins. The conservation of charged residues, particularly in the S4 domains, is consistent with the role of the  $\alpha$ 1G and  $\alpha$ 1H proteins as ion channels. However, two of the glutamates associated with ion

specificity in other calcium channels have been replaced with aspartate, suggesting altered ion selectivity. Strikingly, both  $\alpha 1G$  and  $\alpha 1H$  display only low homology to sequences linking the membrane-spanning regions within each domain, and even less homology between the intracellular loops linking domains. Notably, neither  $\alpha 1G$  nor  $\alpha 1H$  possesses sequences known to bind  $\beta$  subunits or  $Ca^{2+}$  ions.

## EXAMPLE 2

This example demonstrates that the two cloned putative T-type calcium channels exhibit T-type current-voltage relationships.

The  $\alpha 1G$  and  $\alpha 1H$  proteins were produced in *Xenopus laevis* oocytes by linearizing the DNA vectors containing the coding sequences, and translating the coding sequences *in vitro* by standard methods. Oocytes were then injected with the capped RNA as described.

Current traces were elicited by depolarizing voltage clamp pulses of the membranes of cells. Figures 4A-5E depict data obtained from these experiments using cells injected with  $\alpha 1G$  and  $\alpha 1H$  (Figure 4A and 4B, respectively) and  $\alpha 1E$  (Figure 4C), as well as undifferentiated NIE-115 cells (Figure 4D), which exhibit classic T-type calcium current (Shuba et al., *J. Physiol. (London)*, 443, 25-44 (1991)). These data indicate that cells expressing  $\alpha 1G$  and  $\alpha 1H$  (Figure 4A) exhibit T-type calcium current, while oocytes expressing  $\alpha 1E$  (Figure 4C) as well as uninjected oocytes (Figure 6A) do not.

Current voltage curves were developed using cells injected with  $\alpha 1G$ ,  $\alpha 1H$ , and  $\alpha 1E$ , as well as undifferentiated NIE-115 cells. Figure 5A depicts such data generated in a 10 mM  $Ba^{2+}$  test solution. These data were transformed into conductance (Figure 5B) and fit with a Boltzman equation to determine the midpoint of activation ( $V_{0.5}$ ). Both NIE-115 cells and  $\alpha 1G$  currents exhibited low gating potentials ( $-41 \text{ mV} \pm 1 \text{ mV}$ ,  $n=10$  and  $-38 \pm 1 \text{ mV}$ ,  $n=8$ , respectively), while  $\alpha 1E$  required significantly more positive potentials to open ( $-2.6 \text{ mV} \pm .4 \text{ mV}$ ,  $n=3$ ).

To compare the characteristics with published values (Huguenard, *Ann. Rev. Physiol.*, 58, 329-48 (1996)), the  $\alpha 1G$  current was recorded at varying concentrations of  $Ba^{2+}$ . As indicated in Figure 5C, in solutions containing 2 mM  $Ba^{2+}$ ,  $V_{0.5}$  was  $-46.5 \text{ mV}$ , and the slope factor ( $k$ ) was 6.6 ( $n=7$ ). However, when the  $Ba^{2+}$  concentration was 40 mM,  $V_{0.5}$  was recorded at  $-21 \text{ mV}$ , presumably due to the results of barium on surface charge screening (see, e.g., Wilson et al., *J. Membrane Biol.*, 72, 117-30 (1983)). Similar values were recorded for  $\alpha 1H$ .

These results indicate that  $\alpha 1G$  and  $\alpha 1H$  are low-voltage activated calcium channels.

## EXAMPLE 3

This example demonstrates that the cloned putative T-type calcium channels exhibit T-type kinetics.

To measure activation and inactivation kinetics, oocytes injected with  $\alpha 1E$  or  $\alpha 1G$  were pulsed with -20 mV current in 40 mM  $Ba^{2+}$ . Data representing the average of five sweeps recorded at 2 kHz and filtered at 1 kHz are presented in Figure 6A. The time constants for  $\alpha 1G$  inactivation and activation were determined by fitting the data with exponentials. These data are depicted in Figure 6B. These values correspond with the kinetics of the T-type calcium current.

## EXAMPLE 4

This example demonstrates that the cloned putative T-type calcium channels exhibit T-type tail deactivation current.

Tail current was measured by prepulsing the cells expressing  $\alpha 1G$  (oocytes) and  $\alpha 1H$  (HEK 293 cells) at -90 mV followed by periodic pulses at -10 mV or a pulse at -50 mV. The recordings in Figures 7A and 7B indicate that the current elicited at -50 mV follows the current measured at -10 mV. These data confirm that the decline in current is due to inactivation, rather than activation of a contaminating outward current.

The voltage-dependence of tail current was measured at varying test potentials. Data representing such studies are presented in Figures 7C and 7D, respectively. The data were fit with a single exponential and plotted as a function of depolarization potential (Figures 7E and 7F, respectively). These results demonstrate that the tail currents for the two cloned calcium channels,  $\alpha 1G$  and  $\alpha 1H$ , are voltage-dependent, consistent with known T-type calcium tail currents.

## EXAMPLE 5

This example demonstrates that the cloned putative T-type calcium channels exhibit T-type voltage dependent inactivation.

To measure inactivation, oocytes expressing  $\alpha 1G$  or  $\alpha 1E$  were subjected to 200 ms pre-pulses at various potentials followed by a test pulse to -20 mV. The results of these assays are depicted in Figure 8A.

The data for the 200 ms prepulse experiments were averaged and plotted as a function of prepulse potential (Figure 8B,  $n = 2$  or 4), with a control defined as the current measured after a prepulse of -100 mV.

To approximate steady state conditions, similar experiments were conducted using 10 s prepulses. Inactivation of  $\alpha 1G$  occurred as sub-threshold potentials and displayed a

steep voltage dependence ( $V_{0.5} = -50.0 \pm 0.2$  mV,  $k = -3.2 \pm 0.2$ ,  $n=5$ ), while inactivation of cloned  $\alpha 1E$  exhibited more positive potential and weaker voltage dependence ( $V_{0.5} = -30.0 \pm 0.4$  mV,  $k = -9.4 \pm 0.3$ ,  $n=6$ ). These data are depicted in Figure 8C.

## 5 EXAMPLE 6

This example demonstrates that the cloned putative T-type calcium channels exhibit T-type single channel conductance.

Measurement of single channel conductance is a function of the low probability of channel opening at negative potentials when the driving force is large. Thus, single  
10 channel conductance was measured similarly for measurements of tail currents to enhance channel opening at negative potentials. Single channels were measured with standard depolarizing bath and pipette (115 mM BaCl<sub>2</sub>, 1 mM EGTA, and 10 mM HEPES, pH 7.4) solutions (Lacerda et al., *Biophys. J.*, 66, 1833-43 (1994)). Data were analyzed with TRANSIT (VanDongan, *Biophys J.*, 70, 1303-15 (1996)). Single channel amplitudes  
15 were measured by averaging the values obtained from Gaussian fits to all-points histograms of traces with openings, selected openings, or amplitude histograms of idealized openings. It has been reported that some oocytes contain a native 9 pS channel. These endogenous channels can be distinguished by their 2-fold larger current amplitudes at the potentials tested (e.g., -20 mV,  $i = 0.8$  for endogenous channels as opposed to 0.4 pA for  $\alpha 1G$ ). However, such endogenous channels were not detected either at the whole  
20 cell or single channel level in the oocytes tested.

Data were recorded from a patch in oocytes expressing large (>500 nA)  $\alpha 1G$  currents using a 5 ms step to -20 mV followed by repolarization at potentials indicated in Figure 9A. Data were acquired at 10 kHz and filtered at 2 kHz online and again at 1 kHz  
25 off-line. The numbers on the right in Figure 9A indicate the numbers of channels open at any given time.

Current through the main open state of each open channel was measured at each potential and plotted against each test potential. These data are depicted in Figure 9C. Single channel conductance for seven patches were averaged. The average slope  
30 conductance of the  $\alpha 1G$  channel was measured at  $7.5 \pm 1.5$  pS, which corresponds with the reported values for T-type calcium channels (Hugenard, *Ann. Rev. Physiol.*, 58, 329-48 (1996)).

An ensemble current from 100 sweeps at a -40 mV test current was prepared from the idealized data and fit with a single exponential ( $\tau = 8$  ms). This ensemble current is  
35 depicted in Figure 9B. This ensemble current exhibits decay kinetics similar to that observed in the macroscopic current measured above (see Figure 7A).

These results indicate that the cloned  $\alpha 1G$  protein exhibits T-type single-channel conductance.

#### EXAMPLE 7

5 This example demonstrates that a cloned T-type calcium channel can be used for identifying a drug which affects T-type calcium channels.

Cells were subjected to treatment as indicated above in Example 2, except that an experimental group of cells were exposed to a solution containing 100  $\mu M$  mibefradel, a known inhibitor of T-type calcium current. As depicted in Figure 10A, the presence of  
10 mibefradel almost completely abolished T-type current in cells expressing  $\alpha 1G$ . Cells were similarly treated using various concentrations of mibefradel to determine a dose-response relationship. These results, depicted in Figure 10B, demonstrate that 50% inhibition was achieved at a mibefradel concentration of 23  $\mu M$ .

15 All of the references cited herein, including patents, patent applications, and publications, are hereby incorporated in their entireties by reference.

While this invention has been described with an emphasis upon preferred  
embodiments, it will be obvious to those of ordinary skill in the art that variations of the  
20 preferred embodiments may be used and that it is intended that the invention may be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications encompassed within the spirit and scope of the invention as defined by the following claims.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

5

## (i) APPLICANT:

- (A) NAME: Edward Perez-Reyes  
(B) STREET: 2160 S. First Avenue, Building 102, Room 4669  
(C) CITY: Maywood  
(D) STATE: IL  
(E) COUNTRY: US  
(F) POSTAL CODE (ZIP): 60153  
(G) TELEPHONE: (708) 216-6305  
(H) TELEFAX:  
(I) TELEX:

10

15

(ii) TITLE OF INVENTION: P-Type Voltage-  
Gated Calcium Channels and Method of Using  
Same

20

## (iii) NUMBER OF SEQUENCES: 5

## (iv) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPC)

25

30

## (2) INFORMATION FOR SEQ ID NO: 1:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6096 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: unknown

35



(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

5

ATG ACC GAG GGC GCA CGG GCC GCC GAC GAG GTC CGG GTG CCC CTG GGG 48  
 Met Thr Glu Gly Ala Arg Ala Ala Asp Glu Val Arg Val Pro Leu Gly  
 1 5 10 15

10

CGC CGC CCC TGG CCC TGC GGC GTT GGT GGG GGC GTC CCC GGA GAG CCC 96  
 Arg Arg Pro Trp Pro Cys Gly Val Gly Gly Gly Val Pro Gly Glu Pro  
 20 25 30

15

CGG GGC GCC GGG ACG CGA GGC GGA GGG GGG TTC GAG CTC GGC GTG TCA 144  
 Arg Gly Ala Gly Thr Arg Gly Gly Gly Gly Phe Glu Leu Gly Val Ser  
 35 40 45

20

CCC TCC GAG AGC CCG GCG GCC GAG CGC TGC GCG GAG CTG GGT GCC GAC 192  
 Pro Ser Glu Ser Pro Ala Ala Glu Arg Cys Ala Glu Leu Gly Ala Asp  
 50 55 60

25

GAG GAG CAG CGC GTC CCG TAC CCG GCC TTG GCG GCC ACG GTC TTC TTC 240  
 Glu Glu Gln Arg Val Pro Tyr Pro Ala Leu Ala Ala Thr Val Phe Phe  
 65 70 75 80

30

TGC CTC GGT CAG ACC ACG CGG CCG CGC AGC TGG TCC GTC CGG CTG GTC 288  
 Cys Leu Gly Gln Thr Thr Arg Pro Arg Ser Trp Ser Val Arg Leu Val  
 85 90 95

35

TGC AAC CCA TGG TTC GAG CAC GTG AGC ATG CTG GTA ATC ATG CTC AAC 336  
 Cys Asn Pro Trp Phe Glu His Val Ser Met Leu Val Ile Met Leu Asn  
 100 105 110

TGC GTG ACC CTG GGC ATG TTC CGG CCC TGT GAG GAC GTT GAG TGC GGC 384  
 Cys Val Thr Leu Gly Met Phe Arg Pro Cys Glu Asp Val Glu Cys Gly  
 115 120 125

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

	TCC GAG CGC TGC AAC ATC CTG GAG GCC TTT GAC GCC TTC ATT TTC GCC	432
	Ser Glu Arg Cys Asn Ile Leu Glu Ala Phe Asp Ala Phe Ile Phe Ala	
	130 135 140	
5	TTT TTT GCG GTG GAG ATG GTC ATC AAG ATG GTG GCC TTG GGG CTG TTC	480
	Phe Phe Ala Val Glu Met Val Ile Lys Met Val Ala Leu Gly Leu Phe	
	145 150 155 160	
10	GGG CAG AAG TGT TAC CTG GGT GAC ACG TGG AAC AGG CTG GAT TTC TTC	528
	Gly Gln Lys Cys Tyr Leu Gly Asp Thr Trp Asn Arg Leu Asp Phe Phe	
	165 170 175	
15	ATC GTC GTG GCG GGC ATG ATG GAG TAC TCG TTG GAC GGA CAC AAC GTG	576
	Ile Val Val Ala Gly Met Met Glu Tyr Ser Leu Asp Gly His Asn Val	
	180 185 190	
20	AGC CTC TCG GCT ATC AGG ACC GTG CGG GTG CTG CGG CCC CTC CGC GCC	624
	Ser Leu Ser Ala Ile Arg Thr Val Arg Val Leu Arg Pro Leu Arg Ala	
	195 200 205	
25	ATC AAC CGC GTG CCT AGC ATG CGG ATC CTG GTC ACT CTG CTG CTG GAT	672
	Ile Asn Arg Val Pro Ser Met Arg Ile Leu Val Thr Leu Leu Leu Asp	
	210 215 220	
30	ACG CTG CCC ATG CTC GGG AAC GTC CTT CTG CTG TGC TTC TTC GTC TTC	720
	Thr Leu Pro Met Leu Gly Asn Val Leu Leu Leu Cys Phe Phe Val Phe	
	225 230 235 240	
35	TTC ATT TTC GGC ATC GTT GGC GTC CAG CTC TGG GCT GGC CTC CTG CGG	768
	Phe Ile Phe Gly Ile Val Gly Val Gln Leu Trp Ala Gly Leu Leu Arg	
	245 250 255	
40	AAC CGC TGC TTC CTG GAC AGT GCC TTT GTC AGG AAC AAC AAC CTG ACC	816
	Asn Arg Cys Phe Leu Asp Ser Ala Phe Val Arg Asn Asn Asn Leu Thr	
	260 265 270	
45	TTC CTG CGG CCG TAC TAC CAG ACG GAG GAG GGC GAG GAG AAC CCG TTC	864

5

10

15

20

25

30

35

CTC	ATC	ATC	GTG	GGC	TCC	TTC	TTC	ATG	ATC	AAC	CTG	TGC	CTG	GTG	GTG	1248
Leu	Ile	Ile	Val	Gly	Ser	Phe	Phe	Met	Ile	Asn	Leu	Cys	Leu	Val	Val	
				405				410						415		

ATT GCC ACG CAG TTC TCG GAG ACG AAG CAG CGG GAG AGT CAG CTG ATG 1296  
Ile Ala Thr Gln Phe Ser Glu Thr Lys Gln Arg Glu Ser Gln Leu Met

30

420	425	430	
CGG GAG CAG CGG GCA CGC CAC CTG TCC AAC GAC AGC ACG CTG GCC AGC			1344
Arg Glu Gln Arg Ala Arg His Leu Ser Asn Asp Ser Thr Leu Ala Ser			
435	440	445	
TTC TCC GAG CCT GGC AGC TGC TAC GAA GAG CTG CTG AAG TAC GTG GGC			1392
Phe Ser Glu Pro Gly Ser Cys Tyr Glu Glu Leu Leu Lys Tyr Val Gly			
450	455	460	
CAC ATA TTC CGC AAG GTC AAG CGG CAG CTT GCG CCT CTA CGC CCG CTG			1440
His Ile Phe Arg Lys Val Lys Arg Gln Leu Ala Pro Leu Arg Pro Leu			
465	470	475	480
GCA GAG CCG TGG CGC AAG AAG GTG GAC CCC AGT GCT GTG CAA GGC CAG			1488
Ala Glu Pro Trp Arg Lys Lys Val Asp Pro Ser Ala Val Gln Gly Gln			
485	490	495	
GGT CCC GGG CAC CGC CAG CGC CGG GCA GGC AGG CAC ACA GCC TCG GTG			1536
Gly Pro Gly His Arg Gln Arg Arg Ala Gly Arg His Thr Ala Ser Val			
500	505	510	
CAC CAC CTG GTC TAC CAC CAC CAT CAC CAC CAC CAC CAC CAC TAC CAT			1584
His His Leu Val Tyr His His His His His His His His His Tyr His			
515	520	525	
TTC AGC CAT GGC AGC CCC CGC AGG CCC GGC CCC GAG CCA GGC GCC TGC			1632
Phe Ser His Gly Ser Pro Arg Arg Pro Gly Pro Glu Pro Gly Ala Cys			
530	535	540	
GAC ACC AGG CTG GTC CGA GCT GGC GCG CCC CCC TCG CCA CCT TCC CCA			1680
Asp Thr Arg Leu Val Arg Ala Gly Ala Pro Pro Ser Pro Pro Ser Pro			
545	550	555	560
GGC CGC GGA CCC CCC GAC GCA GAG TCT GTG CAC AGC ATC TAC CAT GCC			1728
Gly Arg Gly Pro Pro Asp Ala Glu Ser Val His Ser Ile Tyr His Ala			
565	570	575	

	GAC TGC CAC ATA GAG GGG CCG CAG GAG AGG GCC CGG GTG GGC ACA TGC	1776
	Asp Cys His Ile Glu Gly Pro Gln Glu Arg Ala Arg Val Gly Thr Cys	
	580 585 590	
5		
	CGC AGC CAC TGC CGC TGC CAG CCT CAG GCT GGC CAC AGG GCT GGG CAC	1824
	Arg Ser His Cys Arg Cys Gln Pro Gln Ala Gly His Arg Ala Gly His	
	595 600 605	
10		
	CAT GAA CTA CCC CAC GAT CCT GCC CTC AGG GGT GGG CAG CGG CAA AGG	1872
	His Glu Leu Pro His Asp Pro Ala Leu Arg Gly Gly Gln Arg Gln Arg	
	610 615 620	
15		
	CAG CAC CAG CCC CGG ACC CAA GGG GAA GTG GGC CGG TGG ACC GCC AGG	1920
	Gln His Gln Pro Arg Thr Gln Gly Glu Val Gly Arg Trp Thr Ala Arg	
	625 630 635 640	
20		
	CAC CGG GGG CAC GGC CCG TTG AGC TTG AAC AGC CCT GAT CCC TAC GAG	1968
	His Arg Gly His Gly Pro Leu Ser Leu Asn Ser Pro Asp Pro Tyr Glu	
	645 650 655	
25		
	AAG ATC CCG CAT GTG GCC GGG GAG CAT GGA CTG GCC AGC CCT GGC CAT	2016
	Lys Ile Pro His Val Ala Gly Glu His Gly Leu Ala Ser Pro Gly His	
	660 665 670	
30		
	CTG TCG GGC CTC AGT GTG CCC TGC CCC CTG CCC AGC CCC CCA GCG GGC	2064
	Leu Ser Gly Leu Ser Val Pro Cys Pro Leu Pro Ser Pro Pro Ala Gly	
	675 680 685	
35		
	ACA CTG ACC TGT GAG CTG AAG AGC TGC CCG TAC TGC ACC CGT GCC CTG	2112
	Thr Leu Thr Cys Glu Leu Lys Ser Cys Pro Tyr Cys Thr Arg Ala Leu	
	690 695 700	
	GAG GAC CCG GAG GGT GAG CTC AGC GGC TCG GAA AGT GGA GAC TCA GAT	2160
	Glu Asp Pro Glu Gly Glu Leu Ser Gly Ser Glu Ser Gly Asp Ser Asp	
	705 710 715 720	

**THE**

725                      730                      735

740                      745                      750

755                      760                      765

770                      775                      780

785                      790                      795                      800

805 810 815

820 825 830

835                      840                      845

850                      855                      860

2640

15  
20

35

GCC ATC CTC GTG GAG GGC TTC CAG GCG GAG GGC GAT GCC AAC AGA TCC 3072  
Ala Ile Leu Val Glu Gly Phe Gln Ala Glu Gly Asp Ala Asn Arg Ser

	1010	1015	1020	
	GAC ACG GAC GAG GAC AAG ACG TCG GTC CAC TTC GAG GAG GAC TTC CAC			3120
	Asp Thr Asp Glu Asp Lys Thr Ser Val His Phe Glu Glu Asp Phe His			
5	1025	1030	1035	1040
	AAG CTC AGA GAA CTC CAG ACC ACA GAG CTG AAG ATG TGT TCC CTG GCC			3168
	Lys Leu Arg Glu Leu Gln Thr Thr Glu Leu Lys Met Cys Ser Leu Ala			
	1045	1050	1055	
10	GTG ACC CCC AAC GGC ACC TGG AGG GAC GAG GCA GCC TGT CCC CTC CCC			3216
	Val Thr Pro Asn Gly Thr Trp Arg Asp Glu Ala Ala Cys Pro Leu Pro			
	1060	1065	1070	
15	TCA TCA TGT GCA CAG CTG CCA CGC CCA TGC CTA CCC CCA AGA GCT CAC			3264
	Ser Ser Cys Ala Gln Leu Pro Arg Pro Cys Leu Pro Pro Arg Ala His			
	1075	1080	1085	
	CAT TCC TGG ATG CAG CCC CCA GCC TCC CAG ACT CTC GGC GTG GCA GCA			3312
	His Ser Trp Met Gln Pro Pro Ala Ser Gln Thr Leu Gly Val Ala Ala			
20	1090	1095	1100	
	GCA GCT CCG GGG ACC CGC CAC TGG GAG ACC AGA AGC CTC CGG CAG CCT			3360
	Ala Ala Pro Gly Thr Arg His Trp Glu Thr Arg Ser Leu Arg Gln Pro			
25	1105	1110	1115	1120
	CCG AAG TTC TCC CTG TGC CCC CTG GGG CCC AGT GGC GCC TGG AGC AGC			3408
	Pro Lys Phe Ser Leu Cys Pro Leu Gly Pro Ser Gly Ala Trp Ser Ser			
	1125	1130	1135	
30	CGG CGC TCC AGC TGG AGC AGC CTG GGC CGT GCC CAG CCT CAA GCG CCG			3456
	Arg Arg Ser Ser Trp Ser Ser Leu Gly Arg Ala Gln Pro Gln Ala Pro			
	1140	1145	1150	
35	GCG TGC CAG TGT GGG GAA CGT GAG TCC CTG CTG TCT GGC GAG GGC AAG			3504
	Ala Cys Gln Cys Gly Glu Arg Glu Ser Leu Leu Ser Gly Glu Gly Lys			
	1155	1160	1165	



5	GGC AGC ACC GAC GAC GAA GCT GAG GAC GGC AGG GCG CGC TCC GGG CCC	3552
	Gly Ser Thr Asp Asp Glu Ala Glu Asp Gly Arg Ala Arg Ser Gly Pro	
	1170 1175 1180	
	CGT GCC ACC CCA CTG CGG CGG GCC GAG TCC CTG GAC CCA CGG CCC CTG	3600
	Arg Ala Thr Pro Leu Arg Arg Ala Glu Ser Leu Asp Pro Arg Pro Leu	
10	1185 1190 1195 1200	
	CGG CGG CCG CCT CCC GCC TAC CAA GTG CGC GAT CGC GAC GGG CAG GTG	3648
	Arg Arg Pro Pro Pro Ala Tyr Gln Val Arg Asp Arg Asp Gly Gln Val	
	1205 1210 1215	
	GTG GCC CTG CCC AGC GAC TTC TTC CTG CGC ATC GAC AGC CAC CGT GAG	3696
15	Val Ala Leu Pro Ser Asp Phe Phe Leu Arg Ile Asp Ser His Arg Glu	
	1220 1225 1230	
	GAT GCA GCC GAG CTT GAC GAC GAC TCG GAG GAC AGC TGC TGC CTC CGC	3744
	Asp Ala Ala Glu Leu Asp Asp Asp Ser Glu Asp Ser Cys Cys Leu Arg	
	1235 1240 1245	
20	CTG CAT AAA GTG CTG GTG CCC TAC AAG CCC CAG CGG TGC CGG AGC AGG	3792
	Leu His Lys Val Leu Val Pro Tyr Lys Pro Gln Arg Cys Arg Ser Arg	
	1250 1255 1260	
	AGG CCT GGG CCC TCT ACC CTC TAC CTC TTC TCC CCA CAG AAC CGG TTC	3840
	Arg Pro Gly Pro Ser Thr Leu Tyr Leu Phe Ser Pro Gln Asn Arg Phe	
25	1265 1270 1275 1280	
	CGC GTC TCC TGC CAG AAG GTC ATC ACA CAC AAG ATG TTT GAT CAC GTG	3888
	Arg Val Ser Cys Gln Lys Val Ile Thr His Lys Met Phe Asp His Val	
	1285 1290 1295	
	GTC CTC GTC TTC ATC TTC CTC AAC TGC GTC ACC ATC GCC CTG GAG AGG	3936
30	Val Leu Val Phe Ile Phe Leu Asn Cys Val Thr Ile Ala Leu Glu Arg	
	1300 1305 1310	
35		

	CCT GAC ATT GAT CCC GGC AGC ACC GAG CGG GTC TTC CTC AGC GTC TCC	3984
	Pro Asp Ile Asp Pro Gly Ser Thr Glu Arg Val Phe Leu Ser Val Ser	
	1315 1320 1325	
5	AAT TAC ATC TTC ACG GCC ATC TTC GTG GCG GAG ATG ATG GTG AAG GTG	4032
	Asn Tyr Ile Phe Thr Ala Ile Phe Val Ala Glu Met Met Val Lys Val	
	1330 1335 1340	
10	GTG GCC CTG GGG CTG CTG TCC GGC GAG CAC GCC TAC CTG CAG AGC AGC	4080
	Val Ala Leu Gly Leu Leu Ser Gly Glu His Ala Tyr Leu Gln Ser Ser	
	1345 1350 1355 1360	
15	TGG AAC CTG CTG GAT GGG CTG CTG GTG CTG GTG TCC CTG GTG GAC ATT	4128
	Trp Asn Leu Leu Asp Gly Leu Leu Val Leu Val Ser Leu Val Asp Ile	
	1365 1370 1375	
20	GTC GTG GCC ATG GCC TCG GCT GGT GGC GCC AAG ATC CTG GGT GTT CTG	4176
	Val Val Ala Met Ala Ser Ala Gly Gly Ala Lys Ile Leu Gly Val Leu	
	1380 1385 1390	
25	CGC GTG CTG CGT CTG CTG CGG ACC CTG CGG CCT CTG AGG GTC ATC AGC	4224
	Arg Val Leu Arg Leu Leu Arg Thr Leu Arg Pro Leu Arg Val Ile Ser	
	1395 1400 1405	
30	CGG CCC CGG CTC AAG CTG GTG GTG GAG ACG CTG ATA TCA TCA CTC AGG	4272
	Arg Pro Arg Leu Lys Leu Val Val Glu Thr Leu Ile Ser Ser Leu Arg	
	1410 1415 1420	
35	CCC ATT GGG AAC ATC GTC CTC ATC TGC TGC GCC TCC TTC ATC ATT TTT	4320
	Pro Ile Gly Asn Ile Val Leu Ile Cys Cys Ala Phe Phe Ile Ile Phe	
	1425 1430 1435 1440	
40	GGC ATT TTG GGT GTG CAG CTC TTC AAA GGG AAG TTC TAC TAC TGC GAG	4368
	Gly Ile Leu Gly Val Gln Leu Phe Lys Gly Lys Phe Tyr Tyr Cys Glu	
	1445 1450 1455	
45	GGC CCC GAC ACC AGG AAC ATC TCC ACC AAG GCA CAG TGC CGG GCC GCC	4416

Gly Pro Asp Thr Arg Asn Ile Ser Thr Lys Ala Gln Cys Arg Ala Ala

1460

1465

1470

CAC TAC CGC TGG GTG CGA CGC AAG TAC AAC TTC GAC AAC CTG GGC CAG

4464

5

His Tyr Arg Trp Val Arg Arg Lys Tyr Asn Phe Asp Asn Leu Gly Gln

1475

1480

1485

GCC CTG ATG TCG CTG TTC GTG CTG TCA TCC AAG GAT GGA TGG GTG AAC

4512

10

Ala Leu Met Ser Leu Phe Val Leu Ser Ser Lys Asp Gly Trp Val Asn

1490

1495

1500

ATC ATG TAC GAC GGG CTG GAT GCC GTG GGT GTC GAC CAG CAG CCT GTG

4560

Ile Met Tyr Asp Gly Leu Asp Ala Val Gly Val Asp Gln Gln Pro Val

1505

1510

1515

1520

15

CAG AAC CAC AAC CCC TGG ATG CTG CTG TAC TTC ATC TCC TTC CTC TGC

4608

Gln Asn His Asn Pro Trp Met Leu Leu Tyr Phe Ile Ser Phe Leu Cys

1525

1530

1535

20

TAC ATC GTC AGC TTC TTC GTG CTC AAC ATG TTC GTG GGC GTC GTG GTC

4656

Tyr Ile Val Ser Phe Phe Val Leu Asn Met Phe Val Gly Val Val Val

1540

1545

1550

25

GAG AAC TTC CAC AAG TGC CGG CCG CAC CAG GAG GCG GAG GAG GCG CGG

4704

Glu Asn Phe His Lys Cys Arg Pro His Gln Glu Ala Glu Glu Ala Arg

1555

1560

1565

30

CGG CGA GAG GAG AAG CGG CTG CGG CGC CTA GAG AGG AGG CGC AGG AGC

4752

Arg Arg Glu Glu Lys Arg Leu Arg Arg Leu Glu Arg Arg Arg Arg Ser

1570

1575

1580

ACT TTC CCC AGC CCA GAG GCC CAG CGC CGG CCC TAC TAT GCC GAC TAC

4800

Thr Phe Pro Ser Pro Glu Ala Gln Arg Arg Pro Tyr Tyr Ala Asp Tyr

1585

1590

1595

1600

35

TCG CCC ACG CGC CGC CGC TCC ATT CAC TCG CTG TGC ACC AGC CAC TAT

4848

Ser Pro Thr Arg Arg Arg Ser Ile His Ser Leu Cys Thr Ser His Tyr

1505 1510 1515 1520 1525 1530 1535 1540 1545 1550 1555 1560 1565 1570 1575 1580 1585 1590 1595 1600

5

10

15

20

25

30

35

ATG GCT ACG GGC ATG CGC GCC CTG CTG GAC ACT GTG GTG CAA GCT CTC 5232  
Met Ala Thr Gly Met Arg Ala Leu Leu Asp Thr Val Val Gln Ala Leu  
1730 1735 1740

CCC CAG GTG GGG AAC CTG GGC CTT CTT TTC ATG CTC CTG TTT TTT ATC 5280  
Pro Gln Val Gly Asn Leu Gly Leu Leu Phe Met Leu Leu Phe Phe Ile  
1745 1750 1755 1760

35

GCA CGC CGG GTG GAC GCG GAC AGG CCT CCC TTG CCC CAG GAG AGT CCG 571  
Ala Arg Arg Val Asp Ala Asp Arg Pro Pro Leu Pro Gln Glu Ser Pro  
1890 1895 1900

	GCG CCA GGG ACG CCC CAA ACC TGG TTG CAC GCA AGG TGT CCG TGT CCA	5760
	Ala Pro Gly Thr Pro Gln Thr Trp Leu His Ala Arg Cys Pro Cys Pro	
	1905 1910 1915 1920	
5	GGA TCT CTC GCT GCC CAA CGA CAG CTA CAT GTT CAG GCC CGT GGT GCC	5808
	Gly Ser Leu Ala Ala Gln Arg Gln Leu His Val Gln Ala Arg Gly Ala	
	1925 1930 1935	
10	TGC CTC GGC GCC CCG GGC CCG CCC GCT GCA GGA GGT GGA GAT GGA GAC	5856
	Cys Leu Gly Ala Pro Gly Pro Pro Ala Ala Gly Gly Gly Asp Gly Asp	
	1940 1945 1950	
15	CTA TGG GGC CGG CAC CCC CTT GGA GTC CTG TGC CAT CCC ATC CAG ATC	5904
	Leu Trp Gly Arg His Pro Leu Gly Val Leu Cys His Pro Ile Gln Ile	
	1955 1960 1965	
20	CCA TTG GCT GTG TCG AAC CCA GCC AGG AGC GGC GAG CCC CTC CAC GCC	5952
	Pro Leu Ala Val Ser Asn Pro Ala Arg Ser Gly Glu Pro Leu His Ala	
	1970 1975 1980	
25	CTG TCC CCT CGG GGC ACA GCC GCT CCC CCA GTC TCA GCC GGC TGC TCT	6000
	Leu Ser Pro Arg Gly Thr Ala Ala Pro Pro Val Ser Ala Gly Cys Ser	
	1985 1990 1995 2000	
30	GCA GAC AGG AGG CTG TGC ACA CCG ATT CCT TGG AAG GGA AGA TTG ACA	6048
	Ala Asp Arg Arg Leu Cys Thr Pro Ile Pro Trp Lys Gly Arg Leu Thr	
	2005 2010 2015	
35	GCC CTA GGG ACA CCC TGG ATC CTG CAG AGC CTG GTG AGA AAC CCC CGG	6096
	Ala Leu Gly Thr Pro Trp Ile Leu Gln Ser Leu Val Arg Asn Pro Arg	
	2020 2025 2030	

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 7720 base pairs

(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: unknown

5 (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

10 GCGGGTGACC GCGCCGCCCG GCGATGCCCC CGGGGACGCC GCCGGCCAGC AGAGCAGGTG 60  
CTGCCGGCCG CCACCATGAC CGAGGGCGCA CGGGCCGCCG ACGAGGTCCG GGTGCCCTG 120  
15 GGGCGCCGCC CCTGGCCCTG CGGCGTTGGT GGGGGCGTCC CCGGAGAGCC CCGGGGCGCC 180  
GGGACGCGAG GCGGAGGGGG GTTCGAGCTC GGCCTGTAC CCTCCGAGAG CCCGGCGGCC 240  
GAGCGCTGCG CGGAGCTGGG TGCCGACGAG GAGCAGCGCG TCCCGTACCC GGCCTTGGCG 300  
20 GCCACGGTCT TCTTCTGCCT CGGTCAGACC ACGCGGCCGC GCAGCTGGTC CGTCCGGCTG 360  
GTCTGCAACC CATGGTTCGA GCACGTGAGC ATGCTGGTAA TCATGCTCAA CTGCGTGACC 420  
CTGGGCATGT TCCGGCCCTG TGAGGACGTT GAGTGGGCT CCGAGCGCTG CAACATCCTG 480  
25 GAGGCCTTTG ACGCCTTCAT TTECGCTTT TTTGCGGTGG AGATGGTCAT CAAGATGGTG 540  
GCCTTGGGGC TGTTGCGGCA GAAGTGTTAC CTGGGTGACA CGTGGAACAG GCTGGATTTC 600  
30 TTCATCGTCG TGGCGGGCAT GATGGAGTAC TCGTTGGACG GACACAACGT GAGCCTCTCG 660  
GCTATCAGGA CCGTGCGGGT GCTGCGGCCC CTCGCGCCA TCAACCGCGT GCCTAGCATG 720  
CGGATCCTGG TCACTCTGCT GCTGGATACG CTGCCCATGC TCGGGAACGT CCTTCTGCTG 780  
35 TGCTTCTTCG TCTTCTTCAT TTTCGGCATC GTTGGCGTCC AGCTCTGGGC TGGCCTCCTG 840

CGGAACCGCT GCTTCCTGGA CAGTGCCTTT GTCAGGAACA ACAACCTGAC CTTCTGCGG 900

CCGTACTACC AGACGGAGGA GGGCGAGGAG AACCCGTTCA TCTGCTCCTC ACGCCGAGAC 960

5 AACGGCATGC AGAAGTGCTC GCACATCCCC GGCCGCCGCG ACGTGCGCAT GCCCTGCACC 1020

CTGGGCTGGG AGGCCTACAC GCAGCCGAG GCGAGGGGG TGGGCGCTGC ACGCAACGCC 1080

TGCATCAACT GGAACCAGTA CTACAACGTG TGCCGCTCGG GTGACTCAA CCCCCACAAC 1140

10 GGTGCCATCA ACTTCGACAA CACCTGCTAC GCCTGGATTG CCATCTTCCA GGTGATCAG 1200

CTGGAAGGCT GGGTGGACAT CATGTACTAC GTCATGGAG CCCACTCATT CTACAACTTC 1260

15 ATCTATTICA TCCTGCTCAT CATCGTGGGC TCCTTCTTCA TGATCAACCT GTGCCTGGTG 1320

GTGATTGCCA CGCAGTTCTC GGAGACGAAG CAGCGGGAGA GTCAGCTGAT GCGGGAGCAG 1380

CGGGCAGCC ACCTGTCAA CGACAGCAG CTGGCCAGCT TCTCCGAGCC TGGCAGCTGC 1440

20 TACGAAGAGC TGCTGAAGTA CGTGGGCCAC ATATTCCGCA AGGTCAAGCG GCAGCTTGCG 1500

CCTCTACGCC CGCTGGCAGA GCCGTGGCGC AAGAAGGTGG ACCCCAGTGC TGTGCAAGGC 1560

25 CAGGGTCCCG GGCACGCCA GCGCCGGGA GGCAGGCACA CAGCCTCGGT GCACCACCTG 1620

GTCTACCACC ACCATACCA CCACCACCAC CACTACCATT TCAGCCATGG CAGCCCCCGC 1680

AGGCCCCGCC CCGAGCCAGG CGCCTGCGAC ACCAGGCTGG TCCGAGCTGG CGCGCCCCC 1740

30 TCGCCACCTT CCCCAGGCCG CGGACCCCC GACGCAGAGT CTGTGCACAG CATCTACCAT 1800

GCCGACTGCC ACATAGAGG GCCGCAGGAG AGGGCCCCGG TGGGCACATG CCGCAGCCAC 1860

35 TGCCGCTGCC AGCCTCAGGC TGGCCACAGG GCTGGGCACC ATGAACTACC CCACGATCCT 1920

GCCCTCAGGG GTGGGCAGCG GCAAAGGCAG CACCAGCCCC GGACCCAAGG GGAAGTGGGC 1980



35

ATGACCTTCG GCAACTATGT GCTCTTCAAC CTGCTGGTGG CCATCCTCGT GGAGGGCTTC 3120

CAGGCGGAGG GCGATGCCAA CAGATCCGAC ACGGACGAGG ACAAGACGTC GGTCCACTTC 3180

5 GAGGAGGACT TCCACAAGCT CAGAGAACTC CAGACCACAG AGCTGAAGAT GTGTTCCCTG 3240

GCCGTGACCC CCAACGGCAC CTGGAGGGAC GAGGCAGCCT GTCCCTCCC CTCATCATGT 3300

10 GCACAGCTGC CACGCCCATG CCTACCCCCA AGAGCTCACC ATTCTGGAT GCAGCCCCCA 3360

GCCTCCAGA CTCTCGCGT GGCAGCAGCA GCTCCGGGA CCGCCACTG GGAGACCAGA 3420

AGCCTCCGGC AGCCTCCGAA GTTCTCCCTG TGCCCCCTGG GGGCCAGTG CGCCTGGAGC 3480

15 AGCCGGCGCT CCAGCTGGAG CAGCCTGGGC CGTGCCAGC CTCAAGCGCC GGCGTGCCAG 3540

TGTGGGAAC GTGAGTCCCT GCTGTCTGGC GAGGGCAAGG GCAGACCGA CGACGAAGCT 3600

GAGGACGGCA GGGCGCGCTC CGGGCCCCGT GCCACCCAC TCGGCGGGC CGAGTCCCTG 3660

20 GACCCACGGC CCCTGCGGCG GCGCCTCCC GCCTACCAAG TCGCGATCG CGACGGGCAG 3720

GTGGTGGCC TGCCAGCGA CTTCTCCTG CGCATCGACA GCCACCGTGA GGATGCAGCC 3780

25 GAGCTTGACG ACGACTCGGA GGACAGCTGC TGCTCCGCC TGCATAAAGT GCTGGTGGCC 3840

TACAAGCCCC AGCGGTGCCG GAGCAGGAGG CCTGGGCCCCT CTACCTCTA CCTCTTCTCC 3900

CCACAGAACC GGTCCGCGT CTCCTGCCAG AAGTCATCA CACACAAGAT GTTTGATCAC 3960

30 GTGGTCCTCG TCTTCATCTT CCTCAACTGC GTCACCATCG CCCTGGAGAG GCCTGACATT 4020

GATCCCGGCA GCACCGAGCG GGTCTTCCTC AGCGTCTCCA ATTACATCTT CACGGCCATC 4080

35 TTCGTGGCGG AGATGATGGT GAAGGTGGTG GCCCTGGGGC TGCTGTCCGG CGAGCACGCC 4140

TACCTGCAGA GCAGCTGGAA CCTGCTGGAT GGGCTGCTGG TGCTGGTGTG CCTGGTGGAC 4200

ATTGTCGTGG CCATGGCCTC GGCTGGTGGC GCCAAGATCC TGGGTGTTCT GCGCGTGCTG	4260
CGTCTGCTGC GGACCCCTGCG GCCTCTGAGG GTCATCAGCC GGCCCCGGCT CAAGCTGGTG	4320
GTGGAGACGC TGATATCATC ACTCAGGCCC ATTGGGAACA TCGTCCTCAT CTGCTGCGCC	4380
TTCTTCATCA TTTTGGCAT TTTGGGTGTG CAGCTCTTCA AAGGGAAGTT CTACTACTGC	4440
GAGGGCCCCG ACACCAGGAA CATCTCCACC AAGGCACAGT GCCGGGCGCG CCACTACCGC	4500
TGGGTGCGAC GCAAGTACAA CTTGACAAC CTGGGCCAGG CCCTGATGTC GCTGTTCGTG	4560
CTCTCATCCA AGGATGGATG GGTGAACATC ATGTACGACG GGCTGGATGC CGTGGGTGTC	4620
GACCAGCAGC CTGTGCAGAA CCACAACCCC TGGATGCTGC TGTACTTCAT CTCCTTCCTC	4680
TGCTACATCG TCAGCTTCTT CGTGCTCAAC ATGTTCTGTT GCGTCGTGGT CGAGAACTTC	4740
CACAAGTGCC GGCCGCACCA GGAGGCGGAG GAGGCGCGGC GCGGAGAGGA GAAGCGGCTG	4800
CGGCGCCTAG AGAGGAGGCG CAGGAGCACT TCCCCAGCC CAGAGGCCCA GCGCCGGCCC	4860
TACTATGCCG ACTACTCGCC CACGCGCCGC CGCTCCATTC ACTCGCTGTG CACCAGCCAC	4920
TATCTCGACC TCTTCATCAC CTTCATCATC TGTGTCAACG TCATCACCAT GTCCATGGAG	4980
CACTATAACC AACCCAAGTC GCTGGACGAG GCCCTCAAGT ACTGCAACTA CGTCTTCACC	5040
ATCGTGTTTG TCTTCGAGGC TGCCTGAAG CTGGTAGCAT TTGGGTTCGG TCGGTTCTTC	5100
AAGGACAGGT GGAACCAGCT GGACCTGGCC ATCGTGCTGC TGTCATCAT GGGCATCAGC	5160
CTGGAGGAGA TAGAGATGAG CGCCGCGCTG CCCATCAACC CCACCATCAT CCGCATCATG	5220
CGCGTGCTTC GCATTGCCCG TGTGCTGAAG CTGCTGAAGA TGGCTACGGG CATGCGCGCC	5280

CTGCTGGACA CTGTGGTGCA AGCTCTCCCC CAGGTGGGGA ACCTGGGCCT TCTTTTCATG 5340

CTCCTGTTTT TTATCTATCT GAGATTGGGA GTGGAGCTGT TCGGGAGGCT GGAGTGCAGT 5400

5 GAAGACAACC CCTGCGAGGG CCTGAGCAGG CACGCCACCT TCAGCAACTT CGGCATGGCC 5460

TTCTCAGCGC TGTTCCGCGT GTCCACGGGG GACAACTGGA ACGGGATCAT GAAGGACACG 5520

CTGCGCGAGT GCTCCCGTGA GGACAAGCAC TSCCTGAGCT ACCTGCCGGC CCCGTCGCCC 5580

10 GTCTACTTCG TGACCTTCGT GCTGGTGCCC CAGTTCGTGC TGGTGAACGT GGTGGTGGCC 5640

GTGCTCATGA AGCACCTGGA GGAGAGCAAC AAGGAGGCTC GGGAGGATCC GGAGCTGGAC 5700

15 GCCGAGATCG AGCTGGAGAT GGCGCAGGGC CCCGGGAGTG CACGCCGGGT GGACGCGGAC 5760

AGGCCTCCCT TGCCCCAGGA GAGTCCGGCG CCAGGGACGC CCCAACCTG GTTGCACGCA 5820

AGGTGTCCGT GTCCAGGATC TCTCGCTGCC CAACGACAGC TACATGTTCA GGCCCGTGGT 5880

20 GCCTGCCTCG GCGCCCCGGG CCCGCCGCT GCAGGAGGTG GAGATGGAGA CCIATGGGGC 5940

CGGCACCCCC TTGGAGTCCT GTGCCATCCC ATCCAGATCC CATTGGCTGT GTCGAACCCA 6000

25 GCCAGGAGCG GCGAGCCCCT CCACGCCCTG TCCCCTCGGG GCACAGCCGC TCCCCAGTC 6060

TCAGCCGGCT GCTCTGCAGA CAGGAGGCTG TGCACACCGA TTCCTTGAA GGAAGATTG 6120

ACAGCCCTAG GGACACCCTG GATCCTGCAG AGCCTGGTGA GAAACCCCG GTGAGGCCGG 6180

30 TGACCCAGGG GGGCTCCCTG CAGTCCCCAC CACGCTCCCC ACGGCCCGCC AGCGTCCGCA 6240

CTCGTAAGCA TACCTTCGGA CAGCGCTGCG TCTCCAGCCG GCCGGCGGCC CCAGGCGGAG 6300

35 AGGAGGCCGA GGCCTCGGAC CCAGCCGACG AGGAGGTCAG CCACATCACC AGCTCCGCCT 6360

GCCCCTGGCA GCCACAGCC GAGCCCCATG GCCCCGAAGC CTCTCCGGTG GCCGGCGGCG 6420

205500-1050

5

10

15

20

25

30

35

AGCGGGACCT GCGCAGGCTC TACAGCGTGG ATGCTCAGGG CTCCTGGAC AAGCCGGGCC 6480

GGGCAGACGA GCAGTGGCTG CCCTCGGGGA GTGGGCAGCG GGGAGCCTGG GGAGGCGAAG 6540

GCCTGGGGCC TGAGGCGAG CCCGCTCTGG GTGCGCGCAG AAAGAAGAAG ATGAGCCCCC 6600

CCTGCATCTC GGTGGAACCC CCTGCGGAGG ACGAGGGCTC TCGCGGGCCC TCCGCGGCAG 6660

AGGGCGGCAG ACCACACTGA GGCTCAGGAC CCCGTCCTGT GAGGCCACGC CTCACAGGGA 6720

CTCCCTGGAG CCCACAGAGG GCTCAGGCGC CGGGGGGGAC CCTGCAGCCA AGGGGGAGCG 6780

CTGGGGCCAG GCCTCCTGCC GGGCTGAGCA CCTGACCGTC CCCAGCTTTG CCTTTGAGCC 6840

GCTGGACCTC GGGGTCCCCA GTGGAGACCC TTTCTTGGAC GGTAGCCACA GTGTGACCCC 6900

AGAATCCAGA GCTTCCTCTT CAGGGGCCAT AGTGCCCTG GAACCCCCAG AATCAGAGCC 6960

TCCCATGCCC GTGGTGACC CCCAGAGAA GAGGCGGGG CTGTACCTCA CAGTCCCCCA 7020

GTGTCCTCTG GAGAAACCAG GGTCCCCCTC AGCCACCCT GCCCCAGGGG GTGGTGAGA 7080

TGACCCCGTG TAGCTCGGGG CTTGGTGCCG CCCACGGCTT TGGCCCTGGG GTCTGGGGGC 7140

CCGCTGGGGT GGAGGCCAG GCAGAACCCT GCATGGACCC TGAATTGGGT CCCGTCGTGA 7200

GCAGAAAGGC CCGGGGAGGA TGACGGCCCA GGCCTGGTT CTCTGCCAG CGAAGCAGGA 7260

GTAGCTGCCG GGCCCCACG AGCCTCCGTC CGTTCTGGTT CGGGTTTCTC CGAGTTTTCG 7320

TACCAGCCGA GGCTGTCCG GCAACTGGGT CAGCCTCCG TCAGGAGAGA AGCCGCGTCT 7380

GTGGGACGAA GACCGGGCAC CCGCCAGAGA GGGGAATGGT ACCAGGTTGC GTCCTTTCAG 7440

GCCCCGCGTT GTTACAGGAT CATCTCGCTG GGGGCCCTGT GCCTCTTGCC GCGGCAGGT 7500

TGCATGCCAC CGCGGCCCGA ATGTCACCTT CACTCACAGT CTGAGTTCTT GTCCGCCTGT 7560

CACGCCCTCA CCACCCTCCC CTTCCAGCCA CCACCCTTTC CGTTCCGCTC GGGCCTTCCC 7620

5 AGAAGCGTCC TGTGACTCTG GGAGAGGTGA CACCTCACTA AGGGGCCGAC CCCATGGAGT 7680

AACGCGCCCG GCCCCGATGC GAATCAGGCC TCCCCCTCCG 7720

10

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6858 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

25 ATG CTC CCC CAC CGG GTC CCC CGT TGC GTG AGG ACA CCT CCT CTG AGG 48

Met Leu Pro His Arg Val Pro Arg Cys Val Arg Thr Pro Pro Leu Arg

2035

2040

2045

GGC TCC GCT CGC CCC TCT TCG GAC CCC CCG GGG CCC CGG CTG GCC AGA 96

30 Gly Ser Ala Arg Pro Ser Ser Asp Pro Pro Gly Pro Arg Leu Ala Arg

2050

2055

2060

GGA TGG ACG AGG AGG AGG ATG GAG CGG GCG CCG AGG AGT CGG GAC AGC 144

Gly Trp Thr Arg Arg Arg Met Glu Arg Ala Pro Arg Ser Arg Asp Ser

35

2065

2070

2075

2080

CCC GTA GCT TCA CGC AGC TCA ACG ACC TGT CCG GGG CCG GGG GCG GCA 192

35

2225	2230	2235	2240	
TCC GCA GTC AGG ACA GTC CGT GTG CTG CGA CCG CTC AGG GCC ATT AAC				672
Ser Ala Val Arg Thr Val Arg Val Leu Arg Pro Leu Arg Ala Ile Asn				
2245	2250	2255		
CGG GTG CCC AGC ATG CGC ATT CTC GTC ACA TTA CTG CTG GAC ACC TTG				720
Arg Val Pro Ser Met Arg Ile Leu Val Thr Leu Leu Leu Asp Thr Leu				
2260	2265	2270		
CCT ATG CTG GGC AAC GTC CTG CTG CTC TGT TTC TTC GTC TTT TTC ATC				768
Pro Met Leu Gly Asn Val Leu Leu Leu Cys Phe Phe Val Phe Phe Ile				
2275	2280	2285		
TTT GGC ATC GTG GGC GTC CAG CTG TGG GCA GGA CTG CTT CGC AAC CGG				816
Phe Gly Ile Val Gly Val Gln Leu Trp Ala Gly Leu Leu Arg Asn Arg				
2290	2295	2300		
TGC TTC CTC CCC GAG AAC TTC AGC CTC CCC CTG AGC GTG GAC CTG GAG				864
Cys Phe Leu Pro Glu Asn Phe Ser Leu Pro Leu Ser Val Asp Leu Glu				
2305	2310	2315	2320	
CCT TAT TAC CAG ACA GAG AAT GAG GAC GAG AGC CCC TTC ATC TGC TCT				912
Pro Tyr Tyr Gln Thr Glu Asn Glu Asp Glu Ser Pro Phe Ile Cys Ser				
2325	2330	2335		
CAG CCT CGG GAG AAT GGC ATG AGA TCC TGC AGG AGT GTG CCC ACA CTG				960
Gln Pro Arg Glu Asn Gly Met Arg Ser Cys Arg Ser Val Pro Thr Leu				
2340	2345	2350		
CGT GGG GAA GGC GGT GGT GGC CCA CCC TGC AGT CTG GAC TAT GAG ACC				1008
Arg Gly Glu Gly Gly Gly Gly Pro Pro Cys Ser Leu Asp Tyr Glu Thr				
2355	2360	2365		
TAT AAC AGT TCC AGC AAC ACC ACC TGT GTC AAC TGG AAC CAG TAC TAT				1056
Tyr Asn Ser Ser Ser Asn Thr Thr Cys Val Asn Trp Asn Gln Tyr Tyr				
2370	2375	2380		



5

10

15

**= 20**

25

30

35

CGA AGG CTG GCC CAG GTC TCT AGG GCT ATA GGC GTG CGG GCT GGG CTG 1488  
Arg Arg Leu Ala Gln Val Ser Arg Ala Ile Gly Val Arg Ala Gly Leu  
2515 2520 2525

	CTC AGC AGC CCA GTG GCC CGT AGT GGG CAG GAG CCC CAG CCC AGT GGC	1536
	Leu Ser Ser Pro Val Ala Arg Ser Gly Gln Glu Pro Gln Pro Ser Gly	
	2530 2535 2540	
5	AGC TGC ACT CGC TCA CAC CGT CGT CTG TCT GTC CAC CAC CTG GTC CAC	1584
	Ser Cys Thr Arg Ser His Arg Arg Leu Ser Val His His Leu Val His	
	2545 2550 2555 2560	
	CAC CAT CAC CAC CAC CAT CAC CAC TAC CAC CTG GGT AAT GGG ACG CTC	1632
10	His His His His His His His His Tyr His Leu Gly Asn Gly Thr Leu	
	2565 2570 2575	
	AGA GTT CCC CGG GCC AGC CCA GAG ATC CAG GAC AGG GAT GCC AAT GGG	1680
	Arg Val Pro Arg Ala Ser Pro Glu Ile Gln Asp Arg Asp Ala Asn Gly	
15	2580 2585 2590	
	TCT CGC CGG CTC ATG CTA CCA CCA CCC TCT ACA CCC ACT CCC TCT GGG	1728
	Ser Arg Arg Leu Met Leu Pro Pro Pro Ser Thr Pro Thr Pro Ser Gly	
	2595 2600 2605	
20	GGC CCT CCG AGG GGT GCG GAG TCT GTA CAC AGC TTC TAC CAT GCT GAC	1776
	Gly Pro Pro Arg Gly Ala Glu Ser Val His Ser Phe Tyr His Ala Asp	
	2610 2615 2620	
25	TGC CAC TTG GAG CCA GTC CGT TGC CAG GCA CCC CCT CCC AGA TGC CCA	1824
	Cys His Leu Glu Pro Val Arg Cys Gln Ala Pro Pro Pro Arg Cys Pro	
	2625 2630 2635 2640	
	TCG GAG GCA TCT GGT AGG ACT GTG GGT AGT GGG AAG GTG TAC CCC ACT	1872
30	Ser Glu Ala Ser Gly Arg Thr Val Gly Ser Gly Lys Val Tyr Pro Thr	
	2645 2650 2655	
	GTG CAT ACC AGC CCT CCA CCA GAG ATA CTG AAG GAT AAA GCA CTA GTG	1920
	Val His Thr Ser Pro Pro Pro Glu Ile Leu Lys Asp Lys Ala Leu Val	
35	2660 2665 2670	
	GAG GTG GCC CCC AGC CCT GGG CCC CCC ACC CTC ACC AGC TTC AAC ATC	1968

Glu Val Ala Pro Ser Pro Gly Pro Pro Thr Leu Thr Ser Phe Asn Ile  
 2675 2680 2685

CCA CCT GGG CCC TTC AGC TCC ATG CAC AAG CTC CTG GAG ACA CAG AGT 2016  
 5 Pro Pro Gly Pro Phe Ser Ser Met His Lys Leu Leu Glu Thr Gln Ser  
 2690 2695 2700

ACG GGA GCC TGC CAT AGC TCC TGC AAA ATC TCC AGC CCT TGC TCC AAG 2064  
 10 Thr Gly Ala Cys His Ser Ser Cys Lys Ile Ser Ser Pro Cys Ser Lys  
 2705 2710 2715 2720

GCA GAC AGT GGA GCC TGC GGG CCG GAC AGT TGT CCC TAC TGT GCC CGG 2112  
 Ala Asp Ser Gly Ala Cys Gly Pro Asp Ser Cys Pro Tyr Cys Ala Arg  
 2725 2730 2735

ACA GGA GCA GGA GAG CCA GAG TCC GCT GAC CAT GTC ATG CCT GAC TCA 2160  
 Thr Gly Ala Gly Glu Pro Glu Ser Ala Asp His Val Met Pro Asp Ser  
 2740 2745 2750

GAC AGC GAG GCT GTG TAT GAG TTC ACA CAG GAC GCT CAG CAC AGT GAC 2208  
 20 Asp Ser Glu Ala Val Tyr Glu Phe Thr Gln Asp Ala Gln His Ser Asp  
 2755 2760 2765

CTC CGG GAT CCC CAC AGC CGG CGG CGA CAG CGG AGC CTG GGC CCA GAT 2256  
 25 Leu Arg Asp Pro His Ser Arg Arg Arg Gln Arg Ser Leu Gly Pro Asp  
 2770 2775 2780

GCA GAG CCT AGT TCT GTG CTG GCT TTC TGG AGG CTG ATC TGT GAC ACA 2304  
 30 Ala Glu Pro Ser Ser Val Leu Ala Phe Trp Arg Leu Ile Cys Asp Thr  
 2785 2790 2795 2800

TTC CGG AAG ATC GTA GAT AGC AAA TAC TTT GGC CGG GGA ATC ATG ATC 2352  
 Phe Arg Lys Ile Val Asp Ser Lys Tyr Phe Gly Arg Gly Ile Met Ile  
 2805 2810 2815

GCC ATC CTG GTC AAT ACA CTC AGC ATG GGC ATC GAG TAC CAC GAG CAG 2400  
 35 Ala Ile Leu Val Asn Thr Leu Ser Met Gly Ile Glu Tyr His Glu Gln

2690 2700 2710 2720 2730 2740 2750 2760 2770 2780 2790 2800 2810 2815

	2820	2825	2830	
	CCC GAG GAG CTC ACC AAC GCC CTG GAA ATC AGC AAC ATC GTC TTC ACC			2448
	Pro Glu Glu Leu Thr Asn Ala Leu Glu Ile Ser Asn Ile Val Phe Thr			
5	2835	2840	2845	
	AGC CTC TTC GCC TTG GAG ATG CTG CTG AAA CTG CTT GTC TAC GGT CCC			2496
	Ser Leu Phe Ala Leu Glu Met Leu Leu Lys Leu Leu Val Tyr Gly Pro			
	2850	2855	2860	
10	TTT GGC TAC ATT AAG AAT CCC TAC AAC ATC TTT GAT GGT GTC ATT GTG			2544
	Phe Gly Tyr Ile Lys Asn Pro Tyr Asn Ile Phe Asp Gly Val Ile Val			
	2865	2870	2875	2880
15	GTC ATC AGT GTG TGG GAG ATT GTG GGC CAG CAG GGA GGT GGC CTG TCG			2592
	Val Ile Ser Val Trp Glu Ile Val Gly Gln Gln Gly Gly Gly Leu Ser			
	2885	2890	2895	
	GTG CTG CGG ACC TTC CGC CTG ATG CGG GTG CTG AAG CTG GTG CGC TTC			2640
	Val Leu Arg Thr Phe Arg Leu Met Arg Val Leu Lys Leu Val Arg Phe			
20	2900	2905	2910	
	CTG CCG GCC CTG CAG CGC CAG CTC GTG GTG CTC ATG AAG ACC ATG GAC			2688
	Leu Pro Ala Leu Gln Arg Gln Leu Val Val Leu Met Lys Thr Met Asp			
25	2915	2920	2925	
	AAC GTG GCC ACC TTC TGC ATG CTC CTC ATG CTG TTC ATC TTC ATC TTC			2736
	Asn Val Ala Thr Phe Cys Met Leu Leu Met Leu Phe Ile Phe Ile Phe			
	2930	2935	2940	
30	AGC ATC CTG GGC ATG CAT CTC TTT GGT TGC AAG TTC GCA TCT GAA CGG			2784
	Ser Ile Leu Gly Met His Leu Phe Gly Cys Lys Phe Ala Ser Glu Arg			
	2945	2950	2955	2960
35	GAT GGG GAC ACG TTG CCA GAC CGG AAG AAT TTC GAC TCC CTG CTC TGG			2832
	Asp Gly Asp Thr Leu Pro Asp Arg Lys Asn Phe Asp Ser Leu Leu Trp			
	2965	2970	2975	

	GCC ATC GTC ACT GTC TTT CAG ATT CTG ACT CAG GAA GAC TGG AAT AAA	2880
	Ala Ile Val Thr Val Phe Gln Ile Leu Thr Gln Glu Asp Trp Asn Lys	
	2980 2985 2990	
5	GTC CTC TAC AAC GGC ATG GCC TCC ACA TCG TCT TGG GCT GCT CTT TAC	2928
	Val Leu Tyr Asn Gly Met Ala Ser Thr Ser Ser Trp Ala Ala Leu Tyr	
	2995 3000 3005	
10	TTC ATC GCC CTC ATG ACT TTT GGC AAC TAT GTG CTC TTT AAC CTG CTG	2976
	Phe Ile Ala Leu Met Thr Phe Gly Asn Tyr Val Leu Phe Asn Leu Leu	
	3010 3015 3020	
15	GTG GCC ATT CTT GTG GAA GGA TTC CAG GCA GAG GGA GAT GCC ACC AAG	3024
	Val Ala Ile Leu Val Glu Gly Phe Gln Ala Glu Gly Asp Ala Thr Lys	
	3025 3030 3035 3040	
20	TCT GAG TCA GAG CCT GAT TTC TTT TCG CCC AGT GTG GAT GGT GAT GGG	3072
	Ser Glu Ser Glu Pro Asp Phe Phe Ser Pro Ser Val Asp Gly Asp Gly	
	3045 3050 3055	
25	GAC AGA AAG AAG CGC TTG GCC CTG GTG GCT TTG GGA GAA CAC GCG GAA	3120
	Asp Arg Lys Lys Arg Leu Ala Leu Val Ala Leu Gly Glu His Ala Glu	
	3060 3065 3070	
30	CTA CGA AAG AGC CTT TTG CCA CCC CTC ATC ATC CAT ACG GCT GCG ACA	3168
	Leu Arg Lys Ser Leu Leu Pro Pro Leu Ile Ile His Thr Ala Ala Thr	
	3075 3080 3085	
35	CCA ATG TCA CAC CCC AAG AGC TCC AGC ACA GGT GTG GGG GAA GCA CTG	3216
	Pro Met Ser His Pro Lys Ser Ser Ser Thr Gly Val Gly Glu Ala Leu	
	3090 3095 3100	
	GCC TCT GGC TCT CGA CGT ACC AGT AGC AGT GGG TCC GCT GAG CCT GGA	3264
	Gly Ser Gly Ser Arg Arg Thr Ser Ser Ser Gly Ser Ala Glu Pro Gly	
	3105 3110 3115 3120	

265027-265035

GCT GCC CAC CAT GAG ATG AAA TGT CCG CCA AGT GCC CGC AGC TCC CCG 3312  
 Ala Ala His His Glu Met Lys Cys Pro Pro Ser Ala Arg Ser Ser Pro  
 3125 3130 3135

5 CAC AGT CCC TGG AGT GCG GCA AGC AGC TGG ACC AGC AGG CGC TCC AGC 3360  
 His Ser Pro Trp Ser Ala Ala Ser Ser Trp Thr Ser Arg Arg Ser Ser  
 3140 3145 3150

10 AGG AAC AGC CTG GGC CGG GCC CCC AGC CTA AAG CGG AGG AGC CCG AGC 3408  
 Arg Asn Ser Leu Gly Arg Ala Pro Ser Leu Lys Arg Arg Ser Pro Ser  
 3155 3160 3165

15 GGG GAG CGG AGG TCC CTG CTG TCT GGA GAG GGC CAG GAG AGT CAG GAT 3456  
 Gly Glu Arg Arg Ser Leu Leu Ser Gly Glu Gly Gln Glu Ser Gln Asp  
 3170 3175 3180

20 GAG GAG GAA AGT TCA GAA GAG GAC CGG GCC AGC CCA GCA GGC AGT GAC 3504  
 Glu Glu Glu Ser Ser Glu Glu Asp Arg Ala Ser Pro Ala Gly Ser Asp  
 3185 3190 3195 3200

CAT CGC CAC AGG GGT TCC TTG GAA CGT GAG GCC AAG AGT TCC TTT GAC 3552  
 His Arg His Arg Gly Ser Leu Glu Arg Glu Ala Lys Ser Ser Phe Asp  
 3205 3210 3215

25 CTG CCT GAC ACT CTG CAG GTG CCG GGG CTG CAC CGC ACA GCC AGC GGC 3600  
 Leu Pro Asp Thr Leu Gln Val Pro Gly Leu His Arg Thr Ala Ser Gly  
 3220 3225 3230

30 CGG AGC TCT GCC TCT GAG CAC CAA GAC TGT AAT GGC AAG TCG GCT TCA 3648  
 Arg Ser Ser Ala Ser Glu His Gln Asp Cys Asn Gly Lys Ser Ala Ser  
 3235 3240 3245

35 GGG CGT TTG GCC CGC ACC CTG AGG ACT GAT GAC CCC CAA CTG GAT GGC 3696  
 Gly Arg Leu Ala Arg Thr Leu Arg Thr Asp Asp Pro Gln Leu Asp Gly  
 3250 3255 3260

GAT GAT GAC AAT GAT GAG GGA AAT CTG AGC AAA GGG GAA CGC ATA CAA 3744

GTC TCC GAC AGC GGC ACC AAG ATC CTT GGC ATG CTG AGG GTG CTG CGG 4176  
Val Ser Asp Ser Gly Thr Lys Ile Leu Gly Met Leu Arg Val Leu Arg

	3410	3415	3420	
	CTG CTG CGG ACC CTG CGT CCA CTC AGG GTC ATC AGC CGG GCC CAG GGA			4224
	Leu Leu Arg Thr Leu Arg Pro Leu Arg Val Ile Ser Arg Ala Gln Gly			
5	3425	3430	3435	3440
	CTG AAG CTG GTG GTA GAG ACT CTG ATG TCA TCC CTC AAA CCC ATT GGC			4272
	Leu Lys Leu Val Val Glu Thr Leu Met Ser Ser Leu Lys Pro Ile Gly			
	3445	3450	3455	
10				
	AAC ATT GTG GTC ATT TGC TGT GCC TTC TTC ATC ATT TTT GGA ATT CTC			4320
	Asn Ile Val Val Ile Cys Cys Ala Phe Phe Ile Ile Phe Gly Ile Leu			
	3460	3465	3470	
15				
	GGG GTG CAG CTC TTC AAA GGG AAG TTC TTC GTG TGT CAG GGT GAG GAC			4368
	Gly Val Gln Leu Phe Lys Gly Lys Phe Phe Val Cys Gln Gly Glu Asp			
	3475	3480	3485	
	ACC AGG AAC ATC ACT AAC AAA TCC GAC TGC GCT GAG GCC AGC TAC CGA			4416
	Thr Arg Asn Ile Thr Asn Lys Ser Asp Cys Ala Glu Ala Ser Tyr Arg			
20	3490	3495	3500	
	TGG GTC CGG CAC AAG TAC AAC TTT GAC AAC CTG GGC CAG GCT CTG ATG			4464
	Trp Val Arg His Lys Tyr Asn Phe Asp Asn Leu Gly Gln Ala Leu Met			
25	3505	3510	3515	3520
	TCC CTG TTT GTG CTG GCC TCC AAG GAT GGT TGG GTT GAC ATC ATG TAT			4512
	Ser Leu Phe Val Leu Ala Ser Lys Asp Gly Trp Val Asp Ile Met Tyr			
	3525	3530	3535	
30				
	GAT GGG CTG GAT GCT GTG GGT GTG GAT CAG CAG CCC ATC ATG AAC CAC			4560
	Asp Gly Leu Asp Ala Val Gly Val Asp Gln Gln Pro Ile Met Asn His			
	3540	3545	3550	
35				
	AAC CCC TGG ATG CTG CTA TAC TTC ATC TCC TTC CTC CTC ATC GTG GCC			4608
	Asn Pro Trp Met Leu Leu Tyr Phe Ile Ser Phe Leu Leu Ile Val Ala			
	3555	3560	3565	



TTC TTT GTC CTG AAC ATG TTT GTG GGC GTG GTG GTG GAG AAC TTC CAT 4656  
Phe Phe Val Leu Asn Met Phe Val Gly Val Val Val Glu Asn Phe His  
3570 3575 3580

5

AAG TGC AGA CAG CAC CAG GAG GAG GAG GAG GCG AGG CGG CGT GAG GAG 4704  
Lys Cys Arg Gln His Gln Glu Glu Glu Glu Ala Arg Arg Arg Glu Glu  
3585 3590 3595 3600

10

AAG CGA CTA CGG AGG CTG GAG AAA AAG AGA AGG AGT AAG GAG AAG CAG 4752  
Lys Arg Leu Arg Arg Leu Glu Lys Lys Arg Arg Ser Lys Glu Lys Gln  
3605 3610 3615

15  
20  
25  
30  
35

ATG GCC GAA GCC CAG TGC AAG CCC TAC TAC TCT GAC TAC TCG AGA TTC 4800  
Met Ala Glu Ala Gln Cys Lys Pro Tyr Tyr Ser Asp Tyr Ser Arg Phe  
3620 3625 3630

CGG CTC CTT GTC CAC CAC CTG TGT ACC AGC CAC TAC CTG GAC CTC TTC 4848  
Arg Leu Leu Val His His Leu Cys Thr Ser His Tyr Leu Asp Leu Phe  
3635 3640 3645

ATC ACT GGT GTC ATC GGG CTG AAC GTG GTC ACT ATG GCC ATG GAA CAT 4896  
Ile Thr Gly Val Ile Gly Leu Asn Val Val Thr Met Ala Met Glu His  
3650 3655 3660

TAC CAG CAG CCC CAG ATC CTG GAC GAG GCT CTG AAG ATC TGC AAT TAC 4944  
Tyr Gln Gln Pro Gln Ile Leu Asp Glu Ala Leu Lys Ile Cys Asn Tyr  
3665 3670 3675 3680

30

ATC TTT ACC GTC ATC TTT GTC TTT GAG TCA GTT TTC AAA CTT GTG GCC 4992  
Ile Phe Thr Val Ile Phe Val Phe Glu Ser Val Phe Lys Leu Val Ala  
3685 3690 3695

35

TTT GCG TTC CGC CGT TTC TTC CAG GAC AGG TGG AAC CAG CTG GAC CTG 5040  
Phe Ala Phe Arg Arg Phe Phe Gln Asp Arg Trp Asn Gln Leu Asp Leu  
3700 3705 3710

	GCT ATT GTG CTT CTG TCC ATC ATG GGC ATC ACA CTG GAG GAG ATT GAG	5088
	Ala Ile Val Leu Leu Ser Ile Met Gly Ile Thr Leu Glu Glu Ile Glu	
	3715 3720 3725	
5	GTC AAT CTG TCG CTG CCC ATC AAC CCC ACC ATC ATC CGT ATC ATG AGG	5136
	Val Asn Leu Ser Leu Pro Ile Asn Pro Thr Ile Ile Arg Ile Met Arg	
	3730 3735 3740	
10	GTG CTC CGC ATT GCT CGA GTT CTG AAG CTG TTG AAG ATG GCT GTG GGC	5184
	Val Leu Arg Ile Ala Arg Val Leu Lys Leu Leu Lys Met Ala Val Gly	
	3745 3750 3755 3760	
15	ATG CGG GCA CTG CTG CAC ACG GTG ATG CAG GCC CTG CCC CAG GTG GGG	5232
	Met Arg Ala Leu Leu His Thr Val Met Gln Ala Leu Pro Gln Val Gly	
	3765 3770 3775	
20	AAC CTG GGA CTT CTC TTC ATG TTA TTG TTT TTC ATC TTT GCA GCT CTG	5280
	Asn Leu Gly Leu Leu Phe Met Leu Leu Phe Phe Ile Phe Ala Ala Leu	
	3780 3785 3790	
25	GGC GTG GAG CTC TTT GGA GAC CTG GAG TGT GAT GAG ACA CAC CCT TGT	5328
	Gly Val Glu Leu Phe Gly Asp Leu Glu Cys Asp Glu Thr His Pro Cys	
	3795 3800 3805	
30	GAG GGC TTG GGT CGG CAT GCC ACC TTT AGG AAC TTT GGT ATG GCC TTT	5376
	Glu Gly Leu Gly Arg His Ala Thr Phe Arg Asn Phe Gly Met Ala Phe	
	3810 3815 3820	
35	CTG ACC CTC TTC CGA GTC TCC ACT GGT GAC AAC TGG AAT GGT ATT ATG	5424
	Leu Thr Leu Phe Arg Val Ser Thr Gly Asp Asn Trp Asn Gly Ile Met	
	3825 3830 3835 3840	
40	AAG GAC CCT TCC CGG GAC TGT GAC CAG GAG TCC ACC TGC TAC AAC ACT	5472
	Lys Asp Pro Ser Arg Asp Cys Asp Gln Glu Ser Thr Cys Tyr Asn Thr	
	3845 3850 3855	
45	GTC ATC TCC CCT ATC TAC TTT GTG TCC TTC GTG CTG ACG GCC CAG TTT	5520

	Val Ile Ser Pro Ile Tyr Phe Val Ser Phe Val Leu Thr Ala Gln Phe	
	3860 3865 3870	
5	GTG CTG GTC AAC GTG GTC ATA GCT GTG CTG ATG AAG CAC CTG GAA GAA Val Leu Val Asn Val Val Ile Ala Val Leu Met Lys His Leu Glu Glu	5568
	3875 3880 3885	
10	AGC AAC AAA GAG GCC AAG GAG GAG GCC GAG CTC GAG GCC GAG CTG GAG Ser Asn Lys Glu Ala Lys Glu Glu Ala Glu Leu Glu Ala Glu Leu Glu	5616
	3890 3895 3900	
15	CTG GAG ATG AAG ACG CTC AGC CCG CAG CCC CAC TCC CCG CTG GGC AGC Leu Glu Met Lys Thr Leu Ser Pro Gln Pro His Ser Pro Leu Gly Ser	5664
	3905 3910 3915 3920	
20	CCC TTC CTC TGG CCC GGG GTG GAG GGT GTC AAC AGT ACT GAC AGC CCT Pro Phe Leu Trp Pro Gly Val Glu Gly Val Asn Ser Thr Asp Ser Pro	5712
	3925 3930 3935	
25	AAG CCT GGG GCT CCA CAC ACC ACT GCC CAC ATT GGA GCA GCC TCG GGC Lys Pro Gly Ala Pro His Thr Thr Ala His Ile Gly Ala Ala Ser Gly	5760
	3940 3945 3950	
30	TTC TCC CTT GAG CAC CCC ACG ATG GTA CCC CAC CCC GAG GAG GTG CCA Phe Ser Leu Glu His Pro Thr Met Val Pro His Pro Glu Glu Val Pro	5808
	3955 3960 3965	
35	GTC CCC CTA GGA CCA GAC CTG CTG ACT GTG AGG AAG TCT GGT GTC AGC Val Pro Leu Gly Pro Asp Leu Leu Thr Val Arg Lys Ser Gly Val Ser	5856
	3970 3975 3980	
	CGG ACG CAC TCT CTG CCC AAT GAC AGC TAC ATG TGC CGC AAT GGG AGC Arg Thr His Ser Leu Pro Asn Asp Ser Tyr Met Cys Arg Asn Gly Ser	5904
	3985 3990 3995 4000	
	ACT GCT GAG AGA TCC CTA GGA CAC AGG GGC TGG GGG CTC CCC AAA GCC Thr Ala Glu Arg Ser Leu Gly His Arg Gly Trp Gly Leu Pro Lys Ala	5952

4005

4010

4015

CAG TCA GGC TCC ATC TTG TCC GTT CAC TCC CAA CCA GCA GAC ACC AGC 6000  
 Gln Ser Gly Ser Ile Leu Ser Val His Ser Gln Pro Ala Asp Thr Ser  
 5 4020 4025 4030

TGC ATC CTA CAG CTT CCC AAA GAT GTG CAC TAT CTG CTC CAG CCT CAT 6048  
 Cys Ile Leu Gln Leu Pro Lys Asp Val His Tyr Leu Leu Gln Pro His  
 4035 4040 4045

GGG GCT CCC ACC TGG GGC GCC ATC CCT AAA CTA CCC CCA CCT GGC CGC 6096  
 Gly Ala Pro Thr Trp Gly Ala Ile Pro Lys Leu Pro Pro Pro Gly Arg  
 4050 4055 4060

TCC CCT CTG GCT CAG AGG CCT CTC AGG CGC CAG GCA GCA ATA AGG ACT 6144  
 Ser Pro Leu Ala Gln Arg Pro Leu Arg Arg Gln Ala Ala Ile Arg Thr  
 4065 4070 4075 4080

GAC TCC CTG GAT GTG CAG GGC CTG GGT AGC CGG GAA GAC CTG TTG TCA 6192  
 Asp Ser Leu Asp Val Gln Gly Leu Gly Ser Arg Glu Asp Leu Leu Ser  
 4085 4090 4095

GAG GTG AGT GGG CCC TCC TGC CCT CTG ACC CGG TCC TCA TCC TTC TGG 6240  
 Glu Val Ser Gly Pro Ser Cys Pro Leu Thr Arg Ser Ser Ser Phe Trp  
 4100 4105 4110

GGC GGG TCG AGC ATC CAG GTG CAG CAG CGT TCC GGC ATC CAG AGC AAA 6288  
 Gly Gly Ser Ser Ile Gln Val Gln Gln Arg Ser Gly Ile Gln Ser Lys  
 4115 4120 4125

GTC TCC AAG CAC ATC CGC CTG CCA GCC CCT TGC CCA GGC CTG GAA CCC 6336  
 Val Ser Lys His Ile Arg Leu Pro Ala Pro Cys Pro Gly Leu Glu Pro  
 4130 4135 4140

AGC TGG GCC AAG GAC CCT CCA GAG ACC AGA AGC AGC TTA GAG CTG GAC 6384  
 Ser Trp Ala Lys Asp Pro Pro Glu Thr Arg Ser Ser Leu Glu Leu Asp  
 4145 4150 4155 4160

10  
15  
20  
25  
30  
35

5

ACG GAG CTG AGC TGG ATT TCA GGA GAC CTC CTT CCC AGC AGC CAG GAA 6432  
 Thr Glu Leu Ser Trp Ile Ser Gly Asp Leu Leu Pro Ser Ser Gln Glu  
 4165 4170 4175

10

GAA CCC CTG TTC CCA CGG GAC CTG AAG AAG TGC TAC AGT GTA GAG ACC 6480  
 Glu Pro Leu Phe Pro Arg Asp Leu Lys Lys Cys Tyr Ser Val Glu Thr  
 4180 4185 4190

15

CAG AGC TGC AGG CGC AGG CCT GGG TTC TGG CTA GAT GAA CAG CGG AGA 6528  
 Gln Ser Cys Arg Arg Arg Pro Gly Phe Trp Leu Asp Glu Gln Arg Arg  
 4195 4200 4205

CAC TCC ATT GCT GTC AGC TGT CTG GAC AGC GGC TCC CAA CCC CGC CTA 6576  
 His Ser Ile Ala Val Ser Cys Leu Asp Ser Gly Ser Gln Pro Arg Leu  
 4210 4215 4220

20

TGT CCA AGC CCC TCA AGC CTC GGG GGC CAA CCT CTT GGG GGT CCT GGG 6624  
 Cys Pro Ser Pro Ser Ser Leu Gly Gly Gln Pro Leu Gly Gly Pro Gly  
 4225 4230 4235 4240

AGC CGG CCT AAG AAA AAA CTC AGC CCA CCC AGT ATC TCT ATA GAC CCC 6672  
 Ser Arg Pro Lys Lys Lys Leu Ser Pro Pro Ser Ile Ser Ile Asp Pro  
 4245 4250 4255

25

CCG GAG AGC CAG GGC TCT CGG CCC CCA TGC AGT CCT GGT GTC TGC CTC 6720  
 Pro Glu Ser Gln Gly Ser Arg Pro Pro Cys Ser Pro Gly Val Cys Leu  
 4260 4265 4270

30

AGG AGG AGG GCG CCG GCC AGT GAC TCT AAG GAT CCC TCG GTC TCC AGC 6768  
 Arg Arg Arg Ala Pro Ala Ser Asp Ser Lys Asp Pro Ser Val Ser Ser  
 4275 4280 4285

35

CCC CTT GAC AGC ACG GCT GCC TCA CCC TCC CCA AAG AAA GAC ACG CTG 6816  
 Pro Leu Asp Ser Thr Ala Ala Ser Pro Ser Pro Lys Lys Asp Thr Leu  
 4290 4295 4300

AGT CTC TCT GGT TTG TCT TCT GAC CCA ACA GAC ATG GAC CCC

6858

Ser Leu Ser Gly Leu Ser Ser Asp Pro Thr Asp Met Asp Pro

4305

4310

4315

5

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 7540 base pairs

10

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

CCGTCTCTGG CGCGGAGCGG GACGATGCTG ACCCCTTAGA TCCTGCTCCA GCTGCGCCGA 60

GGGAAGAGGG GGCGCCCTC CCCGGACCCC CGCCCTCCAT CGGCTGGCCC CTTTTTTTTC 120

TCTTCCTCTC GGGGGCTGCT TCGCCGAAGG TAGCGCTGT TACGGGCAAC CGGAGCCTGG 180

GCGCGAACGA AGAAGCCGA ACAAGTGAG GGAAGCCGC CCGGCTAGTC GGGGAGCCCC 240

CGGGAACCCA GGGGAAGCGG GACTCTACGC CAGGCGGGGC TTCCCTGAGA CCCGGCGCCC 300

CGCGGGCAGC ATGCCCTGAG GGCAGGGGGA GCTGAGCTGA ACTGGCCCTC CTGGGGACTC 360

AGCAAGCTCT CTAGAGCCCC CCACATGCTC CCCACCGGG TCCCCGTTG CGTGAGGACA 420

CCTCCTCTGA GGGGCTCCGC TCGCCCTCT TCGGACCCCC CGGGGCCCCG GCTGGCCAGA 480

GGATGGACGA GGAGGAGGAT GGAGCGGGCG CCGAGGAGTC GGGACAGCCC CGTAGCTTCA 540

CGCAGCTCAA CGACCTGTCC GGGGCCGGGG GCGGCAGGGG CCGGGTCGAC GGAAAAGGAC 600

463737 6005990

5

10

15  
20  
25  
30  
35

CCGGGCAGCG CGGACTCCGA GGC GGAGGGG CTGCCGTACC CGGCGCTAGC CCCGGTGGTT 660

TTCTTCTACT TGAGCCAGGA CAGCCGCCCC CGGAGCTGGT GTCTCCGCAC GGTCTGTAAC 720

CCGTGGTTCG AGCGAGTCAG TATGCTGGTC ATTCTTCTCA ACTGTGTGAC TCTGGGTATG 780

TTCAGGCCGT GTGAGGACAT TGCCTGTGAC TCCCAGCGCT GCCGGATCCT GCAGGCCTTC 840

GATGACTTCA TCTTTGCCTT CTTTGCTGTG GAAATGGTGG TGAAGATGGT GGCCTTGGGC 900

ATCTTTGGGA AGAAATGTTA CCTGGGAGAC ACTTGGGAAC GGCTTGACTT TTTCATTGTC 960

ATTGCAGGGA TGCTGGAGTA TTCGCTGGAC CTGCAGAACG TCAGCTTCTC CGCAGTCAGG 1020

ACAGTCCGTG TGCTGCGACC GCTCAGGGCC ATTAACCGGG TGCCCAGCAT GCGCATTCTC 1080

GTCACATTAC TGCTGGACAC CTTGCCTATG CTGGGCAACG TCCTGCTGCT CTGTTTCTTC 1140

GTCTTTTCA TCTTTGGCAT CGTGGGCGTC CAGCTGTGGG CAGGACTGCT TCGCAACCGG 1200

TGCTTCCTCC CCGAGAACTT CAGCCTCCCC CTGAGCGTGG ACCTGGAGCC TTATTACCAG 1260

ACAGAGAATG AGGACGAGAG CCCCTTCATC TGCTCTCAGC CTCGGGAGAA TGGCATGAGA 1320

TCCTGCAGGA GTGTGCCCAC ACTGCGTGGG GAAGGCGGTG GTGGCCCACC CTGCAGTCTG 1380

GA CTATGAGA CCTATAACAG TTCCAGCAAC ACCACCTGTG TCAACTGGAA CCAGTACTAT 1440

ACCAACTGCT CTGCGGGCGA GCACAACCCC TCAAGGCG CCATCAACTT TGACAACATT 1500

GGCTATGCCT GGATCGCCAT CTTCCAGGTC ATCACACTGG AGGGCTGGGT CGACATCATG 1560

TACTTCGTAA TGGACGCTCA CTCCTTCTAC AACTTCATCT ACTTCATTCT TCTCATCATC 1620

GTGGGCTCCT TCTTCATGAT CAACCTGTGC CTGGTGGTGA TTGCCACGCA GTTCTCCGAG 1680

ACCAAACAGC GGGAGAGTCA GCTGATGCGG GAGCAGCGTG TACGATTCCT GTCCAATGCT 1740

AGCACCCCTGG CAAGCTTCTC TGAGCCAGGC AGCTGCTATG AGGAGCTACT CAAGTACCTG 1800

5 GTGTACATCC TCCGAAAAGC AGCCCGAAGG CTGGCCCAGG TCTCTAGGGC TATAGGCGTG 1860

CGGECTGGGC TGCTCAGCAG CCCAGTGGCC CGTAGTGGGC AGGAGCCCCA GCCCAGTGGC 1920

AGCTGCACTC GCTCACACCG TCGTCTGTCT GTCCACCACC TGGTCCACCA CCATCACCAC 1980

10 CACCATCACC ACTACCACCT GGGTAATGGG ACGCTCAGAG TTCCCCGGGC CAGCCCAGAG 2040

ATCCAGGACA GGGATGCCAA TGGGTCTCGC CGGCTCATGC TACCACCACC CTCTACACCC 2100

15 ACTCCCTCTG GGGGCCCTCC GAGGGGTGCG GAGTCTGTAC ACAGCTTCTA CCATGCTGAC 2160

TGCCACTTGG AGCCAGTCCG TTGCCAGGCA CCCCCTCCA GATGCCCATC GGAGGCATCT 2220

GGTAGGACTG TGGGTAGTGG GAAGGTGTAC CCCACTGTGC ATACCAGCCC TCCACCAGAG 2280

20 ATACTGAAGG ATAAAGCACT AGTGGAGGTG GCCCCAGCC CTGGGCCCCC CACCCCTACC 2340

AGCTTCAACA TCCCACCTGG GCCCTTCAGC TCCATGCACA AGCTCCTGGA GACACAGAST 2400

25 ACGGGAGCCT GCCATAGCTC CTGCAAAATC TCCAGCCCTT GCTCCAAGGC AGACAGTGGA 2460

GCCTGCGGGC CGGACAGTTC TCCCTACTGT GCCCGGACAG GAGCAGGAGA GCCAGAGTCC 2520

GCTGACCATG TCATGCCTGA CTCAGACAGC GAGSCTGTGT ATGAGTTCAC ACAGGACGCT 2580

30 CAGCACAGTG ACCTCCGGGA TCCCCACAGC CGGCGGCGAC AGCGGAGCCT GGGCCCAGAT 2640

GCAGAGCCTA GTTCTGTGCT GGCTTCTGG AGGCTGATCT GTGACACATT CCGGAAGATC 2700

35 GTAGATAGCA AATACTTTGG CCGGGGAATC ATGATCGCCA TCCTGGTCAA TACACTCAGC 2760

ATGGGCATCG AGTACCACGA GCAGCCCGAG GAGCTCACCA ACGCCCTGGA AATCAGCAAC 2820

15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100



5

10

15  
20  
25  
30  
35

25

30

35

ATCGTCTTCA CCAGCCTCTT CGCCTTGGAG ATGCTGCTGA AACTGCTTGT CTACGGTCCC 2880

TTTGGCTACA TTAAGAATCC CTACAACATC TTTGATGGTG TCATTGTGGT CATCAGTGTG 2940

TGGGAGATTG TGGGCCAGCA GGGAGGTGGC CTGTGCGTGC TGCGGACCTT CCGCCTGATG 3000

CGGGTGCTGA AGCTGGTGCG CTTCCTGCCG GCCCTGCAGC GCCAGCTCGT GGTGCTCATG 3060

AAGACCATGG ACAACGTGGC CACCTTCTGC ATGCTCCTCA TGCTGTTTAT CTTTATCTTC 3120

AGCATCCTGG GCATGCATCT CTTTGGTTGC AAGTTCGCAT CTGAACGGGA TGGGGACACG 3180

TTGCCAGACC GGAAGAATTT CGACTCCCTG CTCTGGGCCA TCGTCACTGT CTTTCAGATT 3240

CTGACTCAGG AAGACTGGAA TAAAGTCCTC TACAACGGCA TGGCCTCCAC ATCGTCTTGG 3300

GCTGCTCTTT ACTTCATCGC CCTCATGACT TTTGGCAACT ATGTGCTCTT TAACCTGCTG 3360

GTGGCCATTC TTGTGGAAGG ATTCCAGGCA GAGGGAGATG CCACCAAGTC TGAGTCAGAG 3420

CCTGATTTCT TTTCGCCCAG TGTGGATGGT GATGGGGACA GAAAGAAGCG CTTGGCCCTG 3480

GTGGCTTTGG GAGAACACGC GGAAGTACGA AAGAGCCTTT TGCCACCCCT CATCATCCAT 3540

ACGGCTGCGA CACCAATGTC ACACCCCAAG AGCTCCAGCA CAGGTGTGGG GGAAGCACTG 3600

GGCTCTGGCT CTCGACGTAC CAGTAGCAGT GGGTCCGCTG AGCCTGGAGC TGCCCACCAT 3660

GAGATGAAAT GTCCGCCAAG TGCCCGCAGC TCCCCGCACA GTCCCTGGAG TGCGGCAAGC 3720

AGCTGGACCA GCAGGCGCTC CAGCAGGAAC AGCCTGGGCC GGGCCCCCAG CCTAAAGCGG 3780

AGGAGCCCGA GCGGGGAGCG GAGGTCCCTG CTGTCTGGAG AGGGCCAGGA GAGTCAGGAT 3840

GAGGAGGAAA GTTCAGAAGA GGACCGGGCC AGCCCAGCAG GCAGTGACCA TCGCCACAGG 3900

5

10

15

20

25

30

35

GGTTCCTTGG AACGTGAGGC CAAGAGTTCC TTGACCTGC CTGACACTCT GCAGGTGCCG 3960

GGGCTGCACC GCACAGCCAG CGGCCGGAGC TCTGCCTCTG AGCACCAAGA CTGTAATGGC 4020

AAGTCGGCTT CAGGGCGTTT GGCCCGCACC CTGAGGACTG ATGACCCCCA ACTGGATGGG 4080

GATGATGACA ATGATGAGGG AAATCTGAGC AAAGGGGAAC GCATACAAGC CTGGGTGAGA 4140

TCCCGGCTTC CTGCCTGTTG CCGAGAGCGA GATTCCTGGT CCGCCTATAT CTTTCCTCCT 4200

CAGTCAAGGT TTCGTCTCCT GTGTCACCGG ATCATCACCC ACAAGATGTT TGACCATGTG 4260

GTCCTCGTCA TCATCTTCCT CAACTGTATC ACCATCGCTA TGGAGCGCCC CAAAATTGAC 4320

CCCCACAGCG CTGAGCGCAT CTCCTGACC CTCTCCAAC ACATCTTCAC GGCAGTCTTT 4380

CTAGCTGAAA TGACAGTGAA GGTGGTGGCA CTGGGCTGGT GCTTTGGGGA GCAGGCCTAC 4440

CTGCGCAGCA GCTGGAATGT GCTGGACGGC TTGCTGGTGC TCATCTCCGT CATCGACATC 4500

CTGGTCTCCA TGGTCTCCGA CAGCGGCACC AAGATCCTTG GCATGCTGAG GGTGCTGCGG 4560

CTGCTGCGGA CCCTGCGTCC ACTCAGGGTC ATCAGCCGGG CCCAGGGACT GAAGCTGGTG 4620

GTAGAGACTC TGATGTCATC CCTCAAACCC ATTGGCAACA TTGTGGTCAT TTGCTGTGCC 4680

TTCTTCATCA TTTTGGAA TCTCGGGGTG CAGCTCTTCA AAGGGAAGTT CTTGCTGTGT 4740

CAGGGTGAGG ACACCAGGAA CATCACTAAC AAATCCGACT GCGCTGAGGC CAGCTACCGA 4800

TGGGTCCGGC ACAAGTACAA CTTTGACAAC CTGGGCCAGG CTCTGATGTC CCTGTTTGTG 4860

CTGGCCTCCA AGGATGGTTG GGTGACATC ATGTATGATG GCTGGATGC TGTGGGTGTG 4920

GATCAGCAGC CCATCATGAA CCACAACCCC TGGATGCTGC TATACTTCAT CTCCTTCCTC 4980

CTCATCGTGG CCTTCTTTGT CCTGAACATG TTTGTGGGCG TGGTGGTGGA GAACTTCAT 5040

AAGTGCAGAC AGCACCAGGA GGAGGAGGAG GCGAGGCGGC GTGAGGAGAA GCGACTACGG 5100  
AGGCTGGAGA AAAAGAGAAG GAGTAAGGAG AAGCAGATGG CCGAAGCCCA GTGCAAGCCC 5160  
TACTACTCTG ACTACTCGAG ATTCCGGCTC CTTGTCCACC ACCTGTGTAC CAGCCACTAC 5220  
CTGGACCTCT TCATCACTGG TGTCATCGGG CTGAACGTGG TCACTATGGC CATGGAACAT 5280  
TACCAGCAGC CCCAGATCCT GGACGAGGCT CTGAAGATCT GCAATTACAT CTTTACCGTC 5340  
ATCTTTGTCT TTGAGTCAGT TTCAAACCTT GTGGCCTTTG CGTCCGCGG TTTCTTCCAG 5400  
GACAGGTGGA ACCAGCTGGA CCTGGCTATT GTGCTTCTGT CCATCATGGG CATCACACTG 5460  
GAGGAGATTG AGGTCAATCT GTCGCTGCCC ATCAACCCCA CCATCATCCG TATCATGAGG 5520  
GTGCTCCGCA TTGCTCGAGT TCTGAAGCTG TTGAAGATGG CTGTGGGCAT GCGGGCACTG 5580  
CTGCACACGG TGATGCAGGC CCTGCCCCAG GTGGGGAACC TGGGACTTCT CTTTATGTTA 5640  
TTGTTTTTCA TCTTTGCAGC TCTGGGCGTG GAGCTCTTTG GAGACCTGGA GTGTGATGAG 5700  
ACACACCCTT GTGAGGGGCTT GGGTCGGCAT GCCACCTTTA GGAACCTTTG TATGGCCTTT 5760  
CTGACCCTCT TCCGAGTCTC CACTGGTGAC AACTGGAATG GTATTATGAA GGACCCTTCC 5820  
CGGGACTGIG ACCAGGAGTC CACCTGCTAC AACACTGTCA TCTCCCCTAT CTACTTTGTG 5880  
TCCTTCGTGC TGACGGCCCA GTTTGTGCTG GTCAACGTGG TCATAGCTGT GCTGATGAAG 5940  
CACCTGGAAG AAAGCAACAA AGAGGCCAAG GAGGAGGCCG AGCTCGAGGC CGAGCTGGAG 6000  
CTGGAGATGA AGACGCTCAG CCCGAGCCC CACTCCCCGC TGGGCAGCCC CTCCTCTGG 6060  
CCCGGGGTGG AGGGTGTCAA CAGTACTGAC AGCCCTAAGC CTGGGGCTCC ACACACCACT 6120

CCCCACATTG GAGCAGCCTC GGGCTTCTCC CTGAGCACC CCACGATGGT ACCCCACCCC	6180
GAGGAGGTGC CAGTCCCCCT AGGACCAGAC CTGCTGACTG TGAGGAAGTC TGGTGTACAGC	6240
CGGACGCACT CTCTGCCCAA TGACAGCTAC ATGTGCCGCA ATGGGAGCAC TGCTGAGAGA	6300
TCCCTAGGAC ACAGGGGCTG GGGGCTCCCC AAAGCCCAGT CAGGCTCCAT CTGTGCCGTT	6360
CACTCCCAAC CAGCAGACAC CAGCTGCATC CTACAGCTTC CCAAAGATGT GCACTATCTG	6420
CTCCAGCCTC ATGGGGCTCC CACCTGGGGC GCCATCCCTA AACTACCCCC ACCTGGCCGC	6480
TCCCCTCTGG CTCAGAGGCC TCTCAGGCGC CAGGCAGCAA TAAGGACTGA CTCCTGGAT	6540
GTGCAGGGCC TGGGTAGCCG GGAAGACCTG TTGTGAGAGG TGAGTGGGCC CTCCTGCCCT	6600
CTGACCCGGT CCTCATCCTT CTGGGGCGGG TCGAGCATCC AGGTGCAGCA GCGTTCCGGC	6660
ATCCAGAGCA AAGTCTCCAA GCACATCCGC CTGCCAGCCC CTGCCCAGG CCTGGAACCC	6720
AGCTGGGCCA AGGACCCTCC AGAGACCAGA AGCAGCTTAG AGCTGGACAC GGAGCTGAGC	6780
TGGATTTTACG GAGACCTCCT TCCCAGCAGC CAGGAAGAAC CCCTGTTCCC ACGGGACCTG	6840
AAGAAGTGCT ACAGTGTAGA GACCCAGAGC TGCAGGCGCA GGCCTGGGTT CTGGCTAGAT	6900
GAACAGCGGA GACACTCCAT TGCTGTCAGC TGTCTGGACA GCGGCTCCCA ACCCCGCCTA	6960
TETCCAAGCC CCTCAAGCCT CGGGGGCCAA CCTCTTGGGG GTCTTGGGAG CCGGCCTAAG	7020
AAAAAACTCA GCCCACCAG TATCTCTATA GACCCCCCGG AGAGCCAGGG CTCTCGGCCC	7080
CCATGCAGTC CTGGTGTCTG CCTCAGGAGG AGGGCGCCGG CCAGTGACTC TAAGGATCCC	7140
TCGGTCTCCA GCCCCCTTGA CAGCACGGCT GCCTCACCCT CCCCAGAGAA AGACACGCTG	7200
AGTCTCTCTG GTTTGTCTTC TGACCCAACA GACATGGACC CCTGAGTCTT ACCCACTCTC	7260

5

10

CCCCATCACC TTTCTCCACC GGGTGCAGAT CCTACGTCCG CCTCCTGGGC AGCGTTTCTG 7320

AAAAGTCCCA CGTAAGCAGC AAGCAGCCAC GAGGCACCTC ACCTGCCTTC TTCAGTGGCT 7380

GGTGGGGATG ACGAGCAGAA CTTCCGGAGA GTCGATCTGA AGAGAACACA GCCCTGGAGC 7440

CCCTGCCTCC GGGAAGAAGG AAAAGGAGAA GCCCAGTGTG GCCAAGGCTC CCGACACCAG 7500

GAGCTGTTGG GAGAAGCAAT ACGTTTGTGC AGAATCTCTA 7540

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2297 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

Met Leu Pro His Arg Val Pro Arg Cys Val Arg Thr Pro Pro Leu Arg  
1 5 10 15

Gly Ser Ala Arg Pro Ser Ser Asp Pro Pro Gly Pro Arg Leu Ala Arg  
20 25 30

Gly Trp Thr Arg Arg Arg Met Glu Arg Ala Pro Arg Ser Arg Asp Ser  
35 40 45

Pro Val Ala Ser Arg Ser Ser Thr Thr Cys Pro Gly Pro Gly Ala Ala

50                      55                      60

5

10

Pro Trp Phe Glu Arg Val Ser Met Leu Val Ile Leu Leu Asn Cys Val  
115 120 125

2006-07-20

25

Lys Cys Tyr Leu Gly Asp Thr Trp Asn Arg Leu Asp Phe Phe Ile Val  
180 185 190

Ile Ala Gly Met Leu Glu Tyr Ser Leu Asp Leu Gln Asn Val Ser Phe  
195 200 205

30

Ser Ala Val Arg Thr Val Arg Val Leu Arg Pro Leu Arg Ala Ile Asn  
210 215 220

Arg Val Pro Ser Met Arg Ile Leu Val Thr Leu Leu Leu Asp Thr Leu  
225                    230                    235                    240

35

Pro Met Leu Gly Asn Val Leu Leu Leu Cys Phe Phe Val Phe Phe Ile  
245 250 255

5

10

Thr Lys Gln Arg Glu Ser Gln Leu Met Arg Glu Gln Arg Val Arg Phe  
435 440 445

Leu Ser Asn Ala Ser Thr Leu Ala Ser Phe Ser Glu Pro Gly Ser Cys  
 450 455 460

Tyr Glu Glu Leu Leu Lys Tyr Leu Val Tyr Ile Leu Arg Lys Ala Ala  
 465 470 475 480

Arg Arg Leu Ala Gln Val Ser Arg Ala Ile Gly Val Arg Ala Gly Leu  
 485 490 495

Leu Ser Ser Pro Val Ala Arg Ser Gly Gln Glu Pro Gln Pro Ser Gly  
 500 505 510

Ser Cys Thr Arg Ser His Arg Arg Leu Ser Val His His Leu Val His  
 515 520 525

His His His His His His His His Tyr His Leu Gly Asn Gly Thr Leu  
 530 535 540

Arg Val Pro Arg Ala Ser Pro Glu Ile Gln Asp Arg Asp Ala Asn Gly  
 545 550 555 560

Ser Arg Arg Leu Met Leu Pro Pro Pro Ser Thr Pro Thr Pro Ser Gly  
 565 570 575

Gly Pro Pro Arg Gly Ala Glu Ser Val His Ser Phe Tyr His Ala Asp  
 580 585 590

Cys His Leu Glu Pro Val Arg Cys Gln Ala Pro Pro Pro Arg Cys Pro  
 595 600 605

Ser Glu Ala Ser Gly Arg Thr Val Gly Ser Gly Lys Val Tyr Pro Thr  
 610 615 620

Val His Thr Ser Pro Pro Pro Glu Ile Leu Lys Asp Lys Ala Leu Val  
 625 630 635 640

Glu Val Ala Pro Ser Pro Gly Pro Pro Thr Leu Thr Ser Phe Asn Ile



68

645

650

655

Pro Pro Gly Pro Phe Ser Ser Met His Lys Leu Leu Glu Thr Gln Ser

660

665

670

5

Thr Gly Ala Cys His Ser Ser Cys Lys Ile Ser Ser Pro Cys Ser Lys

675

680

685

Ala Asp Ser Gly Ala Cys Gly Pro Asp Ser Cys Pro Tyr Cys Ala Arg

10

690

695

700

Thr Gly Ala Gly Glu Pro Glu Ser Ala Asp His Val Met Pro Asp Ser

705

710

715

720

15

Asp Ser Glu Ala Val Tyr Glu Phe Thr Gln Asp Ala Gln His Ser Asp

725

730

735

Leu Arg Asp Pro His Ser Arg Arg Arg Gln Arg Ser Leu Gly Pro Asp

740

745

750

20

Ala Glu Pro Ser Ser Val Leu Ala Phe Trp Arg Leu Ile Cys Asp Thr

755

760

765

Phe Arg Lys Ile Val Asp Ser Lys Tyr Phe Gly Arg Gly Ile Met Ile

25

770

775

780

Ala Ile Leu Val Asn Thr Leu Ser Met Gly Ile Glu Tyr His Glu Gln

785

790

795

800

30

Pro Glu Glu Leu Thr Asn Ala Leu Glu Ile Ser Asn Ile Val Phe Thr

805

810

815

Ser Leu Phe Ala Leu Glu Met Leu Leu Lys Leu Leu Val Tyr Gly Pro

820

825

830

35

Phe Gly Tyr Ile Lys Asn Pro Tyr Asn Ile Phe Asp Gly Val Ile Val

835

840

845

"SECRET" 60358600

850                      855                      860

885                      890                      895

915                      920                      925

35 Asp Arg Lys Lys Arg Leu Ala Leu Val Ala Leu Gly Glu His Ala Glu  
1025 1030 1035 1040

Leu Arg Lys Ser Leu Leu Pro Pro Leu Ile Ile His Thr Ala Ala Thr  
 1045 1050 1055

Pro Met Ser His Pro Lys Ser Ser Ser Thr Gly Val Gly Glu Ala Leu  
 1060 1065 1070

Gly Ser Gly Ser Arg Arg Thr Ser Ser Ser Gly Ser Ala Glu Pro Gly  
 1075 1080 1085

Ala Ala His His Glu Met Lys Cys Pro Pro Ser Ala Arg Ser Ser Pro  
 1090 1095 1100

His Ser Pro Trp Ser Ala Ala Ser Ser Trp Thr Ser Arg Arg Ser Ser  
 1105 1110 1115 1120

Arg Asn Ser Leu Gly Arg Ala Pro Ser Leu Lys Arg Arg Ser Pro Ser  
 1125 1130 1135

Gly Glu Arg Arg Ser Leu Leu Ser Gly Glu Gly Gln Glu Ser Gln Asp  
 1140 1145 1150

Glu Glu Glu Ser Ser Glu Glu Asp Arg Ala Ser Pro Ala Gly Ser Asp  
 1155 1160 1165

His Arg His Arg Gly Ser Leu Glu Arg Glu Ala Lys Ser Ser Phe Asp  
 1170 1175 1180

Leu Pro Asp Thr Leu Gln Val Pro Gly Leu His Arg Thr Ala Ser Gly  
 1185 1190 1195 1200

Arg Ser Ser Ala Ser Glu His Gln Asp Cys Asn Gly Lys Ser Ala Ser  
 1205 1210 1215

Gly Arg Leu Ala Arg Thr Leu Arg Thr Asp Asp Pro Gln Leu Asp Gly  
 1220 1225 1230

Asp Asp Asp Asn Asp Glu Gly Asn Leu Ser Lys Gly Glu Arg Ile Gln

SECRET 67090680

1235

1240

1245

Ala Trp Val Arg Ser Arg Leu Pro Ala Cys Cys Arg Glu Arg Asp Ser

1250

1255

1260

5

Trp Ser Ala Tyr Ile Phe Pro Pro Gln Ser Arg Phe Arg Leu Leu Cys

1265

1270

1275

1280

His Arg Ile Ile Thr His Lys Met Phe Asp His Val Val Leu Val Ile

10

1285

1290

1295

Ile Phe Leu Asn Cys Ile Thr Ile Ala Met Glu Arg Pro Lys Ile Asp

1300

1305

1310

15

Pro His Ser Ala Glu Arg Ile Phe Leu Thr Leu Ser Asn Tyr Ile Phe

1315

1320

1325

Thr Ala Val Phe Leu Ala Glu Met Thr Val Lys Val Val Ala Leu Gly

1330

1335

1340

20

Trp Cys Phe Gly Glu Gln Ala Tyr Leu Arg Ser Ser Trp Asn Val Leu

1345

1350

1355

1360

Asp Gly Leu Leu Val Leu Ile Ser Val Ile Asp Ile Leu Val Ser Met

25

1365

1370

1375

Val Ser Asp Ser Gly Thr Lys Ile Leu Gly Met Leu Arg Val Leu Arg

1380

1385

1390

30

Leu Leu Arg Thr Leu Arg Pro Leu Arg Val Ile Ser Arg Ala Gln Gly

1395

1400

1405

Leu Lys Leu Val Val Glu Thr Leu Met Ser Ser Leu Lys Pro Ile Gly

1410

1415

1420

35

Asn Ile Val Val Ile Cys Cys Ala Phe Phe Ile Ile Phe Gly Ile Leu

1425

1430

1435

1440

Gly Val Gln Leu Phe Lys Gly Lys Phe Phe Val Cys Gln Gly Glu Asp  
 1445 1450 1455

5 Thr Arg Asn Ile Thr Asn Lys Ser Asp Cys Ala Glu Ala Ser Tyr Arg  
 1460 1465 1470

Trp Val Arg His Lys Tyr Asn Phe Asp Asn Leu Gly Gln Ala Leu Met  
 1475 1480 1485

10 Ser Leu Phe Val Leu Ala Ser Lys Asp Gly Trp Val Asp Ile Met Tyr  
 1490 1495 1500

Asp Gly Leu Asp Ala Val Gly Val Asp Gln Gln Pro Ile Met Asn His  
 1505 1510 1515 1520

Asn Pro Trp Met Leu Leu Tyr Phe Ile Ser Phe Leu Leu Ile Val Ala  
 1525 1530 1535

20 Phe Phe Val Leu Asn Met Phe Val Gly Val Val Val Glu Asn Phe His  
 1540 1545 1550

Lys Cys Arg Gln His Gln Glu Glu Glu Glu Ala Arg Arg Arg Glu Glu  
 1555 1560 1565

25 Lys Arg Leu Arg Arg Leu Glu Lys Lys Arg Arg Asn Leu Met Leu Asp  
 1570 1575 1580

30 Asp Val Ile Ala Ser Gly Ser Ser Ala Ser Ala Ala Ser Glu Ala Gln  
 1585 1590 1595 1600

Cys Lys Pro Tyr Tyr Ser Asp Tyr Ser Arg Phe Arg Leu Leu Val His  
 1605 1610 1615

35 His Leu Cys Thr Ser His Tyr Leu Asp Leu Phe Ile Thr Gly Val Ile  
 1620 1625 1630

DELETED - 60858580

Gly Leu Asn Val Val Thr Met Ala Met Glu His Tyr Gln Gln Pro Gln  
 1635 1640 1645

5 Ile Leu Asp Glu Ala Leu Lys Ile Cys Asn Tyr Ile Phe Thr Val Ile  
 1650 1655 1660

Phe Val Phe Glu Ser Val Phe Lys Leu Val Ala Phe Ala Phe Arg Arg  
 1665 1670 1675 1680

10 Phe Phe Gln Asp Arg Trp Asn Gln Leu Asp Leu Ala Ile Val Leu Leu  
 1685 1690 1695

Ser Ile Met Gly Ile Thr Leu Glu Glu Ile Glu Val Asn Leu Ser Leu  
 1700 1705 1710

15 Pro Ile Asn Pro Thr Ile Ile Arg Ile Met Arg Val Leu Arg Ile Ala  
 1715 1720 1725

20 Arg Val Leu Lys Leu Leu Lys Met Ala Val Gly Met Arg Ala Leu Leu  
 1730 1735 1740

His Thr Val Met Gln Ala Leu Pro Gln Val Gly Asn Leu Gly Leu Leu  
 1745 1750 1755 1760

25 Phe Met Leu Leu Phe Phe Ile Phe Ala Ala Leu Gly Val Glu Leu Phe  
 1765 1770 1775

Gly Asp Leu Glu Cys Asp Glu Thr His Pro Cys Glu Gly Leu Gly Arg  
 1780 1785 1790

30 His Ala Thr Phe Arg Asn Phe Gly Met Ala Phe Leu Thr Leu Phe Arg  
 1795 1800 1805

35 Val Ser Thr Gly Asp Asn Trp Asn Gly Ile Met Lys Asp Pro Ser Arg  
 1810 1815 1820

Asp Cys Asp Gln Glu Ser Thr Cys Tyr Asn Thr Val Ile Ser Pro Ile

2020 2025 2030

Gly Ala Ile Pro Lys Leu Pro Pro Pro Gly Arg Ser Pro Leu Ala Gln  
 2035 2040 2045

5 Arg Pro Leu Arg Arg Gln Ala Ala Ile Arg Thr Asp Ser Leu Asp Val  
 2050 2055 2060

Gln Gly Leu Gly Ser Arg Glu Asp Leu Leu Ser Glu Val Ser Gly Pro  
 2065 2070 2075 2080

10 Ser Cys Pro Leu Thr Arg Ser Ser Ser Phe Trp Gly Gly Ser Ser Ile  
 2085 2090 2095

15 Gln Val Gln Gln Arg Ser Gly Ile Gln Ser Lys Val Ser Lys His Ile  
 2100 2105 2110

Arg Leu Pro Ala Pro Cys Pro Gly Leu Glu Pro Ser Trp Ala Lys Asp  
 2115 2120 2125

20 Pro Pro Glu Thr Arg Ser Ser Leu Glu Leu Asp Thr Glu Leu Ser Trp  
 2130 2135 2140

Ile Ser Gly Asp Leu Leu Pro Ser Ser Gln Glu Glu Pro Leu Phe Pro  
 2145 2150 2155 2160

25 Arg Asp Leu Lys Lys Cys Tyr Ser Val Glu Thr Gln Ser Cys Arg Arg  
 2165 2170 2175

30 Arg Pro Gly Phe Trp Leu Asp Glu Gln Arg Arg His Ser Ile Ala Val  
 2180 2185 2190

Ser Cys Leu Asp Ser Gly Ser Gln Pro Arg Leu Cys Pro Ser Pro Ser  
 2195 2200 2205

35 Ser Leu Gly Gly Gln Pro Leu Gly Gly Pro Gly Ser Arg Pro Lys Lys  
 2210 2215 2220



15  
20

5

10

15

20

## 25

## 30

35

Gly Trp Thr Arg Arg Arg Met Glu Arg Ala Pro Arg Ser Arg Asp Ser

35

40

45

Pro Val Ala Ser Arg Ser Ser Thr Thr Cys Pro Gly Pro Gly Ala Ala  
50 55 60

5

Gly Ala Gly Ser Thr Glu Lys Asp Pro Gly Ser Ala Asp Ser Glu Ala  
65 70 75 80

Glu Gly Leu Pro Tyr Pro Ala Leu Ala Pro Val Val Phe Phe Tyr Leu  
85 90 95

10

Ser Gln Asp Ser Arg Pro Arg Ser Trp Cys Leu Arg Thr Val Cys Asn  
100 105 110

Pro Trp Phe Glu Arg Val Ser Met Leu Val Ile Leu Leu Asn Cys Val  
115 120 125

15

Thr Leu Gly Met Phe Arg Pro Cys Glu Asp Ile Ala Cys Asp Ser Gln  
130 135 140

20

Arg Cys Arg Ile Leu Gln Ala Phe Asp Asp Phe Ile Phe Ala Phe Phe  
145 150 155 160

Ala Val Glu Met Val Val Lys Met Val Ala Leu Gly Ile Phe Gly Lys  
165 170 175

25

Lys Cys Tyr Leu Gly Asp Thr Trp Asn Arg Leu Asp Phe Phe Ile Val  
180 185 190

30

Ile Ala Gly Met Leu Glu Tyr Ser Leu Asp Leu Gln Asn Val Ser Phe  
195 200 205

Ser Ala Val Arg Thr Val Arg Val Leu Arg Pro Leu Arg Ala Ile Asn  
210 215 220

35

Arg Val Pro Ser Met Arg Ile Leu Val Thr Leu Leu Leu Asp Thr Leu  
225 230 235 240

SECRET 6753680

Pro Met Leu Gly Asn Val Leu Leu Leu Cys Phe Phe Val Phe Phe Ile  
 245 250 255

5 Phe Gly Ile Val Gly Val Gln Leu Trp Ala Gly Leu Leu Arg Asn Arg  
 260 265 270

Cys Phe Leu Pro Glu Asn Phe Ser Leu Pro Leu Ser Val Asp Leu Glu  
 275 280 285

10 Pro Tyr Tyr Gln Thr Glu Asn Glu Asp Glu Ser Pro Phe Ile Cys Ser  
 290 295 300

Gln Pro Arg Glu Asn Gly Met Arg Ser Cys Arg Ser Val Pro Thr Leu  
 305 310 315 320

Arg Gly Glu Gly Gly Gly Gly Pro Pro Cys Ser Leu Asp Tyr Glu Thr  
 325 330 335

20 Tyr Asn Ser Ser Ser Asn Thr Thr Cys Val Asn Trp Asn Gln Tyr Tyr  
 340 345 350

Thr Asn Cys Ser Ala Gly Glu His Asn Pro Phe Lys Gly Ala Ile Asn  
 355 360 365

25 Phe Asp Asn Ile Gly Tyr Ala Trp Ile Ala Ile Phe Gln Val Ile Thr  
 370 375 380

30 Leu Glu Gly Trp Val Asp Ile Met Tyr Phe Val Met Asp Ala His Ser  
 385 390 395 400

Phe Tyr Asn Phe Ile Tyr Phe Ile Leu Leu Ile Ile Val Gly Ser Phe  
 405 410 415

35 Phe Met Ile Asn Leu Cys Leu Val Val Ile Ala Thr Gln Phe Ser Glu  
 420 425 430

Thr Lys Gln Arg Glu Ser Gln Leu Met Arg Glu Gln Arg Val Arg Phe  
 435 440 445

Leu Ser Asn Ala Ser Thr Leu Ala Ser Phe Ser Glu Pro Gly Ser Cys  
 450 455 460

Tyr Glu Glu Leu Leu Lys Tyr Leu Val Tyr Ile Leu Arg Lys Ala Ala  
 465 470 475 480

Arg Arg Leu Ala Gln Val Ser Arg Ala Ile Gly Val Arg Ala Gly Leu  
 485 490 495

Leu Ser Ser Pro Val Ala Arg Ser Gly Gln Glu Pro Gln Pro Ser Gly  
 500 505 510

Ser Cys Thr Arg Ser His Arg Arg Leu Ser Val His His Leu Val His  
 515 520 525

His His His His His His His His Tyr His Leu Gly Asn Gly Thr Leu  
 530 535 540

Arg Val Pro Arg Ala Ser Pro Glu Ile Gln Asp Arg Asp Ala Asn Gly  
 545 550 555 560

Ser Arg Arg Leu Met Leu Pro Pro Pro Ser Thr Pro Thr Pro Ser Gly  
 565 570 575

Gly Pro Pro Arg Gly Ala Glu Ser Val His Ser Phe Tyr His Ala Asp  
 580 585 590

Cys His Leu Glu Pro Val Arg Cys Gln Ala Pro Pro Pro Arg Cys Pro  
 595 600 605

Ser Glu Ala Ser Gly Arg Thr Val Gly Ser Gly Lys Val Tyr Pro Thr  
 610 615 620

Val His Thr Ser Pro Pro Pro Glu Ile Leu Lys Asp Lys Ala Leu Val

2010年12月31日

625					630					635					640
Glu	Val	Ala	Pro	Ser	Pro	Gly	Pro	Pro	Thr	Leu	Thr	Ser	Phe	Asn	Ile
				645					650					655	
Pro	Pro	Gly	Pro	Phe	Ser	Ser	Met	His	Lys	Leu	Leu	Glu	Thr	Gln	Ser
			660					665					670		
Thr	Gly	Ala	Cys	His	Ser	Ser	Cys	Lys	Ile	Ser	Ser	Pro	Cys	Ser	Lys
		675					680					685			
Ala	Asp	Ser	Gly	Ala	Cys	Gly	Pro	Asp	Ser	Cys	Pro	Tyr	Cys	Ala	Arg
	690					695					700				
Thr	Gly	Ala	Gly	Glu	Pro	Glu	Ser	Ala	Asp	His	Val	Met	Pro	Asp	Ser
705					710					715					720
Asp	Ser	Glu	Ala	Val	Tyr	Glu	Phe	Thr	Gln	Asp	Ala	Gln	His	Ser	Asp
			725						730					735	
Leu	Arg	Asp	Pro	His	Ser	Arg	Arg	Arg	Gln	Arg	Ser	Leu	Gly	Pro	Asp
			740					745					750		
Ala	Glu	Pro	Ser	Ser	Val	Leu	Ala	Phe	Trp	Arg	Leu	Ile	Cys	Asp	Thr
		755					760					765			
Phe	Arg	Lys	Ile	Val	Asp	Ser	Lys	Tyr	Phe	Gly	Arg	Gly	Ile	Met	Ile
770						775					780				
Ala	Ile	Leu	Val	Asn	Thr	Leu	Ser	Met	Gly	Ile	Glu	Tyr	His	Glu	Gln
785					790					795					800
Pro	Glu	Glu	Leu	Thr	Asn	Ala	Leu	Glu	Ile	Ser	Asn	Ile	Val	Phe	Thr
				805					810					815	
Ser	Leu	Phe	Ala	Leu	Glu	Met	Leu	Leu	Lys	Leu	Leu	Val	Tyr	Gly	Pro
			820						825				830		

Phe Gly Tyr Ile Lys Asn Pro Tyr Asn Ile Phe Asp Gly Val Ile Val  
 835 840 845

5 Val Ile Ser Val Trp Glu Ile Val Gly Gln Gln Gly Gly Gly Leu Ser  
 850 855 860

Val Leu Arg Thr Phe Arg Leu Met Arg Val Leu Lys Leu Val Arg Phe  
 865 870 875 880

10 Leu Pro Ala Leu Gln Arg Gln Leu Val Val Leu Met Lys Thr Met Asp  
 885 890 895

Asn Val Ala Thr Phe Cys Met Leu Leu Met Leu Phe Ile Phe Ile Phe  
 900 905 910

Ser Ile Leu Gly Met His Leu Phe Gly Cys Lys Phe Ala Ser Glu Arg  
 915 920 925

20 Asp Gly Asp Thr Leu Pro Asp Arg Lys Asn Phe Asp Ser Leu Leu Trp  
 930 935 940

Ala Ile Val Thr Val Phe Gln Ile Leu Thr Gln Glu Asp Trp Asn Lys  
 945 950 955 960

25 Val Leu Tyr Asn Gly Met Ala Ser Thr Ser Ser Trp Ala Ala Leu Tyr  
 965 970 975

Phe Ile Ala Leu Met Thr Phe Gly Asn Tyr Val Leu Phe Asn Leu Leu  
 980 985 990

Val Ala Ile Leu Val Glu Gly Phe Gln Ala Glu Gly Asp Ala Thr Lys  
 995 1000 1005

35 Ser Glu Ser Glu Pro Asp Phe Phe Ser Pro Ser Val Asp Gly Asp Gly  
 1010 1015 1020

Gly Arg Leu Ala Arg Thr Leu Arg Thr Asp Asp Pro Gln Leu Asp Gly

1220

1225

1230

Asp Asp Asp Asn Asp Glu Gly Asn Leu Ser Lys Gly Glu Arg Ile Gln

1235

1240

1245

5

Ala Trp Val Arg Ser Arg Leu Pro Ala Cys Cys Arg Glu Arg Asp Ser

1250

1255

1260

Trp Ser Ala Tyr Ile Phe Pro Pro Gln Ser Arg Phe Arg Leu Leu Cys

1265

1270

1275

1280

10

His Arg Ile Ile Thr His Lys Met Phe Asp His Val Val Leu Val Ile

1285

1290

1295

Ile Phe Leu Asn Cys Ile Thr Ile Ala Met Glu Arg Pro Lys Ile Asp

1300

1305

1310

15

Pro His Ser Ala Glu Arg Ile Phe Leu Thr Leu Ser Asn Tyr Ile Phe

1315

1320

1325

20

Thr Ala Val Phe Leu Ala Glu Met Thr Val Lys Val Val Ala Leu Gly

1330

1335

1340

Trp Cys Phe Gly Glu Gln Ala Tyr Leu Arg Ser Ser Trp Asn Val Leu

1345

1350

1355

1360

25

Asp Gly Leu Leu Val Leu Ile Ser Val Ile Asp Ile Leu Val Ser Met

1365

1370

1375

30

Val Ser Asp Ser Gly Thr Lys Ile Leu Gly Met Leu Arg Val Leu Arg

1380

1385

1390

Leu Leu Arg Thr Leu Arg Pro Leu Arg Val Ile Ser Arg Ala Gln Gly

1395

1400

1405

35

Leu Lys Leu Val Val Glu Thr Leu Met Ser Ser Leu Lys Pro Ile Gly

1410

1415

1420



Asn Ile Val Val Ile Cys Cys Ala Phe Phe Ile Ile Phe Gly Ile Leu  
 1425 1430 1435 1440

5 Gly Val Gln Leu Phe Lys Gly Lys Phe Phe Val Cys Gln Gly Glu Asp  
 1445 1450 1455

Thr Arg Asn Ile Thr Asn Lys Ser Asp Cys Ala Glu Ala Ser Tyr Arg  
 1460 1465 1470

10 Trp Val Arg His Lys Tyr Asn Phe Asp Asn Leu Gly Gln Ala Leu Met  
 1475 1480 1485

15 Ser Leu Phe Val Leu Ala Ser Lys Asp Gly Trp Val Asp Ile Met Tyr  
 1490 1495 1500

Asp Gly Leu Asp Ala Val Gly Val Asp Gln Gln Pro Ile Met Asn His  
 1505 1510 1515 1520

20 Asn Pro Trp Met Leu Leu Tyr Phe Ile Ser Phe Leu Leu Ile Val Ala  
 1525 1530 1535

Phe Phe Val Leu Asn Met Phe Val Gly Val Val Val Glu Asn Phe His  
 1540 1545 1550

25 Lys Cys Arg Gln His Gln Glu Glu Glu Ala Arg Arg Arg Glu Glu  
 1555 1560 1565

30 Lys Arg Leu Arg Arg Leu Glu Lys Lys Arg Arg Ser Lys Glu Lys Gln  
 1570 1575 1580

Met Ala Asp Leu Met Leu Asp Asp Val Ile Ala Ser Gly Ser Ser Ala  
 1585 1590 1595 1600

35 Ser Ala Ala Ser Glu Ala Gln Cys Lys Pro Tyr Tyr Ser Asp Tyr Ser  
 1605 1610 1615

UNRECORDED - 1493

5

10

15

20

25

30

35

Ala Phe Leu Thr Leu Phe Arg Val Ser Thr Gly Asp Asn Trp Asn Gly

1810

1815

1820

Ile Met Lys Asp Pro Ser Arg Asp Cys Asp Gln Glu Ser Thr Cys Tyr

1825

1830

1835

1840

5

Asn Thr Val Ile Ser Pro Ile Tyr Phe Val Ser Phe Val Leu Thr Ala

1845

1850

1855

Gln Phe Val Leu Val Asn Val Val Ile Ala Val Leu Met Lys His Leu

10

1860

1865

1870

Glu Glu Ser Asn Lys Glu Ala Lys Glu Glu Ala Glu Leu Glu Ala Glu

1875

1880

1885

15

Leu Glu Leu Glu Met Lys Thr Leu Ser Pro Gln Pro His Ser Pro Leu

1890

1895

1900

Gly Ser Pro Phe Leu Trp Pro Gly Val Glu Gly Val Asn Ser Thr Asp

1905

1910

1915

1920

20

Ser Pro Lys Pro Gly Ala Pro His Thr Thr Ala His Ile Gly Ala Ala

1925

1930

1935

Ser Gly Phe Ser Leu Glu His Pro Thr Met Val Pro His Pro Glu Glu

25

1940

1945

1950

Val Pro Val Pro Leu Gly Pro Asp Leu Leu Thr Val Arg Lys Ser Gly

1955

1960

1965

30

Val Ser Arg Thr His Ser Leu Pro Asn Asp Ser Tyr Met Cys Arg Asn

1970

1975

1980

Gly Ser Thr Ala Glu Arg Ser Leu Gly His Arg Gly Trp Gly Leu Pro

1985

1990

1995

2000

35

Lys Ala Gln Ser Gly Ser Ile Leu Ser Val His Ser Gln Pro Ala Asp

2005

2010

2015

2020 2025 2030

Gly Arg Ser Pro Leu Ala Gln Arg Pro Leu Arg Arg Gln Ala Ala Ile  
2050 2055 2060

Leu Ser Glu Val Ser Gly Pro Ser Cys Pro Leu Thr Arg Ser Ser Ser  
2085 2090 2095

20 Ser Lys Val Ser Lys His Ile Arg Leu Pro Ala Pro Cys Pro Gly Leu  
2115 2120 2125

25

Leu Asp Thr Glu Leu Ser Trp Ile Ser Gly Asp Leu Leu Pro Ser Ser  
2145 2150 2155 2160

30	2165	2170	2175
Glu Thr Gln Ser Cys Arg Arg Arg Pro Gly Phe Trp Leu Asp Glu Gln			
	2180	2185	2190

35 Arg Arg His Ser Ile Ala Val Ser Cys Leu Asp Ser Gly Ser Gln Pro  
2195 2200 2205

88

Arg Leu Cys Pro Ser Pro Ser Ser Leu Gly Gly Gln Pro Leu Gly Gly  
2210 2215 2220

Pro Gly Ser Arg Pro Lys Lys Lys Leu Ser Pro Pro Ser Ile Ser Ile  
2225 2230 2235 2240

Asp Pro Pro Glu Ser Gln Gly Ser Arg Pro Pro Cys Ser Pro Gly Val  
2245 2250 2255

Cys Leu Arg Arg Arg Ala Pro Ala Ser Asp Ser Lys Asp Pro Ser Val  
2260 2265 2270

Ser Ser Pro Leu Asp Ser Thr Ala Ala Ser Pro Ser Pro Lys Lys Asp  
2275 2280 2285

Thr Leu Ser Leu Ser Gly Leu Ser Ser Asp Pro Thr Asp Met Asp Pro  
2290 2295 2300

(2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

Arg Ile Met Arg Val Leu Arg Ile Ala Arg Val Leu Lys Leu Leu Lys  
1 5 10 15

Met Ala Val Gly Met Arg Ala

20

(2) INFORMATION FOR SEQ ID NO: 8:

5

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: unknown

10

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

Arg Leu Phe Arg Val Met Arg Leu Ile Lys Leu Leu Ser Arg Ala Glu

20

1

5

10

15

Gly Val

25

(2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 amino acids

(B) TYPE: amino acid

30

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

Arg Leu Phe Arg Val Met Arg Leu Val Lys Leu Leu Ser Arg Gly Glu  
1 5 10 15

Gly Ile

(2) INFORMATION FOR SEQ ID NO: 10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: unknown
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

Arg Leu Phe Arg Ala Ala Arg Leu Ile Lys Leu Leu Arg Gln Gly Tyr  
1 5 10 15

Thr Ile

15  
20  
25

What is claimed is:

1. A isolated or substantially purified nucleic acid encoding a protein comprising at least one domain of a T-type calcium channel  $\alpha$  subunit.

5 2. The nucleic acid of claim 1, which encodes an entire T-type calcium channel  $\alpha$  subunit.

3. The nucleic acid of claim 2, wherein said protein comprises SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6 or a derivative of any of said sequences.

4. The nucleic acid of claim 1, wherein said protein comprises SEQ ID NO:7.

10 5. The nucleic acid of claim 2, wherein said protein gates from about -45 mV to about -30 mV in 2 mM  $\text{Ba}^{2+}$ .

6. The nucleic acid of claim 2, wherein said protein exhibits a tail current of from about 2 ms to about 10 ms following repolarization to a membrane potential from about -80 mV to about -60 mV in a solution with a barium concentration of from about 10 mM to about 40 mM.

7. The nucleic acid of claim 2, wherein said protein exhibits a single channel conductance of from 7 pS to about 10 pS in a solution with a barium ion concentration of about 100 mM.

8. A isolated or substantially purified nucleic acid hybridizing to SEQ ID NO:2 or SEQ ID NO:4 under high stringency.

9. A isolated or substantially purified DNA hybridizing to the nucleic acid of claim 8.

10. The DNA of claim 9 comprising a sequence encoding a T-type calcium channel.

11. A vector comprising the nucleic acid of claim 1.

12. A cell into which the vector of claim 11 has been introduced.

13. The cell of claim 12, wherein said nucleic acid is expressed to produce a protein.

14. A method of identifying a drug which affects T-type calcium channels, said method comprising expressing a T-type calcium channel in a cell, exposing said cell to a putative drug, and measuring the calcium flux through the membrane of said cell in response to a change in membrane potential.

15. The method of claim 14, wherein said calcium flux is assayed by using a calcium-sensitive labile dye within said cell.

16. The method of claim 14, wherein said calcium flux is assayed by measuring the electrophysiological properties of said cell.



5

5

19. An isolated or substantially purified antibody molecule recognizing an epitope on a T-type calcium channel protein.

**ABSTRACT**

The present invention provides an isolated or substantially purified nucleic acid encoding a protein comprising at least one domain of a T-type calcium channel  $\alpha$  subunit and cells expressing such nucleic acids. The present invention also provides isolated or substantially purified T-type calcium channels and an isolated or substantially purified antibody molecule recognizing an epitope on a T-type calcium channel protein.

Additionally, the present invention provides an assay for identifying potential drugs affecting T-type calcium channels by exposing cells expressing a nucleic acid encoding a T-type calcium channel to a putative drug and then measuring the calcium flux in response to a change in membrane potential.

838700pp

465077 "H02G02000

Accession: G01534.00

ATGCTCCCCACCGGGTCCCCGTTGCGTGAGGACACCTCCTCTGAGGGGCTCCGCTCGCCCCCTCT  
1 M L P H R V P R C V R T P P L R G S A R P S  
66 TCGGACCCCCCGGGGCCCGGCTGGCCAGAGGATGGACGAGGAGGAGGATGGAGCGGGCGCCGAGGAGTCCGGGAC  
23 S D P P G P R L A R G W T R R R M E R A P R S R D  
141 AGCCCCGTAGCTTCACGCAGCTCAACGACCTGTCCGGGGCCGGGGGCGGCAGGGGCGGGTCCGACGGAAAAGGAC  
48 S P V A S R S S T T C P G P G A A G A G S T E K D  
216 CCGGGCAGCGCGGACTCCGAGGCGGAGGGGCTGCCGTACCCGGCGCTAGCCCCGGTGGTTTTCTTCTACTTGAGC  
73 P G S A D S E A E G L P Y P A L A P V V F F Y L S  
\*\*\*\*\*  
291 CAGGACAGCCCGCCCGGAGCTGGTGTCTCCGCACGGTCTGTAACCCGTGGTTCGAGCGAGTCAGTATGCTGGTC  
98 Q D S R P R S W C L R T V C N P W F E R V S M L V  
\*\*\*\*\*IS1\*\*\*\*\*  
366 ATTCTTCTCAACTGTGTGACTCTGGGTATGTTTCAGGCCGTGTGAGGACATTGCCTGTGACTCCCAGCGCTGCCGG  
123 I L L N C V T L G M F R P C E D I A C D S Q R C R  
\*\*\*\*\*IS2\*\*\*\*\*  
441 ATCCTGCAGGCCTTCGATGACTTCATCTTTGCCTTCTTTGCTGTGGAATGGTGGTGAAGATGGTGGCCTTGGGC  
148 I L Q A F D D F I F A F F A V E M V V K M V A L G  
\*\*\* \*\*\*\*\*IS3\*\*\*\*\*  
516 ATCTTTGGGAAGAAATGTTACCTGGGAGACACTTGAACCGGCTTGACTTTTTTCATTGTTCATTGCAGGGATGCTG  
173 I F G K K C Y L G D T W N R L D F F I V I A G M L  
\*\*\*\*\*IS4\*\*\*\*\*  
591 GAGTATTCGCTGGACCTGCAGAACGTCAGCTTCTCCGCAGTCAGGACAGTCCGTGTGCTGCGACCGCTCAGGGCC  
198 E Y S L D L Q N V S F S A V R T V R V L R P L R A  
\*\*\*\*\*  
666 ATTAACCGGGTGCCCGAGCATGCGCATTCTCGTCACATTACTGCTGGACACCTTGCTATGCTGGGCAACGTCCTG  
223 I N R V P S M R I L V T L L L D T L P M L G N V L  
\*\*\*\*\*IS5\*\*\*\*\*  
741 CTGCTCTGTTTCTTCGTCTTTTTCATCTTTGGCATCGTGGGCGTCCAGCTGTGGGCAGGACTGCTTCGCAACCGG  
248 L L C F F V F F I F G I V G V Q L W A G L L R N R  
816 TGCTTCTCCCCGAGAACTTCAGCCTCCCCCTGAGCGTGAGCCTTATTACCAGACAGAGAATGAGGAC  
273 C F L P E N F S L P L S V D L E P Y Y Q T E N E D  
891 GAGAGCCCCCTTCATCTGCTCTCAGCCTCGGGAGAATGGCATGAGATCCTGCAGGAGTGTGCCACACTGCGTGGG  
298 E S P F I C S Q P R E N G M R S C R S V P T L R G

Figure 1A

966 GAAGGCGGTGGTGGCCACCCTGCAGTCTGGACTATGAGACCTATAACAGTTCCAGCAACACCACCTGTGTCAAC  
 323 E G G G G P P C S L D Y E T Y N S S S N T T C V N

\*\*\*\*\*

1041 TGGAACCAGTACTATACCAACTGCTCTGCGGGCGAGCACAACCCCTTCAAAGGCGCCATCAACTTTGACAACATT  
 348 W N Q Y Y T N C S A G E H N P F K G A I N F D N I

\*\*\*\*\*I P Loop\*\*\*\*\*

1116 GGCTATGCCTGGATCGCCATCTTCCAGGTATCACAAGTGGAGGGCTGGGTGACATCATGTACTTCGTAATGGAC  
 373 G Y A W I A I F Q V I T L E G W V D I M Y F V M D

\*\*\*\*\*IS6\*\*\*\*\*

1191 GCTCACTCCTTCTACAACCTTCATCTACTTCTTCTCATCATCGTGGGCTCCTTCTTCATGATCAACCTGTGC  
 398 A H S F Y N F I Y F I L L I I V G S F F M I N L C

1266 CTGGTGGTGAATGCCACGCACTTCTCCGAGACCAAACAGCGGGAGAGTCAGCTGATGCGGGAGCAGCGTGTACGA  
 423 L V V I A T Q F S E T K Q R E S Q L M R E Q R V R

1341 TTCCTGTCCAATGCTAGCACCTGGCAAGCTTCTCTGAGCCAGGCAGCTGCTATGAGGAGCTACTCAAGTACCTG  
 448 F L S N A S T L A S F S E P G S C Y E E L L K Y L

1416 GTGTACATCCTCCGAAAAGCAGCCCGAAGGCTGGCCAGGTCTCTAGGGCTATAGGCGTGCGGGCTGGGCTGCTC  
 473 V Y I L R K A A R R L A Q V S R A I G V R A G L L

1491 AGCAGCCCAGTGGCCCGTAGTGGGCAGGAGCCCCAGCCCAGTGGCAGCTGCACTCGCTCACACCGTCGTCTGTCT  
 498 S S P V A R S G Q E P Q P S G S C T R S H R R L S

1566 GTCCACCACCTGGTCCACCACCATCACCACCACCATCACCCTACCACTGGGTAATGGGACGCTCAGAGTTCCC  
 523 V H H L V H H H H H H H H Y H L G N G T L R V P

1641 CGGGCCAGCCAGAGATCCAGGACAGGATGCCAATGGGTCTCGCCGGCTCATGCTACCACCACCCCTCTACACCC  
 548 R A S P E I Q D R D A N G S R R L M L P P P S T P

1716 ACTCCCTCTGGGGGCCCTCCGAGGGGTGCGGAGTCTGTACACAGCTTCTACCATGCTGACTGCCACTTGGAGCCA  
 573 T P S G G P P R G A E S V H S F Y H A D C H L E P

1791 GTCCGTTGCCAGGCACCCCTCCAGATGCCATCGGAGGCATCTGGTAGGACTGTGGGTAGTGGGAAGGTGTAC  
 598 V R C Q A P P P R C P S E A S G R T V G S G K V Y

1866 CCCACTGTGCATACCAGCCCTCCACCAGAGATACTGAAGGATAAAGCACTAGTGGAGGTGGCCCCCAGCCCTGGG  
 623 P T V H T S P P P E I L K D K A L V B V A P S P G

1941 CCCCCACCCCTCACCAGCTTCAACATCCCACCTGGGCCCTTTCAGCTCCATGCACAAGCTCCTGGAGACACAGAGT  
 648 P P T L T S F N I P P G P F S S M H K L L E T Q S

2016 ACGGGAGCCTGCCATAGCTCCTGCAAAATCTCCAGCCCTTGCTCCAAGGCAGACAGTGGAGCCTGCGGGCCGGAC  
 673 T G A C H S S C K I S S P C S K A D S G A C G P D

2091 AGTTGTCCCTACTGTGCCCCGACAGGAGCAGGAGAGCCAGAGTCCGCTGACCATGTGCTGCTGACTCAGACAGC  
 698 S C P Y C A R T G A G E P E S A D H V M P D S D S

2166 GAGGCTGTGTATGAGTTCACACAGGACGCTCAGCACAGTGACCTCCGGGATCCCCACAGCCGGCGGACAGCGG  
 723 E A V Y E F T Q D A Q H S D L R D P H S R R R Q R

2241 AGCCTGGGCCAGATGCAGAGCCTAGTTCTGTGCTGGCTTTCTGGAGGCTGATCTGTGACACATTCCGGAAGATC  
 748 S L G P D A E P S S V L A F W R L I C D T F R K I

Figure 1B

U3500T 00500437

\*\*\*\*\*IIS1\*\*\*\*\*  
2316 GTAGATAGCAAATACTTTGGCCGGGGAATCATGATCGCCATCCTGGTCAATACACTCAGCATGGGCATCGAGTAC  
773 V D S K Y F G R G I M I A I L V N T L S M G I E Y  
\*\*\*  
2391 CACGAGCAGCCCGAGGAGCTCACCAACGCCCTGGAAATCAGCAACATCGTCTTACCAGCCTCTTCGCCTTGGAG  
798 H E Q P R E L T N A L E I S N I V F T S L F A L E  
\*\*\*\*IIS2\*\*\*\*\*  
2466 ATGCTGCTGAAACTGCTTGTCTACGGTCCCTTTGGCTACATTAAGAATCCCTACAACATCTTTGATGGTGTCAAT  
823 M L L K L L V Y G P F G Y I K N P Y N I F D G V I  
\*\*\*\*\*  
2541 GTGGTCATCAGTGTGTGGGAGATTGTGGGCCAGCAGGGAGGTGGCCTGTGCGGTGCTGCGGACCTTCCGCCTGATG  
848 V V I S V W E I V G Q Q G G G L S V L R T F R L M  
\*\*\*\*\*IIS4\*\*\*\*\*  
2616 CGGGTGCTGAAGCTGGTGCGCTTCTGCGGCCCTGCAGCGCCAGCTCGTGGTGCTCATGAAGACCATGGACAAC  
873 R V L K L V R F L P A L Q R Q L V V L M K T M D N  
\*\*\*\*\*IIS5\*\*\*\*\*  
2691 GTGGCCACCTTCTGCATGCTCCTCATGCTGTTTCATCTTCATCTTCAGCATCCTGGGCATGCATCTCTTTGGTTGC  
898 V A T F C M L L M L F I F I F S I L G M H L F G C  
\*\*\*  
2766 AAGTTCGCATCTGAACGGGATGGGGACACGTTGCCAGACCGGAAGAATTTGACTCCCTGCTCTGGGCCATCGTC  
923 K F A S E R D G D T L P D R K N F D S L L W A I V  
\*\*\*\*\*II Pore Loop\*\*\*\*\*  
2841 ACTGCTCTTTCAGATTCTGACTCAGGAAGACTGGAATAAAGTCCCTCTACAACGGCATGGCCTCCACATCGTCTTGG  
948 T V F Q I L T Q E D W N K V L Y N G M A S T S S W  
\*\*\*\*\*IIS6\*\*\*\*\*  
2916 GCTGCTCTTTACTTCATCGCCCTCATGACTTTTGGCAACTATGTGCTCTTTAACCTGCTGGTGGCCATTCTTGTG  
973 A A L Y F I A L M T F G N Y V L F N L L V A I L V  
\*\*\*\*\*  
2991 GAAGGATTCCAGGCAGAGGGAGATGCCACCAAGTCTGAGTCAGAGCCTGATTTCTTTTCGCCAGTGTGGATGGT  
998 E G F Q A E G D A T K S E S E P D F F S P S V D G  
3066 GATGGGGACAGAAAGAAGCGCTTGGCCCTGGTGGCTTTGGGAGAACACGCGGAACACGAAAGAGCCTTTTGCCA  
1023 D G D R K K R L A L V A L G E H A E L R K S L L P  
3141 CCCCTCATCATCCATACGGCTGCGACACCAATGTACACCCCCAAGAGCTCCAGCACAGGTGTGGGGGAAGCACTG  
1048 P L I I H T A A T P M S H P K S S S T G V G E A L  
3216 GGCTCTGGCTCTCGACGTACCAGTAGCAGTGGGTCCGCTGAGCCTGGAGCTGCCACCATGAGATGAAATGTCCG  
1073 G S G S R R T S S S G S A E P G A A H H E M K C P  
3291 CCAAGTGCCCGCAGCTCCCCGCACAGTCCCTGGAGTGCGGCAAGCAGCTGGACCAGCAGGCGCTCCAGCAGGAAC  
1098 P S A R S S P H S P W S A A S S W T S R R S S R N  
3366 AGCCTGGGCGGGCCCCCAGCCTAAAGCGGAGGAGCCCGAGCGGGAGCGGAGGTCCCTGCTGTCTGGAGAGGGC  
1123 S L G R A P S L K R R S P S G E R R S L L S G E G

Figure 1C

CAGGAGAGTCAGGATGAGGAGGAAAGTTCAGAAGAGGACCGGGCCAGCCCAGCAGGCAGTGACCATCGCCACAGG  
Q E S Q D E E E S S E E D R A S P A G S D H R H R

GGTTCCTTGGAACTGAGGCCAAGAGTTCCTTTGACCTGCCTGACACTCTGCAGGTGCCGGGGCTGCACCGCACA  
G S L E R E A K S S F D L P D T L Q V P G L H R T

GCCAGCGGCCGAGCTCTGCCCTCTGAGCACCAAGACTGTAATGGCAAGTCGGCTTCAGGGCGTTTGGCCCGCACC  
A S G R S S A S E H Q D C N G K S A S G R L A R T

CTGAGGACTGATGACCCCCAACTGGATGGGGATGATGACAATGATGAGGGAAATCTGAGCAAAGGGGAACGCATA  
L R T D D P Q L D G D D D N D E G N L S K G E R I

CAAGCCTGGGTGAGATCCCGGCTTCCTGCCTGTTGCCGAGAGCGAGATTCTGGTCGGCCTATATCTTCTCCTCT  
Q A W V R S R L P A C C R E R D S W S A Y I F P P

\*\*\*\*\*IIIS1\*\*\*\*\*

CAGTCAAGGTTTCTGCTCTCCTGTGTACCGGATCATCACCACAAAGATGTTTGACCATGTGGTCCTCGTCATCATC  
Q S R F R L L C H R I I T H K M F D H V V L V I I

\*\*\*\*\*

TTCCTCAACTGTATCACCATCGCTATGGAGCGCCCCAAATGACCCCCACAGCGCTGAGCGCATCTTCTGACC  
F L N C I T I A M E R P K I D P H S A E R I F L T

\*\*\*\*\*IIIS2\*\*\*\*\*

CTCTCCAACACTACATCTTACGGCAGTCTTTCTAGCTGAAATGACAGTGAAGGTGGTGGCACTGGGCTGGTGCTTT  
L S N Y I F T A V F L A E M T V K V V A L G W C F

\*\*\*\*\*IIIS3\*\*\*\*\*

GGGGAGCAGGCCTACCTGCGCAGCAGCTGGAATGTGCTGGACGGCTTGCTGGTGCTCATCTCCGTCATCGACATC  
G E Q A Y L R S S W N V L D G L L V L I S V I D I

\*\*\*\*\*

\*\*\*\*\*

CTGGTCTCCATGGTCTCCGACAGCGGCACCAAGATCCTTGGCATGCTGAGGGTGCTGCGGCTGCTGCGGACCCCTG  
L V S M V S D S G T K I L G M L R V L R L L R T L

\*\*\*\*\*IIIS4\*\*\*\*\*

\*\*\*

CGTCCACTCAGGGTCATCAGCCGGGCCAGGGACTGAAGCTGGTGGTAGAGACTCTGATGTCATCCCTCAAACCC  
R P L R V I S R A Q G L K L V V E T L M S S L K P

\*\*\*\*\*IIIS5\*\*\*\*\*

ATTGGCAACATTGTGGTCATTTGCTGTGCCTTCTTCATCATTTTGGGAATTCTCGGGGTGCAGCTCTTCAAAGGG  
I G N I V V I C C A F F I I F G I L G V Q L F K G

\*\*\*

AAGTTCTTCGTGTGTGTCAGGGTGAGGACACCAGGAACATCACTAACAAATCCGACTGCGCTGAGGCCAGCTACCGA  
K F F V C Q G E D T R N I T N K S D C A E A S Y R

\*\*\*\*\*III P Loop\*\*\*\*\*

TGGGTCCGGCACAAGTACAACCTTTGACAACCTGGGCCAGGCTCTGATGTCCCTGTTGTGCTGGCCTCCAAGGAT  
W V R H K Y N F D N L G Q A L M S L P V L A S K D

Figure 1D



CCEDT" GDBHED

\*\*\*\*\*  
5541 GCTGTGCTGATGAAGCACCTGGAAGAAAGCAACAAAGAGGCCAAGGAGGAGGCCGAGCTCGAGGCCGAGCTGGAG  
1848 A V L M K H L E E S N K E A K E E A E L E A E L E  
  
5616 CTGGAGATGAAGACGCTCAGCCCGCAGCCCCACTCCCCGCTGGGCAGCCCCCTTCCTCTGGCCCCGGGTGGAGGGT  
1873 L E M K T L S P Q P H S P L G S P F L W P G V E G  
  
5691 GTCAACAGTACTGACAGCCCTAAGCCTGGGGCTCCACACACCACTGCCCACATTGGAGCAGCCTCGGGCTTCTCC  
1898 V N S T D S P K P G A P H T T A H I G A A S G F S  
  
5766 CTTGAGCACCCACGATGGTACCCACCCCGAGGAGGTGCCAGTCCCCCTAGGACCAGACCTGCTGACTGTGAGG  
1923 L E H P T M V P H P E E V P V P L G P D L L T V R  
  
5841 AAGTCTGGTGTGACCCGACGCACTCTCTGCCCAATGACAGCTACATGTGCCGCAATGGGAGCACTGCTGAGAGA  
1948 K S G V S R T H S L P N D S Y M C R N G S T A E R  
  
5916 TCCCTAGGACACAGGGGCTGGGGGCTCCCCAAAGCCCAGTCAGGCTCCATCTTGTCCGTTCCTCCCAACCAGCA  
1973 S L G H R G W G L P K A Q S G S I L S V H S Q P A  
  
5991 GACACCAGCTGCATCCTACAGCTTCCCAAAGATGTGCACTATCTGCTCCAGCCTCATGGGGCTCCACCTGGGGC  
1998 D T S C I L Q L P K D V H Y L L Q P H G A P T W G  
  
6066 GCCATCCCTAAACTACCCCCACCTGGCCGCTCCCCCTCTGGCTCAGAGGCCTCTCAGGCGCCAGGCAGCAATAAGG  
2023 A I P K L P P P G R S P L A Q R P L R R Q A A I R  
  
6141 ACTGACTCCCTGGATGTGACAGGGCTGGGTAGCCGGGAAGACCTGTTGTGACAGAGGTGAGTGGGCCCTCCTGCCCT  
2048 T D S L D V Q G L G S R E D L L S E V S G P S C P  
  
6216 CTGACCCGGTCTCATCCTTCTGGGGCGGGTTCGAGCATCCAGGTGCAGCAGCGTTCCGGCATCCAGAGCAAAGTC  
2073 L T R S S S F W G G S S I Q V Q Q R S G I Q S K V  
  
6291 TCCAAGCACATCCGCTGCCAGCCCCCTTGGCCAGGCCTGGAACCCAGCTGGGCCAAGGACCCCTCCAGAGACCAGA  
2098 S K H I R L P A P C P G L E P S W A K D P P E T R  
  
6366 AGCAGCTTAGAGCTGGACACGGAGCTGAGCTGGATTTCAGGAGACCTCCTTCCAGCAGCCAGGAAGAACCCTG  
2123 S S L E L D T E L S W I S G D L L P S S Q E E P L  
  
6441 TTCCACGGGACCTGAAGAAGTGCTACAGTGTAGAGACCCAGAGCTGCAGGCGCAGGCCTGGGTTCTGGCTAGAT  
2148 F P R D L K K C Y S V E T Q S C R R R P G F W L D  
  
6516 GAACAGCGGAGACACTCCATTGCTGTGCTGACAGCGGCTCCCAACCCCGCCTATGTCCAAGCCCCCTCA  
2173 E Q R R H S I A V S C L D S G S Q P R L C P S P S  
  
6591 AGCCTCGGGGGCCAACTCTTGGGGTCTGGGAGCCGGCCTAAGAAAAAACTCAGCCCACCCAGTATCTCTATA  
2198 S L G G Q P L G G P G S R P K K K L S P P S I S I  
  
6666 GACCCCCCGAGAGCCAGGGCTCTCGGCCCCCATGCAGTCTGGTGTCTGCCTCAGGAGGAGGGCGCCGGCCAGT  
2223 D P P E S Q G S R P P C S P G V C L R R R A P A S  
  
6741 GACTCTAAGGATCCCTCGGTCTCCAGCCCCCTTGACAGCAGGGCTGCCTCACCTCCCCAAAGAAAGACACGCTG  
2248 D S K D P S V S S P L D S T A A S P S P K K D T L  
  
6816 AGTCTCTCTGGTTTGTCTTCTGACCCAACAGACATGGACCCCTG SEQ ID NO:1  
2273 S L S G L S S D P T D M D P @ SEQ ID NO:1

Figure 1F



CG502T-1005550

1 ATGACCGAGGGCGCACGGGCGCCGACGAGGTCCGGGTGCCCCCTGGGGCGCCGCCCTGGCCCTGCGGGCGTTGGT  
26 M T E G A R A A D E V R V P L G R R P W P C G V G  
  
76 GGGGGCGTCCCCGAGAGCCCCGGGGCGCCGGGACCGAGGCGGAGGGGGGTTCGAGCTCGGGCGTGTACCCCTCC  
51 G G V P G E P R G A G T R G G G G F E L G V S P S  
  
151 GAGAGCCCGGCGCCGAGCGCTGCGCGGAGCTGGGTGCCGACGAGGAGCAGCGCGTCCCGTACCCGGCCTTGGCG  
76 E S P A A E R C A E L G A D E E Q R V P Y P A L A  
\*\*\*\*\*  
226 GCCACGGTCTTCTTCTGCTCGGTGAGACCGCGCGCGCAGCTGGTCCGTCCGGCTGGTCTGCAACCCATGG  
101 A T V F F C L G Q T T R P R S W S V R L V C N P W  
  
\*\*\*\*\*IS1\*\*\*\*\*  
301 TTCGAGCACGTGAGCATGCTGGTAATCATGCTCAACTGCGTGACCCCTGGGCATGTTCCGGCCCTGTGAGGACGTT  
126 F E H V S M L V I M L N C V T L G M F R P C E D V  
  
\*\*\*\*\*IS2\*\*\*\*\*  
376 GAGTGCGGCTCCGAGCGCTGCAACATCCTGGAGGCCTTTGACGCCCTTCATTTTCGCCTTTTTTGGCGGTGGAGATG  
151 E C G S E R C N I L E A F D A F I F A F F A V E M  
  
\*\*\*\*\*  
451 GTCATCAAGATGGTGGCCTTGGGGCTGTTCCGGGCGAAGTGTACCTGGGTGACACGTGGAACAGGCTGGATTTC  
176 V I K M V A L G L F G Q K C Y L G D T W N R L D F  
  
\*\*\*\*\*IS3\*\*\*\*\*  
526 TTCATCGTCGTGGCGGGCATGATGGAGTACTCGTTGGACGGACACAACGTGAGCCTCTCGGCTATCAGGACCGTG  
201 F I V V A G M M E Y S L D G H N V S L S A I R T V  
  
\*\*\*\*\*IS4\*\*\*\*\*  
601 CGGGTGCTGCGGCCCTCCGCGCCATCAACCGCGTGCCTAGCATGCGGATCCTGGTCACTCTGCTGCTGGATACG  
226 R V L R P L R A I N R V P S M R I L V T L L L D T  
  
\*\*\*\*\*IS5\*\*\*\*\*  
676 CTGCCCATGCTCGGGAACGTCCTTCTGCTGTGCTTCTTCTGCTTCTTTCATTTTCGGCATCGTTGGCGTCCAGCTC  
251 L P M L G N V L L L C F F V F F I F G I V G V Q L  
  
\*\*\*\*  
751 TGGGCTGGCCTCCTGCGGAACCGCTGCTTCTTGGACAGTGCCCTTGTGTCAGGAACAACAACCTGACCTTCTGCGG  
276 W A G L L R N R C F L D S A F V R N N N L T F L R  
  
826 CCGTACTACCAGACGGAGGAGGGCGAGGAGAACCCGTTTCATCTGCTCCTCACGCCGAGACAACGGCATGCAGAAG  
301 P Y Y Q T E E G B E N P F I C S S R R D N G M Q K  
  
901 TGCTCGCACATCCCCGGCCCGCGGACGTGCGCATGCCCTGCACCTGGGCTGGGAGGCCTACACGCAGCCGCAG  
326 C S H I P G R R D V R M P C T L G W E A Y T Q P Q  
  
976 GCCGAGGGGGTGGGCGCTGCACGCAACGCTGCATCAACTGGAACAGTACTACAACGTGTGCCGCTCGGGTGAC  
351 A E G V G A A R N A C I N W N Q Y Y N V C R S G D

Figure 2A

**Loop\*\*\*\*\***

1951 AGCCCTGATCCCTACGAGAAGATCCCGCATGTGGCCGGGAGCATGGACTGGCCAGCCCTGGCCATCTGTGGGGC  
676 S P D P Y E K I P H V A G E H G L A S P G H L S G

Figure 2B

CCAGGCCCAGG

2026 CTCAGTGTGCCCTGCCCCCTGCCAGCCCCCAGCGGGCACACTGACCTGTGAGCTGAAGAGCTGCCCCGTACTGC  
701 L S V P C P L P S P P A G T L T C E L K S C P Y C

2101 ACCCGTGGCCTGGAGGACCCGGAGGGTGAGCTCAGCGGCTCGGAAAGTGGAGACTCAGATGGCCGTGGCGTCTAT  
726 T R A L E D P E G E L S G S E S G D S D G R G V Y

2176 GAATTCACGCAGGACGTCCGGCACGGTGACCGCTGGGACCCACGCGACCACCCCGTGGACGGACACACCAGGC  
751 E F T Q D V R H G D R W D P T R P P R A T D T P G

2251 CCAGGCCCAGGACGCCCCCAGCGGCGGGCACAGCAGAGGGCAGCCCCGGGCGAGCCAGGCTGGATGGGCGCCTC  
776 P G P G S P Q R R A Q Q R A A P G E P G W M G R L

\*\*\*\*\*IIS1\*\*\*\*\*

2326 TGGGTTACCTTCAGCGGCAAGCTGCGCCGCATCGTGGACAGCAAGTACTTCAGCCGTGGCATCATGATGGCCATC  
801 W V T F S G K L R R I V D S K Y F S R G I M M A I

\*\*\*\*\*

2401 CTTGTCAACACGCTGAGCATGGGCGTGGAGTACCATGAGCAGCCCCAGGAGCTGACTAATGCTCTGGAGATCAGC  
826 L V N T L S M G V E Y H E Q P E E L T N A L E I S

\*\*\*\*\*IIS2\*\*\*\*\*

2476 AACATCGTGTTCACCAGCATGTTTGCCCTGGAGATGCTGCTGAAGCTGCTGCGCGCTGTCCCTCTGGGCTACATC  
851 N I V F T S M F A L E M L L K L L R A V P L G Y I

\*\*\*\*\*IIS3\*\*\*\*\*

2551 CGGAACCCGTACAACATCTTCGACGGCATCATCGTGGTTCATCAGCGTCTGGGAGATCGTGGGGCAGGCGGACGGT  
876 R N P Y N I F D G I I V V I S V W E I V G Q A D G

\*\*\*\*\*IIS4\*\*\*\*\*

2626 GGCTTGTCTGTGCTGCGCACCTTCGGGCTGCTGCGTGTGCTGAAGCTGGTGGCTTTCTGCCAGCCCTGCGGCGC  
901 G L S V L R T F R L L R V L K L V R F L P A L R R

\*\*\*\*\*

\*\*\*\*\*IIS5\*\*\*\*\*

2701 CAGCTCGTGGTGTGCTGGTGAAGACCATGGACAACGTGGCTACCTTCTGCACGCTGCTCATGCTCTTCATTTTCATC  
926 Q L V V L V K T M D N V A T F C T L L M L F I F I

\*\*\*\*\*

2776 TTCAGCATCCTGGGCATGCACCTTTTCGGCTGCAAGTTTCAGCCTGAAGACAGACACCGGAGACACCGTGCCTGAC  
951 F S I L G M H L F G C K F S L K T D T G D T V P D

\*\*\*\*\*II P Loop\*\*\*\*\*

2851 AGGAAGAACTTCGACTCCCTGCTGTGGGCCATCGTCACCGTGTTCAGATCCTGACCCAGGAGGACTGGAACGTG  
976 R K N F D S L L W A I V T V F Q I L T Q E D W N V

Figure 2C

\*\*\*\*\*IIS6\*\*\*\*\*

\*\*\*\*\*

\*\*\*\*\*IIIS1\*\*\*\*\*

\*\*\*\*\*

\*\*\*\*\*IIIS2\*\*\*\*\*

\*\*\*\*\*IIIS3\*\*\*\*\*

4051 TCCGGCGAGCACGCCTACCTGCAGAGCAGCTGGAACCTGCTGGATGGGCTGCTGGTGCTGGTGTCCCTGGTGGAC  
1376 S G E H A Y L Q S S W N L L D G L L V L V S L V D

Figure 2D



455021-505050

```
*****IVS4*****
5101 ATGAGCGCCGCGCTGCCCATCAACCCACCATCATCCGCATCATGCGCGTGCTTCGCATTGCCCGTGTGCTGAAG
1726 M S A A L P I N P T I I R I M R V L R I A R V L K

*****
5176 CTGCTGAAGATGGCTACGGGCATGCGCGCCCTGCTGGACACTGTGGTGAAGCTCTCCCCAGGTGGGGAACCTG
1751 L L K M A T G M R A L L D T V V Q A L P Q V G N L

*****IVS5*****
5251 GGCCTTCTTTTCATGCTCCTGTTTTTTATCTATCTGAGATTGGGAGTGGAGCTGTTCGGGAGGCTGGAGTGCAGT
1776 G L L F M L L F F I Y L R L G V E L F G R L E C S

*****IV P Loop*****
5326 GAAGACAACCCCTGCGAGGGCCTGAGCAGGCACGCCACCTTCAGCAACTTCGGCATGGCCTTCCTCACGCTGTTC
1801 E D N P C E G L S R H A T F S N F G M A F L T L F

*****
5401 CGCGTGTCCACGGGGGACAACCTGGAACGGGATCATGAAGGACACGCTGCGCGAGTGCTCCCGTGAGGACAAGCAC
1826 R V S T G D N W N G I M K D T L R E C S R E D K H

*****IVS6*****
5476 TGCCTGAGCTACCTGCCGCCCCGTCGCCCCGTCTACTTCGTGACCTTCGTGCTGGTGGCCCCAGTTCGTGCTGGTG
1851 C L S Y L P A P S P V Y F V T F V L V P Q F V L V

*****
5551 AACGTGGTGGTGGCCGTGCTCATGAAGCACCTGGAGGAGAGCAACAAGGAGGCTCGGGAGGATGCGGAGCTGGAC
1876 N V V V A V L M K H L E E S N K E A R E D A E L D

5626 GCCGAGATCGAGCTGGAGATGGCGCAGGGCCCCGGGAGTGACGCGCGGTGGACGCGGACAGGCCTCCCTTGCCC
1901 A E I E L E M A Q G P G S A R R V D A D R P P L P

5701 CAGGAGAGTCCGGCGCCAGGGACGCCCCAAACCTGGTTGCACGCAAGGTGTCCGTGTCCAGGATCTCTCGCTGCC
1926 Q E S P A P G T P Q T W L H A R C P C P G S L A A

5776 CAACGACAGCTACATGTTTCAGGCCCGTGGTGCCTGCCTCGGCGCCCCGGGCCCCGCTGCAGGAGGTGGAGAT
1951 Q R Q L H V Q A R G A C L G A P G P P A A G G G D

5851 GGAGACCTATGGGGCCGGCACCCCTTGGAGTCCTGTGCCATCCCATCCAGATCCCATTGGCTGTGTGCAACCCA
1976 G D L W G R H P L G V L C H P I Q I P L A V S N P

5926 GCCAGGAGCGGCGAGCCCTCCACGCCCTGTCCCCTCGGGGCACAGCCGCTCCCCCAGTCTCAGCCGGCTGCTCT
2001 A R S G E P L H A L S P R G T A A P P V S A G C S

6001 GCAGACAGGAGGCTGTGCACACCGATTCCCTTGAAGGGAAGATTGACAGCCCTAGGGACACCCTGGATCCTGCAG
2026 A D R R L C T P I P W K G R L T A L G T P W I L Q

6076 AGCCTGGTGAGAAACCCCGG SEQ ID NO:3
2051 S L V R N P R SEQ ID NO:3
```

Figure 2F

2550277 1005195800

$\alpha$ 1G	RIMRVLRIARVLKLLKMA	SEQ ID NO 7
$\alpha$ 1H	RIMRVLRIARVLKLLKMA	SEQ ID NO 7
$\alpha$ 1S	RLFRVMRLIKLLSRAEGV	SEQ ID NO 8
$\alpha$ 1C	RLFRVMRLVKLLSRGEGI	SEQ ID NO 9
$\alpha$ 1D	RLFRVMRLVKLLSRGEGI	SEQ ID NO 9
$\alpha$ 1A	RLFRAARLIKLLRQGYTI	SEQ ID NO 10
$\alpha$ 1B	RLFRAARLIKLLRQGYTI	SEQ ID NO 10
$\alpha$ 1E	KLFRAARLIKLLRQGYTI	SEQ ID NO 10

Fig. 3

Fig. 4A




Fig. 4B




Fig. 4C





Fig. 4D





● Fig. 5A





Fig. 5B



[BaCl<sub>2</sub>], mM  
2 10 40

Fig. 5C




Fig. 6A




Fig. 6B




Fig. 7A




Fig. 7B







Fig. 7C



**Fig. 7d**



**Fig. 7e**



**Fig. 7f**




Fig. 8A




Fig. 8B







Fig. 8C



**Fig. 9A**



**Fig. 9B**



**Fig. 9C**




Fig. 10A




Fig. 10B

